



8th Annual Conference of the International Society for Quality of Life Research

November 7-10, 2001
Amsterdam, The Netherlands



Final Program

Table of Contents

3	Schedule at a Glance
4	Scientific Program Committee / ISOQOL Leadership
5	Letter from the Chairpersons
6	General Information / About ISOQOL
7	Social Program
8	Scientific Program
12	Plenary Sessions
14	Satellite Meetings
16	Training Workshops
20	Poster Sessions / Scientific Awards Description
21	Oral Sessions
32	Poster Sessions
50	Poster Discussion Sessions
56	Acknowledgements
57	Exhibitors
58	Institutional Membership

Wednesday, November 7	Thursday, November 8	Friday, November 9	Saturday, November 10
	8:00 - "Current Issues in QOL 9:00 am Measurement: Differing Perspectives" A (Room M) B (Room N)	8:00 - "Current Issues in 9:00 am QOL Measurement: Differing Perspectives" A (Room M) B (Room N)	
9:00 am Registration Opens (Lounge Forum)	9:00 - Plenary II (Forum) 10:30 am	9:00 - Plenary III (Forum) 10:30 am	8:00 am - Workshop 3 11:00 am (Room N)
10:00 - Satellite Meeting: 11:30 am "Quality of Life Research in Europe and North America: Psycho- metric Health Status Measures versus Utilities/ QALYs" (Room M)	10:30 - Break (Lounge Forum) 11:00 am	10:30 - Break (Lounge Forum) 11:00 am	
12:00 - Posters Up 4:00 pm (Lounge Forum)	10:30 am - Posters Up 5:00 pm (Lounge Forum)	10:30 am - Posters Up 5:00 pm (Lounge Forum)	9:00 am - Workshops 12:00 pm 1, 4, 5, 9, 11 1 (Room M) 4 (Room L) 5 (Room N1-01) 9 (Room O) 11 (Room P)
1:00 - Presidential 1:15 pm Welcome (Forum)	11:00 am - Oral Session II 12:30 pm A (Room M) B (Room O) C (Room P) D (Room N1-01) E (Room N)	11:00 am - Oral Session IV 12:30 pm A (Room O) B (Room M) C (Room L) D (Room N1-01) E (Room N)	
1:15 - Plenary I (Forum) 2:45 pm	12:30 - ISOQOL Business 2:00 pm Meeting/Lunch (Forum)	12:30 - Lunch on your own 2:00 pm (Policy Forum discussion session) (Forum)	12:00 - Lunch 1:00 pm on your own
2:45 - Posters - Meet the 3:15 pm Authors (Lounge Forum)	2:00 - Special Multi-speaker 3:30 pm Sessions A (Room P) B (Room M) C (Room N1-01) D (Room N)	2:00 - Oral Session V 3:30 pm A (Room O) B (Room L) C (Room N1-01) D (Room N) E (Room M)	1:00 - Workshops 4:00 pm 2, 6, 7, 8, 10, 12 2 (Room M) 6 (Room O) 7 (Room P) 8 (Room N) 10 (Room L) 12 (Room N1-01)
3:15 - Posters - 3:45 pm Discussion Session I A (Room P) B (Room M) C (Room O) D (Room N) E (Room N1-01)	3:30 - Posters - Meet the 4:00 pm Authors (Lounge Forum)	3:30 - Posters - Meet the 4:00 pm Authors (concurrent with break) (Lounge Forum)	
3:45 - Break (Lounge Forum) 4:00 pm	4:00 - Posters - Discussion 4:30 pm Session II A (Room N1-01) B (Room M) C (Room N) D (Room O) E (Room P)	4:00 - Posters - Discussion 4:30 pm Session III A (Room L) B (Room M) C (Room N) D (Room N1-01) E (Room O)	
4:00 - Oral Session I 5:30 pm A (Room M) B (Room P) C (Room N) D (Room N1-01) E (Room O)	4:30 - Break (Lounge Forum) 4:45 pm	4:30 - Plenary IV (Forum) 6:00 pm	
5:45 - Welcome Reception 6:45 pm (Park Restaurant)	4:45 - Oral Session III 6:15 pm A (Room P) B (Room M) C (Room N) D (Room O) E (Room N1-01)	6:00 - Awards & Closing 6:15 pm Ceremonies (Forum)	
	6:15 - "Assembly of Nations" 7:15 pm panel discussion (Forum)	7:30 pm Dinner at the Koepelkerk (Renaissance Hotel)	
	7:15 - Satellite Meeting: "Spiritual 8:30 pm Aspects of Quality of Life: Development of an Assessment Module for use in Cross Cultural Settings" (Room N1-01)		

* POSTERS will remain on display in LOUNGE FORUM, even during Poster Discussion Sessions

**SPEAKER READY ROOM (to view slides) will be in PRESS FORUM

ISOQOL 2001 Scientific Program Committee /Leadership

Chairs

Neil Aaronson, PhD, The Netherlands
Mirjam Sprangers, PhD, The Netherlands

Committee Members

Jordi Alonso, MD, PhD, Spain
Rick Berzon, DrPH, USA
Monica Bullinger, PhD, Germany
Ann Cull, PhD, Scotland
Diane Fairclough, DrPH, USA
Gordon Guyatt, MD, Canada
Paul Kind, MPhil, UK
Donald Patrick, PhD, USA
Dennis Revicki, PhD, USA
Carolyn Schwartz, ScD, USA
Marianne Sullivan, PhD, Sweden

President

Ivan Barofsky, PhD, USA

President-Elect

David Osoba, MD, Canada

Immediate Past President

Sharon Wood-Dauphinee, PhD, Canada

Editor of Journal

Neil Aaronson, PhD, The Netherlands

Secretary-Treasurer

Dennis Revicki, PhD, USA

Board Members

Marianne Amir, PhD, Israel
Jordi Alonso, MD, PhD, Spain
Rick Berzon, DrPH, USA
David Cella, PhD, USA
Diane Fairclough, DrPH, USA
Peter Fayers, PhD, Scotland
Shunichi Fukuhara, MD, Japan
Geraldine Padilla, PhD, USA
Mirjam Sprangers, PhD, The Netherlands
Albert Wu, MD, USA

ISOQOL Executive Office

ISOQOL is managed by Degnon Associates
George K. Degnon, CAE-Executive Director
Laura Degnon-Associate Executive Director
Bette Anne German-Association Manager
Sarah-Jane Ziaya-Association Manager

6728 Old McLean Village Drive
McLean, Virginia 22101-3906 USA

Phone: 703-556-9222

Fax: 703-556-8729

Email: info@isoqol.org

www.isoqol.org

Letter from the Chairpersons

Dear Colleague,

On behalf of the International Society for Quality of Life Research (ISOQOL), it is our pleasure to welcome you to the 8th Annual Conference in Amsterdam, the Netherlands, November 7-10, 2001.

This year's meeting has four themes: HRQL in Daily Clinical Practice, Health-related Quality of Life (HRQL) and Mental Health, Psychosocial Modeling of HRQL Outcomes, and HRQL, Happiness, and Social Indicators Research. The program includes, for each theme, two plenary lectures by distinguished colleagues in the field. These state-of-the-art lectures will hopefully serve as a catalyst for lively discussions of these and other topical issues during the course of the meeting. The success of the meeting will, as always, depend largely on the active participation and contribution of HRQL researchers representing a broad spectrum of professional disciplines. We encourage you to participate actively in this meeting.

As in previous years, proffered papers will be presented in both parallel oral sessions and in poster (discussion) sessions, and there will be opportunities to meet with various experts during early morning sessions. Additionally, this year we are offering, for the first time, four special, multi-speaker sessions around the themes: Clinical Significance of HRQL Outcomes, HRQL in Ethnic Minority Cancer Populations, HRQL and the Cognitive Sciences, and Summary Measures of Population Health. These sessions will combine brief presentations with ample opportunity for audience discussion. Yet another addition this year is the morning sessions on "Current Issues in QOL Measurement: Differing Perspectives." On the final day of the meeting, intensive workshops will be held covering a range of conceptual and methodological topics.

Amsterdam is a beautiful, historical and vibrant city, combining old world charm with a contemporary pulse. We are pleased to welcome you to a productive professional meeting and, we hope, an enriching personal experience.

The image shows two handwritten signatures in black ink. The signature on the left is for Neil Aaronson, characterized by a large, stylized 'A' followed by a series of loops. The signature on the right is for Mirjam Sprangers, with a more fluid, cursive style.

Drs. Neil Aaronson and Mirjam Sprangers
Co-Chairs, 8th Annual ISOQOL Conference

General Information

Conference Venue

All plenary, invited, oral and poster sessions and training workshops will take place at the **RAI Congress Center**, Europaplein, The Netherlands; Telephone: +31 (0) 20 549 1949; Fax: +31 (0) 20 549 1949.

Official Language

English, no simultaneous translation.

Registration

Registration fees include: participation in the Conference and access to the poster area, abstracts and program, certificate of attendance, welcome reception on Wednesday, November 7, refreshments/coffee breaks on Thursday and Friday, November 8 and 9, and lunch Thursday, November 8 for those that attend the Business Meeting.

Identification Badges

Identification badges are necessary to enter all sessions.

About ISOQOL

ISOQOL Mission

The scientific study of Quality of Life relevant to health and healthcare is the mission of the International Society for Quality of Life Research (ISOQOL). The Society promotes the rigorous investigation of health-related quality of life measurement from conceptualization to application and practice. ISOQOL fosters the worldwide exchange of information through:

- Scientific Publications
- Educational Outreach
- International Conferences
- Collaborative Support for HRQOL Initiatives

ISOQOL Committees

ISOQOL members are encouraged to serve on the following Society committees and subcommittees:

- Membership
- Communications — Newsletter, Website
- Finances and Budget Planning — Fundraising and Grantwriting
- Education — Scholarship and Training, Policy Guidelines, Conferences and Workshops
- Scientific Program Committee
- Health Policy and Practices

Social Program

The organizer reserves the right to cancel events. In the unlikely event of cancellation, the admission charge will be refunded or transferred to another event chosen by the delegate. No other claim will be accepted.

Opening Reception (Wednesday, November 7, 5:45 - 6:45 pm)

An opening reception will be held at the **RAI Centre, Park Restaurant**. This reception is included with the conference registration fee.

Conference Dinner (Friday, November 9, 7:30 pm)

A conference dinner will be held on Friday, November 9 at the famed **Koepelkerk, Amsterdam (Renaissance Hotel)**, a 15th century copper-domed former Lutheran Church in Downtown Amsterdam. This building has been made famous by an 1885 painting by Vincent van Gogh. While van Gogh was meeting a friend at the Central Station in Amsterdam, he stumbled upon this distinctive building, sat on a bench in front of the station and painted the domed Koepelkerk.

The Koepelkerk is located in the very heart of downtown Amsterdam, between Dam Square and Central Station, and is connected to the Renaissance Amsterdam Hotel. The address of the Koepelkerk, and the Renaissance Amsterdam Hotel, is Kattengat 1, Amsterdam, 1012 SZ, Noord Holland, Netherlands; telephone is +31 (0) 20-621 22 23. **This special event will begin with a reception at 7:30 pm, followed by a sit-down dinner to begin at 8:30 pm.** Please come and share this unique experience with old and new friends in a truly exquisite setting.



The conference dinner is not included in the registration fee; unless ticket was purchased in advance, an additional onsite fee of \$95 US is required. Also, accompanying persons are invited to attend these two events--please see registration form for details and registration fees.

Wednesday, November 7, 2001

Location

9:00 am - 5:30 pm	Registration	Lounge Forum
10:00 - 11:30 am	Satellite Meeting (Description, Page 14) "Quality of Life Research in Europe and North America: Psychometric Health Status Measures versus Utilities/QALYs"/ Dennis Revicki/MEDTAP International	Room M
12:00 - 4:00 pm	Posters on Display	Lounge Forum
1:00 - 1:15 pm	Presidential Welcome	Forum
1:15 - 2:45 pm	Plenary Session I (Description, Page 12) HRQL in Daily Clinical Practice: Michael Baum (UK) and John Ware (USA), Chair: Neil Aaronson (NL)	Forum
2:45 - 3:15 pm	Posters - Meet the Authors	Lounge Forum
3:15 - 3:45 pm	Posters - Discussion Session I A. Contribution of Psychosocial Factors to HRQL; Chair: Hanna McGee B. HRQL in Patients Caregivers; Chair: Sharon Wood-Dauphinee C. Longer Term Outcomes in Cancer Patients; Chair: Andrew Bottomley D. Socio-Economic, Lifestyle Factors and HRQL; Chair: Astrid Wahl E. What Should We Be Measuring to Inform Decision Making/Policy; Chair: Donald Patrick	Room P Room M Room O Room N Room N1-O1
3:45 - 4:00 pm	Break	Lounge Forum
4:00 - 5:30 pm	Oral Session I A. Utility I; Chair: John Brazier B. Oncology I; Chair: Ann Cull C. Score Distribution; Chair: Jane Scott D. Instrument Potpourri; Chair: Kathryn Wyrwich E. QOL in Chronic Disease; Chair: Rick Berzon	Room M Room P Room N Room N1-O1 Room O
5:45 - 6:45 pm	Welcome Reception	Park Restaurant

Thursday, November 8, 2001

Location

8:00 - 9:00 am	"Current Issues in QOL Measurement: Differing Perspectives" A. Different Utility Approaches such as the HUI versus EQ-5D David Feeny (Canada) and Paul Kind (UK) B. Issues around the Use of Generic versus Disease-specific HRQL Questionnaires John Ware (USA) and Gordon Guyatt (USA)	Room M Room N
9:00 - 10:30 am	Plenary Session II (Description, Page 12) HRQL and Mental Health: "Assessments of Quality of Life in Schizophrenia — Have They Fulfilled Their Promise?" Hans Ormel (NL) and George Awad (USA) Chair: William Lenderking (USA)	Forum
10:30 am - 5:00 pm	Posters on Display	Lounge Forum
10:30 - 11:00 am	Break	Lounge Forum
11:00 am -12:30 pm	Oral Session II A. Questionnaire Development; Chair: Carol Ferrans B. Pediatrics; Chair: Jeanne Landgraf C. Respiratory Diseases; Chair: Dennis Revicki D. IRT; Chair: Jacob Bjorner E. Response Shift; Chair: Nancy Mayo	Room M Room O Room P Room N1-O1 Room N
12:30 - 2:00 pm	ISOQOL Business Meeting/Lunch	Forum
2:00 - 3:30 pm	Special Multi-Speaker Sessions A. Clinical Significance of HRQL Outcomes, Chair: Jeff Sloan (USA) Presenters: Gordon Guyatt: Methods Used to Date for Clinical Significance, Monika Bullinger: Group versus Individual Clinical Significance Differences, Jeff Sloan: Single Item versus Summated Scale Scores, Marlene Frost: Patient versus Clinician versus Population Perspective of Clinical Significance, Mirjam Sprangers: Assessing Changes over Time, Tara Symonds: Communicating Clinical Significance to Specific Audiences B. HRQL in Ethnic Minority Cancer Populations, Chair: Claudette Varricchio (USA) Presenters: Carolyn Gotay: QoL Assessment in Cancer Patients of Asian, Pacific Islander and European Ancestry, Carol Ferrans: QoL Index for Black and Hispanic Patients, Frank Baker: Measuring the QoL of Culturally Diverse Cancer Survivors, Carol Moinpour: Using Structural Equation Modeling to Test Measurement Equivalence of English and Spanish Questionnaires, David Cella: An Item Response Theory (IRT) Based Approach to Evaluating QoL Measurement Equivalence Across Languages, Cultures and Literacy Levels C. HRQL and the Cognitive Sciences, Chair: Ivan Barofsky (USA) Presenters: Keith Meadows: Applying Cognitive Aspects of Survey Methods (CASM) to Health-Related Quality of Life Assessment: The Hull Meeting, Paul Beatty: The History and Use of the Single, Self-Assessed Health Status Item in Health Surveys and Clinical Applications, Debbie Collins: Cognitive Interviewing: Methods and Analysis of Data, Ivan Barofsky: The Cognitive Interviewing/Self-Assessed Health Status Protocol: Draft Protocol D. Summary Measures of Population Health: Design and Applications Chair: David Feeny (Canada); Presenters: David Feeny: Designing Preference-Based Summary Measures of Population Health, Jean-Marie Berthelot: Using Summary Measures of Population Health to Make Comparisons Across Time and Space: Results from Population Health Surveys in Canada, Colin D. Mathers: New Methods for Improving the Cross-Population Comparability of Health Status Data for Summary Measures of Population Health. Discussant: Donald L. Patrick	Room P Room M Room N1-O1 Room N
3:30 - 4:00 pm	Posters - Meet the Authors	Lounge Forum
4:00 - 4:30 pm	Posters – Discussion Session II A. Aging, Social Participation and HRQL; Chair: Mogens Groenvold B. Cardiovascular Diseases and HRQL; Chair: Gaietà Permanyer-Miralda C. HRQL in Cancer and HIV Patients; Chair: David Cella D. Interpretation HRQL Scores; Chair: Jeff Sloan E. Methodological Issues in HRQL Measures; Chair: Ron Hays	Room N1-O1 Room M Room N Room O Room P
4:30 - 4:45 pm	Break	Lounge Forum
4:45 - 6:15 pm	Oral Session III A. Cardiology; Chair: Montserrat Ferrer B. Translation/Cross-Cultural Issues; Chair: Patrick Marquis C. Utility II; Chair: Paul Krabbe D. Neurological Diseases; Chair: Ted Ganiats E. Missing Data; Chair: Desmond Curran	Room P Room M Room N Room O Room N1-O1
6:15 - 7:15 pm	Assembly of Nations Panel Discussion: "Patients Rights Relative to Their Quality of Life: National Perspectives" An open forum in which attendees are given the opportunity to discuss issues of concern relative to HRQOL assessment that may be of particular concern for their culture and setting. To start the discussion, Dr. Ivan Barofsky will present "A Declaration of a Patient's Rights Concerning their Quality of Life." He will lead a discussion of the relevance of the "Declaration" to specific cultures and settings.	Forum
7:15 - 8:30 pm	Satellite Meeting (Description, Page 15) "Spiritual Aspects of Quality of Life: Development of an Assessment Module for use in Cross Cultural Settings," Dr. Shekhar Saxena/WHO and Dr. Lynn Underwood/Fetzer	Room N1-O1

Friday, November 9, 2001

Location

8:00 - 9:00 am	"Current Issues in QOL Measurement: Differing Perspectives" A. Approaches to Determine Distribution versus Anchor-based Clinical Meaningfulness Geoff Norman (Canada) and David Osoba (Canada) B. Approaches to Dealing with Missing Data in Longitudinal HRQL Investigations Diane Fairclough (USA) and Koos Zwinderman (NL),	Room M Room N
9:00 - 10:30 am	Plenary Session III (Description, Page 13) Psychosocial Modeling of HRQL Outcomes: Susan Folkman (USA) and Hannah McGee (Ireland) Chair: Carolyn Schwartz (USA)	Forum
10:30 am - 5:00 pm	Posters on Display	Lounge Forum
10:30 - 11:00 am	Break	Lounge Forum
11:00 am -12:30 pm	Oral Session IV A. Oncology II; Chair: Joseph Lipscomb B. Quality of Life in Schizophrenia; Chair: Paul Kind C. Interpreting QOL; Chair: John Ware D. QOL Potpourri; Chair: Carolyn Gotay E. Psychometric Methods; Chair: Peter Fayers	Room O Room M Room L Room N1-O1 Room N
12:30 - 2:00 pm	Lunch on your own/ Policy Forum Discussion Session: "Measurement Issues in Palliative Care: Can We Measure Suffering?"	Forum
2:00 - 3:30 pm	Oral Session V A. Musculoskeletal Disease; Chair: Marianne Sullivan B. Psychological Aspects; Chair: Carol Moynour C. Predicting Outcomes; Chair: Geri Padilla D. Assessing Change; Chair: Tara Symonds E. Mixed Methods; Chair: Madeleine King	Room O Room L Room N1-O1 Room N Room M
3:30 - 4:00 pm	Posters - Meet the Authors (concurrent with break)	Lounge Forum
4:00 - 4:30 pm	Posters - Discussion Session III A. Analytical Methods for HRQL Measurement; Chair: Thomas Kohlmann B. Cross Cultural Research; Chair: Michael Herdman C. Endocrine Diseases and HRQL; Chair: SD Mathias D. HIV/AIDS and HRQL; Chair: Albert Wu E. Mental Health and HRQL; Chair: Hans Ormel	Room L Room M Room N Room N1-O1 Room O
4:30 - 6:00 pm	Plenary Session IV (Description, Page 13) HRQL, Happiness and Social Indicators Research: Alex Michalos (USA) and Ruut Veenhoven (NL) Chair: Mirjam Sprangers (NL)	Forum
6:00 - 6:15 pm	Awards & Closing Ceremonies	Forum
7:30 pm	Dinner at the Koepelkerk	Renaissance Hotel

Saturday, November 10, 2001

Location

Special Time:

8:00 am - 11:00 am **Workshop 3 (see page 16 for description)**

3 Introduction to Population Health: Pennifer Erickson, PhD Room N

9:00 am - 12:00 pm **Workshops 1, 4, 5, 9, 11 (see page 16-17 for descriptions)**

1 Quality of Life Assessment: Introduction and Overview: Sharon Wood-Dauphinee, PhD, PT Room M

4 Assessing Clinical Significance for QOL Measurement: Jeff Sloan, PhD and Tara Symonds, PhD Room L

5 Introduction to Rasch Analysis: Alan Tennant, PhD and Luis Prieto PhD Room N1-O1

9 Introduction to Health State Preference/Utility Assessment: Dennis Revicki, PhD, Room O

Mary Kay Margolis, MHA, MPH and Les Lenart, MD

11 Technical Aspects of Questionnaire Development: Hanne Thorsen, PhD Room P

12:00 - 1:00 pm Lunch on your own

1:00 pm - 4:00 pm **Workshops 2, 6, 7, 8, 10, 12 (see page 18-19 for descriptions)**

2 QL in Economic Studies: John Brazier, PhD Room M

6 Children and Youth: Monika Bullinger, PhD and Ulrike Ravens-Sieberer, PhD Room O

7 Imputation for Non-randomly Missing QOL Data in Longitudinal Studies: Diane Fairclough, DrPH Room P

8 Cross Cultural Issues in HRQL: Francis Guilleme, MD, PhD Room N

10 Can We Believe the Patients? Interpreting HRQL Data: Room L

Marianne Sullivan, PhD and Lars-Olaf Persson, PhD

12 Modern Psychometric Methods, Adaptive Testing, Dynamic Health Assessment, and the Internet: Room N1-O1

John Ware, Jr., PhD, Jakob Bjorner, MD, PhD and Mark Kosinski MS

Please note: These workshops require additional fees and registration is required.

Plenary Session I: Wednesday, November 7 (1:00 - 2:45 pm)**Forum**HRQL in Daily Clinical Practice, *Chair: Neil Aaronson (NL)***The Humane Practice of Evidence Based Medicine (EBM)***Michael Baum, University College London, London (UK)*

RCTs and overview analyses provide the best evidence of efficacy of treatment, yet treatment decisions alone cannot be based on the p value alone. Active experience with recent cancer trials of the meta-analysis will illustrate the human face of EBM.

The Status of Health Assessment in Clinical Practice 2001: Are We Measuring the Right Concepts With the Wrong Methods?

John E. Ware, Jr., Chief Science Officer and CEO, QualityMetric, Inc., Executive Director, Health Assessment Lab (HAL), Research Professor, Tufts University School of Medicine, Adjunct Professor, Harvard School of Public Health, Lincoln, RI (USA)

The usefulness of advances in health status assessment may be the greatest in everyday clinical practice. However, the challenges are also greatest in the clinic because of the more stringent requirements of measurement at the individual patient level. Changes in the way health is conceptualized along with changes in the way data are collected and results are aggregated and displayed are likely to make health status assessments more useful to clinicians. In this presentation, Dr Ware identifies areas of measurement research in which the field has gotten some things right and some things wrong and offers his views on their implications for applications of health status assessment to clinical practice.

Plenary Session II: Thursday, November 8 (9:00 - 10:30 am)**Forum**

HRQL and Mental Health: "Assessments of Quality of Life in Schizophrenia — Have They Fulfilled Their Promise?" *Chair: William Lenderking (USA)*

The Impact of Depression and Anxiety on Health-Related Quality of Life*Hans Ormel, University of Groningen, Groningen (NL)*

Recent studies have shown that mental disorders exact substantial personal costs from individuals who experience them as well as from their families and communities in terms of finances, role functioning and quality of life. In addition, mental disorders which are co-morbid to physical disorders appear to worsen the prognosis of physical disorders. An overview of the impact of mental ill health on quality of life will be presented and possible mediators of the impact will be discussed. The focus will be on the emotional disorders (Depression and anxiety).

Health Related Quality of Life Assessments in Schizophrenia—Have they Fulfilled their Promise?*George Awad, Penn State University, University Park, PA (USA)*

Schizophrenia is a serious mental illness that impacts on significant mental functions such as thinking, feeling, communications and general behavior. It requires long-term psychosocial support as well as medications that often have significant side effects. Health Related Quality of Life (HRQOL) is an important construct that captures well the interaction and impact of the illness, its treatment and the psychological functioning of the individual. In spite of the challenges in measuring HRQOL in schizophrenia, adequate methodology already exists and several good studies have frequently demonstrated the significantly compromised HRQOL. The current major challenges include the lack of integration of HRQOL, measurements in the clinical management plans as well as a lack of interest in researching basic aspects of HRQOL beyond measurement.

Plenary Session III: Friday, November 9 (9:00 - 10:30 am)**Forum****Psychosocial Modeling of HRQL Outcomes, Chair: Carolyn Schwartz (USA)****Coping, Emotion and Quality of Life****Susan Folkman, Osher Center for Integrative Medicine, University of California, San Francisco, CA (USA)**

Theories are useful. They help systematize research by suggesting cause-effect relationships and processes that may mediate those relationships. My own work is primarily in the area of psychological stress and the coping process. Our theories are more like a series of well-reasoned hypotheses compared, for example, to theories of physics, which are more like laws. This is an important difference, because it means our theories are more likely to be subject to revision, based on research and clinical findings. A case in point is the way in which stress and coping theory has traditionally been focused on the regulation of distress. Findings from a growing body of research suggests that the emphasis placed on the regulation of distress has led to an incomplete understanding of fundamental questions about how people get through very difficult circumstances. This presentation will focus on what researchers are learning about the role of positive emotion in the stress process including its co-occurrence with distress, the functional significance of positive emotions, the coping processes that support positive emotions, and the ways in which these coping processes differ from those that regulate distress. The new findings and revised theory have important implications for understanding subjective aspects of Quality of Life.

Psychological Influences on Quality of Life Outcomes**Hanna McGee, Royal College of Surgeons, Dublin (IRL)**

Health-related quality of life judgements by individuals are made in the context of expectations and comparisons. These may be established through perceptions of particular illnesses; comparisons with others similar in health condition or features salient for the individual, eg age; or comparisons with previous or expected self. The presentation illustrates these influences in various studies and discusses implications for quality of life research.

Plenary Session IV: Friday, November 9 (4:30 - 6:00 pm)**Forum****HRQL, Happiness and Social indicators Research, Chair: Mirjam Sprangers (NL)****Social Indicators Research and Health-Related QOL Research****Alex Michalos, University of Northern British Columbia, Prince George, BC (Canada)**

The aim of this essay is to build a bridge between two intersecting areas of research, social indicators research on the one hand and health-related quality of life research on the other. The first substantive section of the paper introduces key concepts and definitions in the social indicators research tradition, eg, social indicators, positive, negative, input and output indicators, social reports and quality of life. After that, there is a section reviewing some historical origins and motives of social indicators researchers, beginning roughly with Jeremy Bentham's 'felicific calculus' and ending with the search for a comprehensive accounting scheme capable of measuring the quality of human existence with social, economic and environmental indicators.

Research on HQOL and Happiness**Ruut Veenhoven, Erasmus University, Rotterdam (NL)**

Quality-of-life research is highly segmented. The biggest segments are health related quality of life research (HQOL) and social indicators research. Smaller segments are the psycho-physiology of sensory pleasure and the interdisciplinary study of happiness. This paper compares the clusters of HQOL and happiness studies. It explains the differences and pleas for concurrence. Both these research traditions root in the same ground, both emerged in the social climate of the 1970s and both pair utilitarian philosophy with empirical questionnaire research. The difference is largely in the conceptualization of quality of life. HQOL research covers many different qualities of life with a focus on performance status. Happiness research is concerned with the enjoyment of life as a whole. This difference is traced back to user demands and options in psychological measurement. Since HQOL scales are multi-dimensional, they could easily include items on happiness. Some do indeed, but the information yielded with these items gets often lost in amorph 'emotion' subscales. Most HQOL inventories do not assess happiness at all. There are several reasons reasons for this practice: firstly qualms about the value of happiness, secondly doubts about its measurability and thirdly disenchantment with observed relations with health. These objections are reconsidered in the light of the current state of knowledge and largely discarded. It is concluded that we can get a better view on the consequences of illness and treatment by assessing impact on happiness, in particular on hedonic level of affect. QALY's can best be expressed in years lived happily (HLY's). Inclusion of items on happiness in HQOL scales will also contribute to a better understanding of happiness.

Satellite Meeting I: Wednesday, November 7 (10:00 - 11:30 am)**Room M****Quality of Life Research in Europe and North America: Psychometric Health Status Measures versus Utilities/QALYs**

Chairpersons: *Dennis Revicki, MEDTAP International, Bethesda, MD (USA) and Agota Szende, MEDTAP International, Jisp (NL)*

Presenters: *Alan Williams, York University, York, UK; David Cella, Northwestern University, Chicago, IL (USA), David Feeny, University of Alberta, Edmonton, AB (CA), Ingela Wiklund, AstraZeneca, Moelndal (SWE)*

Discussant: *Dennis Revicki, MEDTAP International, Bethesda, MD (USA)*

The overall objective of this session is to summarize the health status assessment and health state preference/utility approaches to measuring patient health outcomes. Clearly, no one health outcome measure or technique is best for all study applications and each measurement method has associated disadvantages and advantages. Emphasis will be placed on the methodological and measurement aspects of these techniques and will include the advantages and disadvantages of these health outcomes for different applications.

There will be four 15 minute presentations, a 10 minute discussant comment, and then 20-30 minutes for panel discussion and audience questions and participation. The intent is to have an informative and lively discussion of these measurement approaches, and international representation on these methods and applications in health-related quality of life research.

Satellite Meeting II: Thursday, November 8 (7:15 - 8:30 pm)

Room N1-O1

Spiritual, Religious and Personal Belief Aspects of Quality of Life: Results of a Cross-Cultural Study

Chairpersons: *Shekhar Saxena, World Health Organisation and All India Institute of Medical Sciences, New Delhi, India and Lynn Underwood, Fetzer Institute, Kalamazoo, MI (USA)*

Presenters: *Lynn Underwood, Fetzer Institute, Kalamazoo, MI (USA), Shekhar Saxena, World Health Organisation and All India Institute of Medical Sciences, New Delhi, India, Kate O'Connell Marcelo Fleck, Dr. Omolo*

Discussant: *Dr. Lynn Underwood, Fetzer Institute, Kalamazoo, MI (USA)*

This symposium will present recent work done in the area of spirituality, religiousness and personal beliefs (SRPB) and their relation to quality of life (QoL) and health as part of the World Health Organisations Quality of Life (WHOQOL) project. A module to assess QoL within the domain of SRPB will be presented. The work has been conducted in cross-cultural settings involving persons from diverse spiritual and religious backgrounds.

The three phases of this project are (1) Findings from the expert group which generated additional facets and definitions for the assessment of SRPB. (2) The results of focus groups from 12 countries which explored the adequacy of these concepts to quality of life and suggested items for inclusion into a pilot module. (3) The analysis of 4000 cases of WHOQOL-100 and the 115 piloted SRPB items collected from 17 diverse cross cultural sites. The psychometric properties will also be presented. In addition, two sites will provide insight findings from their centre. Implications and future research will also be presented. The outcomes of this symposium will be (1) Increased awareness of SRPB as an integral component of QoL (2) Psychometric information on SRPB modules of the WHOQOL (3) Recommendations for use of SRPB module in clinical work and further research.

Structure of Symposium:

Spirituality, Quality of Life and Health, *Dr. Lynn Underwood*

Exploration of the relationship between concepts and measurement, examples and findings of previous research in this area, value of research into spirituality, quality of life and health (10 mins.)

Qualitative Phase Results, *Dr. Shekhar Saxena*

Includes expert review, focus groups and development of facets and their definitions (10 mins.)

Quantitative Phase Results, *Ms. Kate O'Connell*

Result of pilot analysis, preliminary psychometric properties of field test instrument, relationship between SRPB facets and QoL in brief (10 mins.)

WHOQOL SRPB Module, *Dr. Shekhar Saxena*

(5 mins.)

Implications of Research, *TBA*

Likely uses and future directions (5 mins.)

Viewpoints from Brazilian Site, *Dr. Marcelo Fleck*

Presenting findings at a country level (10 mins.)

View points from Kenyan Site, *Dr. Omolo*

Presenting findings at a country level (10 mins.)

Discussion (15 mins.).

Workshops I: Saturday, November 10 (9:00 am-12:00 pm*)**Location****1. Quality of Life Assessment: Introduction and Overview, *Sharon Wood-Dauphinee, PhD, PT* Room M**

In this introductory workshop the following topics will be presented: conceptualization of the quality of life (QoL) construct; why, when, how, and by whom should QoL be assessed, classification of QoL measures, modes of administering QoL measures, criteria for selecting QoL measures for clinical practice and research, the relationship between study design and QoL information, and issues related to analysis, interpretation and culture in QoL studies. A generic and a disease-specific measure will be completed by attendees on behalf of a simulated case history.

After participation in the workshop the attendee should be able to:

- a. describe what is meant by the terms quality of life and health-related quality of life
- b. discuss the value of QoL assessment
- c. discuss the circumstances in which QoL should be assessed
- d. classify QoL measures
- e. list ways of administering QoL measures and the strengths and weaknesses of each
- f. list the criteria for selecting QoL measures for different purposes
- g. describe the different kinds of information obtainable from different study designs
- h. describe issues related to analyzing and interpreting QoL data
- i. discuss the relationship between culture and QoL assessment

*** Workshop 3, Introduction to Population Health, will take place from 8:00 - 11:00 am:**

3. Introduction to Population Health, *Pennifer Erickson, PhD* Room N

This workshop introduces basic concepts, principles, and methods for assessing the health status and quality of life of populations, rather than of selected groups of individuals that are defined by illness or high-risk characteristics. Thus, the discussion focusses on conceptual and methodological issues involved in describing, explaining, predicting and monitoring population health. To illustrate these uses of population health measures, various indicators, sources of these data, and methods of analysis and interpretation will be described and evaluated. The presentation will include examples from a wide range of sources. Specific focus throughout the workshop will be on measures of health-related quality of life, including respondent reports of activity limitation, perceived health, and quality-adjusted life years that are appropriate for assessing population health.

At the end of the workshop, participants should be able to:

- specify a conceptual framework for measuring population health and its determinants
- select methods for assessing population health that are appropriate for the specified framework
- identify relevant types of data and their sources
- analyze levels of and changes in health status and quality of life and present these findings for input into the decision-making process

4. Assessing Clinical Significance for QOL Measurement, *Jeff Sloan, PhD and Tara Symonds, PhD* Room L

This workshop will begin with a discussion of what is meant by the concept of "clinical significance." A review of the most widely known assessment of clinical significance - Minimum Clinically Important Difference—will be presented with some ideas for moving this area forward. A newer approach - the Empirical Rule of Effect Size—will be discussed in detail as a useful additional means of determining the clinical significance of QoL results.

Examples of how to assess clinical significance will be used. The workshop will also provide some guidance on how to design studies to assess clinical significance and then how to report this information. Although no one technique for assessing clinical significance is proposed there is a pulling together of what we currently know about what constitutes a clinically significant change using a variety of techniques, which allows a 'rule of thumb' to be recommended for use in the absence of any other appropriate data for calculating clinical significance directly.

5. Introduction to Rasch Analysis, *Alan Tennant, PhD and Luis Prieto, PhD* Room N1-O1

This workshop is an introduction to the basic concepts of measurement, including unidimensionality, item bias, scaling properties, and their link to the traditional psychometrics of reliability, validity and responsiveness. The presentation will explore an introduction to Rasch analysis and its one stop approach to examination of a wide variety of measurement issues. It will also cover a worked example of fitting data from the Nottingham Health Profile to the Rasch model. The workshop will also include a discussion of issues arising from the application of IRT.

Delegates can expect to learn from the workshop:

- A basic understanding of the principles of measurement
- A basic understanding of what IRT is trying to achieve
- What to look for in published papers which use IRT
- Support links for those who wish to do Rasch analysis

Workshops I: Saturday, November 10 (9:00 am-12:00 pm) Location

9. Introduction to Health State Preference/Utility Assessment

Room O

Dennis Revicki, PhD, Mary Kay Margolis, MHA, MPH and Les Lenart, MD

This workshop provides an introduction to the theory and the direct and indirect methods of health state preference and utility assessment.

It includes a basic overview of the rating scale, standard gamble, time trade-off, and multi-attribute techniques. The presentation includes a discussion of important issues associated with developing health state preference/utility measures and selecting a scaling method. We will introduce and summarize critical issues associated with preference/utility measurement including population effects, contextual effects, cognitive processing, and beliefs and attitudes. Examples will be provided of several techniques for measuring preferences/utilities. A computerized standard gamble exercise will be completed and compared to alternative methods of measuring preferences/utilities.

After completing this workshop, participants will be able to:

- Understand the basic principles of preference/utility measurement
- Identify frequently used methods for measuring preferences/utilities
- Understand the strengths and limitations of preference/utility measures in evaluating health outcomes

11. Technical Aspects of Questionnaire Development, *Hanne Thorsen, PhD*

Room P

In recent years there have been major advances in methods for gathering questionnaire content designed to assess some form of subjective health status, for example, the use of face-to-face interviews with representatives of patient groups and focus groups. However, there has been a decline in the amount of attention paid to the more detailed aspects of questionnaire design such as the instructions to respondents, the format, layout and wording of items and interpretation of items by different groups. Also the choice of user friendly response options seems to be a topic which is seldom discussed. All of these can have profound effects on responses and missing data. It is suggested that too much emphasis has been placed upon quantitative methods for the establishment of validity and not enough on qualitative work with individuals.

The emphasis of the workshop will be on ensuring "respondent friendliness" of questionnaires, an issue that is often neglected. The participants will be asked to complete several pre-existing questionnaires.

Based on this exercise the following topics will be raised and discussed after short introductions by the lecturer and some other members of the EQUAL group.

- General introduction to technical aspects of questionnaire developments:
- Generation of items from different sources;
- Interpretation of questionnaire items;
- The influence of the title of a questionnaire on respondents willingness to complete;
- Questionnaire layout & appearance; effects on responding;
- Layout of response option(s) and ease of completion;
- Advantages and disadvantages of different kinds of response options.

Workshops II: Saturday, November 10 (1:00 pm - 4:00 pm) Location

2. QL in Economic Studies, *John Brazier, PhD*

Room M

Instruments for assessing health related quality of life (HRQL) are increasingly being used as end points in clinical trials. An important stimulus for the use of HRQL instruments has been the increasing pressure on health care budgets throughout the world. These same pressures have also lead Governments and other health funders to examine the cost-effectiveness of new developments (for example, through agencies such as NICE in the UK). Whilst enhancements to HRQL is an important benefit of health, many of the instruments used to assess these and related concepts have not been designed for use in economic evaluation and are not able to address the question cost-effectiveness. At the same time, there has been the development in health economics of a single measure of health benefit called the quality adjusted life year (QALY).

This workshop is concerned with the use of HRQL measures in economic evaluation, including their use in deriving the health state values required to calculate QALYs. It is designed to provide a practical introduction. It is divided into four parts: (1.) The limitations of using HRQL measure in economic evaluation This introduces the potential pitfalls of using non-preference based measures of HRQL life (such as the SF-36, WOMAC, and EORTC) in economic evaluation and their limitations; (2.) Methods for adapting non-preference-based measures for use in economic evaluation This section includes a description of the pros and cons of different practical methods for the adapting non-preference-based measures for use in economic evaluation, including arbitrary weighting, verbal mapping, estimation of exchange rates and the estimation of preferences from special valuation studies; (3.) A review of existing preference-based measures (e.g. HUI-III and EQ-5D) This review will examine the descriptive, valuation and use of these measures in detail; (4.) Estimation of a preference-based measure of health from the SF-36 This session provides an update on the results of a valuation survey of 836 members of the general population where respondents were asked to value a set of health states defined by the SF-6D (derived from the SF-36) using standard gamble. This workshop includes a wide range of applications of the new preference-based algorithm to a range of patient groups in order to examine their abilities to discriminate between groups and sensitivity to change over time. It also considers future development of this method and its application to condition specific measures.

Learning objectives: Understand the limitations of HRQL measures in economic evaluation; appreciate the pros and cons of different methods to obtaining a health state values from HRQL measures; be able to review the appropriateness of existing preference-based measures for an economic study. This course assumes a basic knowledge HRQL measurement and preference-elicitation techniques. Students unfamiliar with the latter are recommended to attend the ISOQOL workshop introducing Health State Preference/Utility Assessment.

6. Children and Youth, *Monika Bullinger, PhD and Ulrike Ravens-Sieberer, PhD*

Room O

While quality of life research in adults has progressed substantially over the past 15 years, health-related quality of life of children has only recently been addressed. QOL research in children is important because children can be confronted with disease and treatment as patients. It is important to know how children feel and how treatment can be optimised. Also, children can suffer substantial strain from diseases in other family members. Lastly, epidemiological research has so far neglected living conditions that might be detrimental to the health-related quality of life of children; exceptions are a few studies published in the area of public health and clinical psychology.

Reflections on how to assess quality of life of children also bear on the focus of such assessment. Basically, there are three dimensions to quality of life assessment in children. The first concerns the specificity of assessment intended. Disease specific assessments aim at substantial and comprehensive analyses of the health-related quality of life of children suffering from specific chronic conditions. In contrast, generic assessment focuses on relevant aspects of children's perceived health independent of the actual medical condition of the child. A second dimension concerns the type of assessment intended, i.e. the use of questionnaires or interviews or of observational methods. The questionnaire method is usually favoured for the economy of its use, as well as the psychometric quality criteria, which include reliability, validity and sensitivity. Finally, and most critically, is the dimension of who assesses the quality of life of children. In general, expert ratings, that is external observation of children's quality of life, have been favoured; however, the essence of quality of life assessment is the self rating method. The question of whether and at which age children are able to report on their feelings has been intensively discussed, and principally deemed realisable under the condition that an instrument corresponding to the child's abilities can be chosen.

This workshop reviews the state of the art of quality of life assessment in children/adolescents as it relates to the underlying concepts the instruments available, and application in research and practice. Presentation will include a comprehensive literature review, demonstration of instruments as well as their computer assisted versions, and a thorough evaluation of the evidence of their use in clinical studies and patient care. Generic as well as disease-specific measures (e.g. asthma, diabetes, epilepsy, rheumatoid arthritis) will be focussed on. The material presented will profit from results of recent discussions within an international expert group, collaborating in two large EC funded projects on "Quality of Life of Children with Disabilities (DISABKIDS)" and "Assessing Health Related Quality of Life in Representative Samples of European Children (KIDSCREEN)."

7. Imputation for Non-randomly Missing QOL Data in Longitudinal Studies

Room P

Diane Fairclough, DrPH

This course will examine methods of imputation for longitudinal studies when the missing HRQOL assessments are believed to be non-ignorable. It includes a brief review of simple imputation methods (e.g. mean substitution, LVCF) and their limitations. The focus of the course will be on multiple imputation methods such as Approximate Bayesian Bootstrap (ABB), explicit regression, closest predictor and MCMC (Multiple Chain Monte Carlo) for multivariate normal data. We will discuss the strengths and weaknesses of these methods in the context of longitudinal studies with non-ignorable (NMAR) missing data. The workshop will include hands-on experience with selected techniques (participants are encouraged to bring a hand calculator).

After completing this workshop, participants will be able to:

- a. Understand the limitations of simple imputation and the motivation for multiple imputation techniques
- b. Identify settings where multiple imputation is appropriate and will facilitate the analysis of longitudinal studies with missing HRQOL data
- c. Identify which imputation techniques that are suitable for missing data in longitudinal studies
- d. Perform analyses of multiply imputed data

Participants should have some experience with multivariate analysis for longitudinal data or repeated measures including MANOVA and mixed-effects models.

Workshops II: Saturday, November 10 (1:00 pm - 4:00 pm) Location

8. Cross Cultural Issues in HRQL, *Francis Guilleme, MD, PhD*

Room N

Interpreting HRQL outcomes from multi-national trials, comparing HRQL outcomes across different health care systems and various populations, developing trans-cultural research using subjective individual measurements requires to have instruments measuring equivalently the same HRQL concept. However, it may express differently in each cultural context. This workshop will provide a review of the various methods used to develop new instruments internationally, and to translate and adapt existing measures. Pitfalls and limitations will be pointed out. Guidelines will be provided to conduct such cross-cultural adaptation in a standardized manner, and some training will be offered to participants interactively, based on experiences gained from different settings and various fields of research.

Workshop Outline

- a. Presentation of the topic
- b. Identification of native English and Non English speaking participants
- c. Separation in sub-groups (as many as needed with maximum 10 people per group mixing English and Non English members at least 2 sub-groups)

Training phase 1: Each group gets a set of source items (sampled from a variety of HRQL questionnaires: 2 sets are prepared in advance) Non English group members translate in their own language: firstly without communication with English members, secondly with communication;

Training phase 2: 1. Plenary presentation of the problems encountered will be helpful to highlight difficulties at the translation step; 2. Specific problems to back-translation step will be pointed out; 3. Guidelines will be presented and discussed with participants

10. Can We Believe the Patients? Interpreting HRQL Data

Room L

Marianne Sullivan, PhD and Lars-Olaf Persson, PhD

Interpreting HRQL results from clinical studies is oftentimes perplexing and complex. Patient groups with severe and/or chronic conditions often do not report worse health status than healthy respondents and clinically effective treatments/ interventions frequently do not improve HRQL, particularly mental and psychological health status. Such seemingly counterintuitive results lead clinicians to either question the reliability of patient reports, the validity and/or responsiveness of the HRQL instruments used, or the value of the interventions performed. Or are there other ways to explain the results?

The major questions that will be discussed at the workshop are:

- Can we believe the patients?
- To what extent are patient reports related to behavioural and/ or clinical data?
- Can we integrate patient-based information in medical decision-making?

We will provide illustrative research examples and interpret the results from a psychological point of view. In particular, we will discuss the role of personality traits, coping and illusionary thinking in HRQL ratings. We will also challenge the traditional view that treatments improving lab tests and other surrogate measures must also benefit the patient's HRQL. A recent evidence-based review will be presented where HRQL was for the first time used as one of four primary outcome measures.

Participants will obtain:

- Introduction to psychological interpretation models that may help in understanding HRQL results;
- Concrete examples from studies illustrating the phenomena discussed;
- Arguments for integrating patient-based information in medical decision-making.

12. Modern Psychometric Methods, Adaptive Testing, Dynamic Health Assessment, and the Internet

Room N1-01

John Ware, Jr., PhD, Jakob Bjorner, MD, PhD and Mark Kosinski, MS

This workshop covers advances in methods for monitoring health outcomes based on item response theory, the logic of computerized dynamic methods of data collection and processing, and the connectivity made possible by the Internet. The advantages of scoring health status on a standard metric, regardless of assessment method, will be demonstrated across different applications, including: (a) population health monitoring; (b) clinical trials and outcomes research; and (c) screening and monitoring individual patients in everyday clinical practice.

Poster Sessions

Each poster is assigned a specific number. This number can be found in the program just before the abstract title. Each poster station will be numbered—please mount your poster at the correct poster number/station. All authors are requested to be at their posters during the “Meet the Author” session for the day in which their posters are being displayed. This will be followed by poster discussion sessions for selected abstracts. The Poster Discussion Sessions have been designed to allow for more interactive discussion of selected posters. Poster sessions will be held in **Lounge Forum**.

Please view posters prior to going to poster discussion sessions. Posters will not be re-displayed in poster discussion rooms.

Scientific Awards

ISOQOL presents five Annual Awards honoring individuals in three different categories. ISOQOL is committed to promoting excellence in quality of life research; therefore, again this year, the **Young Investigators’ Awards** will be presented during the conference closing plenary ceremony. These awards recognize the best overall oral and poster presentations made by individuals under age 35.

New in 2001, **The President’s Award** will be given to someone who has advanced QLR and has made outstanding contributions to ISOQOL in one or more of the following areas: education of professionals, patients or lay individuals about HRQOL’s value; promotion or execution of HRQOL or other scholarly activities; facilitating or furthering policy initiatives that have an impact on HRQOL. The awardee will be selected by the Executive Committee and endorsed by the Board. Individuals who excel in one or more of the named areas may be nominated by a colleague, student or friend. This year's President's Award will be presented in the Closing Ceremony, which takes place on Friday, November 9, from 6:00 - 6:15 pm.

Oral I: Wednesday, November 7 (4:00 - 5:30 pm)**Location****A. Utility I****Room M****Chair: John Brazier****1/ COMPARING FIVE METHODS OF UTILITY ASSESSMENT ACROSS DIFFERENT DISEASE STATES**

Patrick W. Sullivan, Michael B. Nichol, Denise R. Globe, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA

2/ COMPARISON OF THREE MEASURES OF UTILITY WITHIN DIVERSE ETHNIC GROUPS

Denise R. Globe, Joanne Wu, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA

3/ CAN UTILITY-WEIGHTED HRQOL ESTIMATES CAPTURE HEALTH EFFECTS OF QI FOR DEPRESSION?

Cathy Sherbourne, Health Program, RAND, Santa Monica, CA

4/ CONVERGENT VALIDITY OF SF-36 UTILITIES IN PATIENTS WITH INTERMITTENT CLAUDICATION

Johanna L. Bosch, Decision Analysis and Technology Assessment Group, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Molly T. Beinfeld, Elkan F. Halpern, Scott G. Gazelle, DATA Group, MGH, HMS, Boston, MA

5/ ESTIMATION AND VALIDATION OF DERIVED UTILITY SCORES FROM THE SF-36 IN LUNG TRANSPLANT PATIENTS

Francis S. Lobo, Cynthia R. Gross, Barbara Mathees, University of Minnesota, Minneapolis, MN

B. Oncology I**Room P****Chair: Ann Cull****6/ CANCER PATIENTS' PREFERENCES FOR COMMUNICATING QUALITY OF LIFE INFORMATION: A QUALITATIVE STUDY**

Michael D. Brundage, Radiation Oncology Research Unit, Queen's University, Kingston, ON, Canada; Anne Leis, Psychology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; Andrea Bezzak, Radiation Oncology, University of Toronto, Toronto, ON, Canada; Deb Feldman-Stewart, Radiation Oncology Research Unit, Queen's University, Kingston, ON, Canada; Lesley Degner, Nursing, University of Manitoba, Winnipeg, Manitoba, Canada; Karima Velji, Radiation Oncology, University of Toronto, Toronto, ON, Canada; Dongsheng Tu, Joseph Pater, NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; Paul Ritvo, Family Physicians Research Section, SCRN, University of Toronto, Toronto, ON, Canada

7/ DOCTOR-PATIENT COMMUNICATION ABOUT HRQL ISSUES IN DAILY CLINICAL ONCOLOGY PRACTICE

Symone B. Detmar, Child Health Division, TNO Prevention and Health, Leiden, The Netherlands; Neil K. Aaronson, Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands

8/ PHYSICIAN'S COMMUNICATION STYLE, CONSULTATION TIME AND PATIENT'S PARTICIPATION IN ONCOLOGY SETTINGS

Tomoko Takayama, Yoshihiko Yamazaki, Health Sociology, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Atsushi Fukuuchi, Tsunehiro Nishi, Mitsui Memorial Hospital, Chiyoda-ku, Tokyo, Japan; Masakazu Toi, Katsumasa Kuroi, Kazuo Hayashi, Tokyo Metropolitan Komagome Hospital, Bunkyo-ku, Tokyo, Japan

9/ MEASURING QUALITY OF LIFE IN CLINICAL PRACTICE IMPROVED PATIENT SATISFACTION

Fabienne Empereur, Epidemiologie Evaluation Cliniques, Chu de Nancy, Nancy, France; Emmanuel Desandes, Recherche Clinique, Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France; Francis Guillemin, Isabelle Leonard, Sylvie Klein, Serge Briancon, Epidemiologie Evaluation Cliniques, Chu de Nancy, Nancy, France

10/ THE IMPACT OF SHARED TREATMENT DECISION-MAKING ON QUALITY OF LIFE IN WOMEN WITH BREAST CANCER

Ann F. Chou, Health Services and Policy Analysis, Joan R. Bloom, School of Public Health, University of California at Berkeley, Berkeley, CA

C. Score Distribution**Room N****Chair: Jane Scott****11/ EVALUATING THE LATENT DISTRIBUTION IN IRT MODELS OF HRQOL DATA**

Jakob B. Bjorner, Department of Work Psychology and Sociology, National Institute of Occupational Health, Copenhagen, Denmark

12/ CAN THE CAMCOG MEASURE OF COGNITIVE STATUS BE MODELLED USING ITEM RESPONSE THEORY?

Rob J. de Haan, Rebecca Holman, Robert Lindeboom, B. Schmand, Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, The Netherlands

13/ COMPARISON OF THREE DIFFERENT STATISTICAL ANALYSIS STRATEGIES FOR ANALYZING SEATTLE ANGINA QUESTIONNAIRE QUALITY OF LIFE DATA

Colleen Norris, APPROACH Project, Edmonton, AB, Canada; W. Ghali, University of Calgary, Calgary, AB, Canada; D. Saunders, University of Alberta, Edmonton, AB, Canada; R. Brant, University of Calgary, Calgary, AB, Canada; D. Galbraith, Foothills Hospital, Calgary, AB, Canada; P. Faris, University of Calgary, Calgary, AB, Canada; M. Knudtson, Foothills Hospital, Calgary, AB, Canada

14/ THE AMSTERDAM LINEAR DISABILITY SCORE PROJECT (ALDS): DEVELOPMENT AND CALIBRATION RESULTS OF AN ADL-ITEMBANK

Robert Lindeboom, Rebecca Holman, M. Vermeulen, Rob de Haan, Clinical Epidemiology and Biostatistics, Academic Medical Centre, KEB, Amsterdam, The Netherlands

15/ THE NOTTINGHAM HEALTH PROFILE IN POPULATION RESEARCH: FLOOR EFFECTS PERSIST IN GROUPS WITH IMPAIRED HEALTH

Sonja Boehmer, Thomas Kohlmann, Institute for Social Medicine, Medical University of Luebeck, Luebeck, Germany

Withdrawn

D. Instrument Potpourri**Room N1-O1****Chair: Kathryn Wyrwich**

16/ USING ITEM RESPONSE THEORY TO SHORTEN THE LENGTH OF SCALES IN A QUESTIONNAIRE FOR PALLIATIVE CARE. AN EORTC QUALITY OF LIFE GROUP STUDY

Mogens Groenvold, Morten A. Petersen, Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen NV, Denmark; Jakob B. Bjorner, National Institute of Occupational Health, Copenhagen OE, Denmark

17/ A COMPARISON OF ANALYSIS METHODS FOR HEALTH-RELATED QUALITY-OF-LIFE (HRQL) OUTCOMES OF CLINICAL TRIALS

David Osoba, QOL Consulting, West Vancouver, BC, Canada; Grazyna Lieberman, Biostatistics, Genentech, Inc., South San Francisco, CA

18/ THE GOAL INTERFERENCE SCALE: EVALUATION OF A NEW INDIVIDUALIZED HEALTH OUTCOME MEASURE

Amy Peterman, Ph.D., David Cella, Ph.D., Marianne Brady, Ph.D., Northwestern University, Evanston, IL

19/ COMPARISON OF THE HEALTH UTILITY INDEX MARK III (HUI-III) AND THE SELF-ASSESSED HEALTH STATUS IN THE CANADIAN POPULATION.

Julie Bernier, Jean-Marie Berthelot, Health Analysis and Modeling Group, Statistics Canada, Ottawa, ON, Canada; Ivan Barofsky, The Johns Hopkins University, Baltimore, MD; Pennifer Erickson, Pennsylvania State University, State College, PA

20/ HEMOPHILIA: CONSTRUCT VALIDITY OF THE HEALTH UTILITIES INDEX

William J. Furlong, Department of Clinical Epidemiology and Biostatistic, Ronald D. Barr, Department of Pediatrics, McMaster University, Hamilton, ON, Canada; Mahassen Saleh, Department of Pediatrics, Hamilton Health Sciences Corporation, Hamilton, ON, Canada; John Horsman, Department of Clinical Epidemiology and Biostatistic, McMaster University, Hamilton, ON, Canada; Julia Sek, Mohan Pai, Department of Pediatrics, Hamilton Health Sciences Corporation, Hamilton, ON, Canada; Irwin Walker, McMaster University Medical Centre, Hamilton Health Sciences Corporation, Hamilton, ON, Canada

E. QOL in Chronic Disease**Room O****Chair: Rick Berzon**

21/ ONE YEAR OUTCOMES OF HEMODIALYSIS AND PERITONEAL DIALYSIS IN AN INCIDENT COHORT OF PATIENTS WITH END STAGE RENAL DISEASE (ESRD)

Albert W. Wu, Health Policy and Management, Jane Marsh, Nancy E. Fink, Department of Epidemiology, Kraig Kinchen, Neil R. Powe, Department of Medicine, Johns Hopkins University, Baltimore, MD

22/ USE OF ERYTHROPOIETIN IN EARLY ANAEMIA IMPROVES HRQOL IN PREDIALYSIS CHRONIC RENAL FAILURE PATIENTS

M. S. Salek, Centre for Socioeconomic Research, Cardiff University, Cardiff, UK; N. Pratheepawanit, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand

23/ ORODENTAL HEALTH, ACUTE AND LATE MORBIDITIES, AND QUALITY OF LIFE IN IRRADIATED INDIAN HEAD AND NECK CANCER PATIENTS

Manishi Bansal, Bidhu Mohanti, Naseem Shah, ~~withdrawn~~ Rishi Chaudhry, Sudhir Bahadur, Nootan Shukla Institute Rotary Cancer Hospital, AIIMS, Ansari Nagar New Delhi, India

24/ QUALITY OF LIFE AFTER ESOPHAGEAL RESECTION FOR CANCER AND BARRETT'S

Claude Deschamps, Francis C. Nichols, Mark S. Allen, Peter C. Pairolero, Daniel L. Miller, Victor F. Trastek, Division of General Thoracic Surgery, Mayo Clinic, Rochester, MN

25/ DIABETES AND CHANGE IN PSYCHOSOCIAL WELL-BEING

Siri Naess, John Eriksen, NOVA - Norwegian Social Research, Oslo, Norway

Oral II: Thursday, November 8 (11:00 am - 12:30 pm)**Location****A. Questionnaire Development****Room M****Chair: Carol Ferrans**

26/ THE REVISED KINDL-R: FINAL RESULTS ON RELIABILITY, VALIDITY AND RESPONSIVENESS OF A MODULAR HRQOL INSTRUMENT FOR CHILDREN AND ADOLESCENTS

Ulrike Ravens-Sieberer, Child and Adolescent Health, Robert Koch Institute, Berlin, Germany; Monika Bullinger, Department of Medical Psychology, University of Hamburg, Hamburg, Germany

27/ RETEST RELIABILITY AND VALIDITY OF A SURVEILLANCE MEASURE OF HEALTH-RELATED QUALITY OF LIFE

E. Andresen, T. Catlin, K. Wyrwich, Saint Louis University, St. Louis, MO; J. Jackson-Thompson, Missouri Department of Health, Jefferson City, MO

28/ THE SEXUAL RELATIONS SCALE: PSYCHOMETRIC CHARACTERISTICS IN PATIENTS WITH HIV DISEASE, GERD, UTERINE FIBROIDS, AN PERIPHERAL ARTERIAL DISEASE

Dennis A. Revicki, Karin Coyne, Carol Koro, Center for Health Outcomes Research, MEDTAP International, Bethesda, MD; Albert W. Wu, Health Services Research and Development Center, Johns Hopkins University, Baltimore, MD; Anne Rentz, Center for Health Outcomes Research, MEDTAP International, Bethesda, MD

29/ VALIDATION OF THE UFS-QOL, A DISEASE-SPECIFIC SYMPTOM AND HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE FOR UTERINE FIBROIDS

Karin Coyne, Center for Health Outcomes Research, MEDTAP International, Bethesda, MD; James Spies, Department of Inter-Radiology, Georgetown University, Washington, DC; Deneane Boyle, Center for Health Outcomes Research, MEDTAP International, Bethesda, MD; Kerry Skymaraz-Murphy, Sheila Gonzalves, Department of Inter Radiology, Georgetown University, Washington, DC

30/ PSYCHOMETRIC EVALUATION OF TWO OBESITY AND WEIGHT LOSS QUALITY OF LIFE INSTRUMENTS: THE OWLQOL AND WRSM

Donald L. Patrick, Department of Health Services, University of Washington, Seattle, WA; Donald M. Bushnell, Health Research Associates, Seattle, WA; Laura A. Glauda, Dennis D. Gagnon, Margaret Rothman, The R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ

B. Pediatrics**Room O****Chair: Jeanne Landgraf**

31/ COPING STYLES PREDICT QUALITY OF LIFE IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE

Hester J. Loonen, Bert H. Derkx, Pediatrics, Martha A. Grootenhuis, Bob F. Last, Psychosocial Department, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands

32/ "I THINK MY LIFE IS BETTER THAN MOST KIDS" LIFE SATISFACTION IN HEALTHY AND CHRONICALLY ILL CHILDREN

Kirsten Moenkemoeller, Kinderkrankenhaus, Universität Witten/Herdecke, Köln, Germany; Anne Wrede, IFAS, Universität zu Köln, Köln, Germany; Guido Buerk, Vestische Kinderklinik, Universität Witten/Herdecke, Datteln, Germany; Ulrike Ravens-Sieberer, Forschungsgruppe, Robert-Koch-Institut, Berlin, Germany

33/ QOL AFTER PEDIATRIC STEM CELL TRANSPLANTATION: A CASE FOR RESPONSE SHIFT?

Susan K. Parsons, Christopher J. Recklitis, Dana-Farber Cancer Institute, Boston, MA

34/ PEDIATRIC SPINE DEFORMITY: ASSESSING PATIENT OUTCOMES AND QUALITY OF LIFE

Michael G. Vitale, Pediatric Orthopaedics, Children's Hospital of New York, New York, NY; Julie C. Choe, Douglas E. Levy, Pediatric Orthopaedics, Annetine C. Gelijns, Alan J. Moskowitz, Surgery, InCHOIR, New York, NY; Joshua E. Hyman, Francis Y. Lee, David P. Roye, Pediatric Orthopaedics, Children's Hospital of New York, New York, NY

35/ HEALTH RELATED QUALITY OF LIFE OF CHILDREN WITH CHRONIC DISEASES

Martha A. Grootenhuis, Bob F. Last, Psychosocial Department, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands

C. Respiratory Diseases**Room P****Chair: Dennis Revicki**

36/ THE RELATIONSHIP BETWEEN RESOURCE CONSUMPTION AND ASTHMA SEVERITY AMONG ASTHMATIC OUTPATIENTS IN THREE EUROPEAN COUNTRIES

David U. Himmelberger, Health Outcomes Group, Palo Alto, CA; Leonardo Antonicelli, Hospital Umberto I, Ancona, Italy

37/ THE EFFECT OF ASTHMA SEVERITY ON HEALTH-RELATED QUALITY OF LIFE AND WORK PERFORMANCE: DOES THE DEFINITION OF SEVERITY MAKE A DIFFERENCE?

Steven R. Erickson, Duane M. Kirking, College of Pharmacy, University of Michigan, Ann Arbor, MI; Nancy Kline Leidy, Center for Health Outcomes Research, MEDTAP International, Bethesda, MD

38/ QUALITY OF LIFE AFTER INTENSIVE CARE FOR ACUTE LUNG INJURY

Cynthia R. Gross, Academic Health Center, University of Minnesota (UMN), Minneapolis, MN; Craig R. Weinert, Medical School, Minneapolis, MN; Carol Albright, Caron L. Bury, William A. Marinelli, UMN, Minneapolis, MN

39/ EFFECTS OF DISEASE MANAGEMENT ON QUALITY OF LIFE IN PATIENTS WITH ASTHMA

Wolfgang Greiner, Matthias J. Graf v.d. Schulenburg, Institut für Versicherungsbetriebslehre, University of Hannover, Hannover, Germany

40/ COPING AND QUALITY OF LIFE IN ADULTS WITH ASTHMA

Edgar A. Correia, Instituto Superior de Psicologia Aplicada, Lisboa, Portugal; Jose L. Pais-Ribeiro, Faculdade de Psicologia, Universidade do Porto, Porto, Portugal; Nuno B. Neuparth, Pedro L. Mata, Fisiopatologia, Faculdade de Ciências Médicas, Universidade Nova, Lisboa, Portugal

D. IRT**Room N1-O1****Chair: Jacob Bjorner**

41/ USING ITEM RESPONSE THEORY TO IMPROVE QOL MEASURES FOR CHILDREN — FIRST RESULTS FROM THE CHILD DYNAMIC HEALTH ASSESSMENT PROJECT

Ute Ellert, Christiane Thomas, Ulrike Ravens-Sieberer, Department for Child and Adolescent Health, Robert Koch Institute, Berlin, Germany; Mark Kosinski, Quality Metric Inc., Lincoln, RI; Jakob B. Bjorner, National Institute of Occupational Health, Copenhagen, Denmark, Jim Dewey, John E. Ware, Quality Metric Inc., Lincoln, RI

42/ ITEM BANKING TO IMPROVE, SHORTEN AND COMPUTERIZE SELF-REPORTED FATIGUE

Jin-shei Lai, David Cella, Chih-Hung Chang, Evanston Northwestern Healthcare (ENH), Northwestern University (NU), Evanston, IL; Rita K. Bode, Rehabilitation Institute of Chicago (RIC), Allen W. Heinemann, RIC, NU, Chicago, IL

43/ ONE- VERSUS TWO-PARAMETER ITEM RESPONSE THEORY (IRT) MEASUREMENT MODELS APPLIED TO MOS PF-10 SCORES: HOW MUCH DOES IT REALLY MATTER?

Chih-Hung Chang, David Cella, Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Evanston, IL

44/ DO MEASURES OF FUNCTIONAL ABILITY FULFIL THE ASSUMPTIONS ON DIMENSIONALITY REQUIRED BY ITEM RESPONSE THEORY?

Rebecca Holman, Robert Lindeboom, M. Vermeulen, Rob de Haan, Clinical Epidemiology and Biostatistics, Academic Medical Center (AMC), Amsterdam, The Netherlands

E. Response Shift**Room N****Chair: Nancy Mayo**

45/ FACTORS ASSOCIATED WITH STABILITY IN QUALITY OF LIFE RATINGS AMONG PEOPLE LIVING WITH HIV/AIDS: RESPONSE SHIFT'S "SMOKING GUN"?

Bruce D. Rapkin, Rosy Chhabra, Carolyn Smith, Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY; Bruce Agins, Clefens M. Steinbock, AIDS Institute, New York State Department of Health, New York, NY; Mark Sharp, Ira Feldman, AIDS Institute, New York State Department of Health, Albany, NY

46/ RESPONSE SHIFT EFFECTS OF AN ADVANCE CARE PLANNING INTERVENTION WITH AMBULATORY GERIATRIC PATIENTS

Carolyn E. Schwartz, Department of Family Medicine & Community Health, University of Massachusetts Medical School, Worcester, MA; Noreen Basque, VNA Care Network, Worcester, MA; George Reed, Yungsheng Ma, Medicine, H. Brownell Wheeler, Surgery, University of Massachusetts Medical School, Worcester, MA

47/ USING ITEM RESPONSE THEORY (IRT) AND STRUCTURAL EQUATION MODELING (SEM) TO INVESTIGATE RESPONSE SHIFTS

Frans J. Oort, Pythia T. Nieuwkerk, Mirjam A. Sprangers, Medical Psychology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

48/ RESPONSE SHIFT IN THE ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE (HRQL) POST-STROKE

Sara Ahmed, Nancy E. Mayo, Sharon Wood-Dauphinee, Jim Hanley, Epidemiology, McGill University, Montreal, QC, Canada

49/ RESPONSE SHIFT IN PATIENTS' LIVING WITH ADVANCED CANCER

Nessa Coyle, Richard Payne, Neurology, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY

Oral III: Thursday, November 8 (4:45 pm - 6:15 pm)**Location****A. Cardiology****Room P****Chair: Montserrat Ferrer**

50/ SYMPTOM EXPERIENCE AND HEALTH RELATED QUALITY OF LIFE AFTER IMPLANTATION OF A CARDIOVERTER DEFIBRILLATOR
 Susan F. Marden, Clinical Center Nursing Department, National Institutes of Health, Bethesda, MD

51/ PREDICTING UTILIZATION AND COSTS IN A ONE-YEAR FOLLOW-UP OF HEART FAILURE PATIENTS: THE CONTRIBUTIONS OF GENERIC AND DISEASE SPECIFIC HRQOL ASSESSMENTS
 Deborah M. Miller, Mellen Center, Neurology, Cleveland Clinic Foundation, Cleveland, OH; D. Nelson, M. Karafa, Biostatistics and Epidemiology, J. Michaels, Center for Clinical Outcomes, J. B. Young, Cardiology, CCF, Cleveland, OH

52/ LONG TERM QUALITY OF LIFE AFTER OPEN HEART SURGERY
 Djordje Jakovljevic, Zoran R. Potic, Bogoljub Mihajlovic, Marijela M. Potic, Ninoslav D. Radovanovic, Cardiovascular Surgery, Institute of CVD, Sremska Kamenica, Vojvodina, Yugoslavia

53/ DETERMINANTS OF THE QUALITY OF LIFE OF PATIENTS WITH CONGENITAL HEART DISEASE
 M. Rose, K. Köhler, Psychosomatic, F. Köhler, Cardiology, Charité Humboldt University, Berlin, Germany

54/ PSYCHOMETRIC PROPERTIES OF THE MACNEW HEART DISEASE QUESTIONNAIRE IN PATIENTS AFTER MYOCARDIAL INFARCTION
 Stefan Höfer, Medical Psychology and Psychotherapy, University of Innsbruck, Innsbruck, Austria, Werner Benzer, Working Group on CR & SP, Austrian Society of Cardiology, Feldkirch, Austria; Dieter Brandt, Working Group on CR & SP, Austrian Society of Cardiology, St. Radegund, Austria; Herbert Laimer, Working Group on CR & SP, Austrian Society of Cardiology, Bad Tatzmannsdorf, Austria; Peter Schmidt, Working Group on CR & SP, Austrian Society of Cardiology, Bad Schallerbach, Austria; Arthur Bernardo, Clinic of Cardiac and Psychosomatic Rehabilitation, Gais, Switzerland

B. Translation/Cross-Cultural Issues**Room M****Chair: Patrick Marquis**

55/ THE FACTOR STRUCTURE OF THE SF-36 PHYSICAL AND MENTAL HEALTH SUMMARY MEASURES BY RACE/ETHNICITY AND LANGUAGE IN A US PATIENT POPULATION
 Leo S. Morales, Department of Medicine, Steven P. Reise, Department of Psychology, Ron D. Hays, Department of Medicine, University of California, Los Angeles, CA

56/ VALIDATION OF THE WHOQOL-BREF IN A NORWEGIAN GENERAL POPULATION
 Berit R. Hanestad, Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway; Astrid K. Wahl, Faculty of Health, Buskerud College, Drammen, Norway; Tone Rustoen, Faculty of Nursing, Oslo University College, Oslo, Norway; Annors Lerdal, Øistein Knudsen, Faculty of Health, Buskerud College, Drammen, Norway

57/ HOW WELL DO HEALTH STATE VALUATION TECHNIQUES CROSS CULTURES? IMPLICATIONS OF CONCEPTIONS OF DEATH AMONGST THE KAMBA OF KENYA
 Charles Nzioka, Sociology, University of Nairobi, Nairobi, Kenya; Julia A. Fox-Rushby, Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK; Patrick I. Muia, Anthropology, University of Nairobi, Nairobi, Kenya

58/ TRANSLATION AND DEVELOPMENT OF A DUTCH PROSTATE CANCER QUALITY OF LIFE QUESTIONNAIRE
 Ida J. Korfage, Marie-Louise Essink-Bot, Joanna M. Madalinska, Department of Public Health, Wim J. Kirkels, Erasmus Medical Centre Rotterdam (EMCR), Rotterdam, The Netherlands; Mark S. Litwin, Department of Urology, UCLA, Los Angeles, CA; Harry J. de Koning, Department of Public Health, EMCR, Rotterdam, The Netherlands

59/ QUALITY OF LIFE ASSESSMENT IN HIV: MODIFYING INSTRUMENTS FOR A CHANGING DISEASE?
 Waldo H. Belloso, Infectious Diseases Section, Hospital Italiano de Buenos Aires, Buenos Aires, Capital Federal, Argentina; Ezequiel Consiglio, CVAr Coordinating Center, Buenos Aires, Capital Federal, Argentina

C. Utility II
Chair: Paul Krabbe

Room N

60/ NEGATIVE UTILITY SCORES: THEORETICAL AND PRACTICAL DIFFICULTIES WITH AN ESSENTIAL COMPONENT OF UTILITY INSTRUMENTS
 Graeme Hawthorne, Centre for Health Program Evaluation, The University of Melbourne, West Heidelberg, Victoria, Australia; Jeffrey Richardson, Centre for Health Program Evaluation, Monash University, West Heidelberg, Victoria, Australia

61/ MEASURING THE QUALITY OF LIFE AND QUALITY-ADJUSTED LIFE SPAN OF THE U.S. POPULATION, 1984-1994
 Pennifer Erickson, Biobehavioral Health and Health Evaluation Sciences, Penn State University, State College, PA

62/ WHOSE VALUES COUNT? A CRITIQUE OF DISABILITY ADJUSTED LIFE YEARS (DALYS)
 Julia A. Fox-Rushby, Public Health and Policy, London School of Hygiene and Tropical Medicine, London, England

63/ COMPARING COMMUNITY-PREFERENCE BASED AND DIRECT STANDARD GAMBLE UTILITY SCORES: EVIDENCE FROM ELECTIVE HIP ARTHROPLASTY
 David Feeny, Chris Blanchard, Institute of Health Economics, Edmonton, AB, Canada; Jeffrey Mahon, Department of Epidemiology and Biostatistics, Robert Bourne, Cecil Rorabeck, Department of Surgery, Larry Stitt, Susan Webster-Bogaert, Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada

64/ PATIENT PREFERENCE AND COMPREHENSION OF UTILITY INSTRUMENTS
 Deborah G. Dobrez, Elizabeth Calhoun, Institute for Health Services Research & Policy Studies, Northwestern University, Chicago, IL

D. Neurological Diseases
Chair: Ted Ganiats

Room O

65/ THE COMPLEX RELATIONSHIP BETWEEN COGNITIVE IMPAIRMENT AND HEALTH-RELATED QUALITY OF LIFE AFTER CLOSED HEAD INJURY
 Bernd-Otto Hütter, Joachim-Michael Gilsbach, Department of Neurosurgery, Medical Faculty of the RWTH Aachen, Aachen, Germany

66/ VALIDATION OF THE EUROQOL STROKE UTILITY MEASURE (EQ-SUM)
 Lise Poissant, Nancy E. Mayo, Sharon Wood-Dauphinee, Ann Clarke, Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada

67/ CONTRIBUTIONS OF HEALTH-RELATED QUALITY OF LIFE (HRQL) TO UNDERSTANDING HEALTH CARE COSTS POST STROKE
 Sharon L. Wood-Dauphinee, School of Physical and Occupational Therapy, McGill University, Montreal, QC, Canada, Josephine Teng, Nancy E. Mayo, Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada

68/ THE MS SYMPTOM AND IMPACT DIARY: A NEW INSTRUMENT TO MEASURE THE DAY TO DAY IMPACT OF MS
 Joanne Greenhalgh, Nuffield Institute for Health, University of Leeds, Leeds, West Yorkshire, UK; Helen Ford, Neurology, St. James's University Hospital, Leeds, West Yorkshire, UK; Amanda Georgiou, Keith Hurst, Nuffield Institute for Health, University of Leeds, Leeds, West Yorkshire, UK; Ann Jacoby, Department of Primary Care, Whelan Building, Liverpool, Merseyside, UK; Andrew F. Long, Health Care Practice R&D Unit, University of Salford, Salford, Greater Manchester, UK; Carolyn A. Young, Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool, Merseyside, UK

69/ PDQ-39SI, PDQ-8SI: TOWARDS A FRENCH VERSION OF THESE TWO SUMMARY INDEXES IN PARKINSON'S DISEASE
 Christophe Sapin, Public Health Department, Medical School, Marseille, France; Marc Ziegler, Neurology Department, Bellan Hospital, Paris, France; Mohammed El Khammar, Public Health Department, Medical School, Marseille, France; Jean-Luc Thiault, Lilly France Laboratories, St. Cloud, France; Pascal Auquier, Public Health Department, Medical School, Marseille, France

E. Missing Data
Chair: Desmond Curran

Room N1-O1

70/ DEFINING SYMPTOM AND FUNCTIONAL HEALTH "RESPONSE" IN CLINICAL TRIAL-BASED HEALTH-RELATED QUALITY OF LIFE (HRQL) ASSESSMENT IN ONCOLOGY
 Martin J. Muller, Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Johannes A. Langendijk, Radiation Oncology, Vrije University Hospital, Amsterdam, The Netherlands; Neil K. Aaronson, Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

71/ AGREEMENT BETWEEN PROXY ASSESSMENT AND PATIENT SELF-ASSESSMENT IN STROKE: A COMPARISON OF GENERIC HEALTH STATUS MEASURES
 Simon Pickard, Jeffrey Johnson, David Feeny, KC Carriere, Institute of Health Economics (IHE), Edmonton, AB, Canada; Ashfaq Shuaib, University of Alberta, Edmonton, AB, Canada

72/ THE IMPORTANCE OF CONSIDERING MISSING DATA IN COHORT STUDIES OF STROKE OUTCOME
 Nancy E. Mayo, Sharon L. Wood-Dauphinee, Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada

73/ INCORPORATING DEATH INTO THE STATISTICAL ANALYSIS OF LONGITUDINAL HEALTH STATUS DATA
 Laura L. Johnson, Department of Biostatistics, University of Washington, Seattle, WA

74/ IMPACT OF MISSING HRQL DATA. IS IT REALLY MISSING?
 Diane L. Fairclough, Center for Research Methodology and Biometry, AMC Cancer Research Center, Denver, CO

Oral IV: Friday, November 9 (11:00 am - 12:30 pm)**Location****A. Oncology II****Room O****Chair: Joseph Lipscomb****75/ HRQOL OUTCOMES AMONG MEN MANAGED WITHOUT SURGERY OR RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER: RESULTS FROM THE PROSTATE CANCER OUTCOMES STUDY**

Arnold L. Potosky, Bryce B. Reeve, Applied Research Program, Limin X. Clegg, Surveillance Research Program, National Cancer Institute, Bethesda, MD; Richard M. Hoffman, Medical Service, Veterans Affairs Medical Center, Albuquerque, NM; Robert A. Stephenson, Division of Urology, University of Utah, Salt Lake City, UT; Peter C. Albertsen, Division of Urology, University of Connecticut Health Center, Farmington, CT; Frank D. Gilliland, Preventive Medicine, USC Keck School of Medicine, Los Angeles, CA; Janet L. Stanford, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA

76/ IS MORE BETTER? QUALITY OF LIFE (QOL) RESULTS OF A CANADIAN PALLIATIVE RADIOTHERAPY TRIAL IN PATIENTS WITH UNRESECTABLE LUNG CANCER (NCIC CTG SC.15)

Andrea Bezjak, DRO, Princess Margaret Hospital, Toronto, ON, Canada; Michael Brundage, Department of Radiation Oncology, Kingston Regional Cancer Center, Kingston, ON, Canada; Peter F. Dixon, Department of Radiation Oncology, Kingston Regional Cancer Center, Kingston, ON, Canada; Michael Palmer, Joseph Pater, Dongsheng Tu, Central Office, NCIC Clinical Trials Group, Kingston, ON, Canada; Clive Grafton, Department of Radiation Oncology, BC Cancer Agency, Vancouver, BC, Canada; Paul Blood, Department of Radiation Oncology, Vancouver Island Cancer Centre, Vancouver, BC, Canada; Carson Leong, Department of Radiation Oncology, Surrey Memorial Hospital, Surrey, BC, Canada; Liam A. Mulroy, Department of Radiation Oncology, Nova Scotia Cancer Centre, Halifax, NS, Canada; Jim Wright, Department of Radiation Oncology, Hamilton Regional Cancer Center, Hamilton, ON, Canada

77/ SYMPTOMATOLOGY OF CANCER PATIENTS IN PALLIATIVE CARE: CONTENT VALIDATION OF SELF-ASSESSMENT QUESTIONNAIRES AGAINST MEDICAL RECORDS

Annette S. Stromgren, Mogens Groenvold, Lise Pedersen, Alf K. Olsen, Department of Palliative Medicine, Per Sjogren, Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark

78/ BRIEF ASSESSMENT OF PRIORITY SYMPTOMS IN ADVANCED CANCER

S. Yount, Evanston Northwestern Healthcare (ENH), Northwestern University (NU), Evanston, IL; D. Cella, ENH and NU, Evanston, IL; D. Paul, R. Winn, National Comprehensive Cancer Network (NCCN), Rockledge, PA; C.H. Chang, ENH and NU, Evanston, IL, J. Weeks, Dana-Farber Cancer Institute, Boston, MA; D. Banik, ENH, Evanston, IL; N. Heffernan, Memorial Sloan-Kettering Cancer Center, New York, NY; K. Webster, ENH, Evanston, IL; R. Van Gool, Janssen Research Foundation, Beerse, Belgium; L. Odom, ENH, Evanston, IL

79/ DEVELOPMENT OF THE SHORT FORM MCGILL QUALITY OF LIFE QUESTIONNAIRE

N. Pratheepawanit, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand; M. S. Salek, P. L. Lua, Centre for Socioeconomic Research, Cardiff University, Cardiff, UK; I. G. Finlay, Velindre NHS Trust & University of Wales College of Medicine, Cardiff, UK

B. Quality of Life in Schizophrenia**Room M****Chair: Paul Kind****80/ DEVELOPMENT AND VALIDATION OF QUALITY OF LIFE MEASUREMENT IN SCHIZOPHRENIA: SCHIZO-QOL**

Christophe Lancon, Psychiatry Department, Pascal Auquier, Public Health Department, Marie-Claude Simeoni, Public Health Department, Medical School, Jean-Michel Azorin, Psychiatry Department, Marseille, France; Jean Dallery, Psychiatry Department, Lyon, France; Alain Lepage, Inserm U292, Le Kremlin Bicêtre, France; Pierre-Michel Liorca, Psychiatry Department, Clermont-Ferrand, France; Michel Goudeman, Psychiatry Department, Lille, France; Julien-Daniel Guelphi, Marie-France Poirier, Psychiatry Department, Paris, France; Gilles Reine, Psychiatry Department, Toulon, France; Jean-Claude Samuelian, Psychiatry Department, Marseille, France; Héliène Verdoux, Psychiatry Department, Bordeaux, France

81/ THE PATIENT'S PERSPECTIVE IN SCHIZOPHRENIA: IS IT VALID, RELIABLE, AND RESPONSIVE?

Benoit Arnould, Mapi Values, Lyon, France; Anthony F. Lehman, University of Maryland School of Medicine, Baltimore, MD; Céline Laforêt, Mapi Values, Lyon, France; Mike Ingham, Inge Duchesne, Janssen Research Foundation, Beerse, Belgium

82/ SOAP-51: A SELF-ADMINISTERED, HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR INDIVIDUALS WITH SCHIZOPHRENIA LIVING IN THE COMMUNITY

Judith T. Barr, Gerald E. Schumacher, School of Pharmacy, Emanuel Mason, Counseling Psychology, Susan Ohman, NERCOA, Northeastern University, Boston, MA

83/ ETHNIC DIFFERENCES IN VALUES FOR HEALTH OUTCOMES IN SCHIZOPHRENIA

Leslie Lenert, Health Services Research, VA San Diego Healthcare System, San Diego, CA; Ann Sturly, San Diego Veterans Medical Research Foundation, San Diego, CA; Mark Rapaport, Shannon Chavez, Department of Psychiatry, University of California, San Diego, La Jolla, CA; Marcia Rupnow, Amy Grogg, Janssen Pharmaceuticals, Titusville, NJ

C. Interpreting QOL

Room L

Chair: John Ware

84/ WHAT ROLE DO SYMPTOMS PLAY IN HEALTH-RELATED QUALITY OF LIFE?

Nancy Kline Leidy, Deborah L. Jonas, MEDTAP International, Inc., Bethesda, MD; Cheryl C. Silberman, AstraZeneca, Wilmington, DE; Mary Kay Margolis, MEDTAP International, Inc., Bethesda, MD; Anne Heyes, AstraZeneca, Cheshire, UK

85/ SUBJECTIVE VERSUS OBJECTIVE QUALITY OF LIFE IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS

Maren Gesina Glueer, Bundesanstalt fuer Milchforschung, Hamburg, Germany; Helmut W. Minne, Institut fuer klinische Osteologie, Bad Pyrmont, Germany; Ana D. Lazarescu, Klinik Der Fuerstenhof, Bad Pyrmont, Germany; Michael Pfeifer, Bettina Begerow, Institut fuer klinische Osteologie, Bad Pyrmont, Germany

86/ HOW IMPORTANT IS HEALTH FOR OVERALL QUALITY OF LIFE?

Thomas V. Perneger, Philippe Garnerin, Quality of Care Unit, Geneva University Hospitals, Geneva, Switzerland

87/ WHAT IS SUBJECTIVE QUALITY OF LIFE? A PHILOSOPHICAL PERSPECTIVE.

Bengt Brülde, Department of Philosophy, Practical Philosophy, Helge Malmgren, Department of Philosophy, Theoretical Philosophy, Göteborg University, Göteborg, Sweden

88/ QUALITY OF LIFE IN SERIOUSLY ILL ADULTS AFTER HOSPITALIZATION: WHAT IS IT LIKE AND CAN WE PREDICT IT?

Kitty S. Chan, RAND Corporation, Santa Monica, CA; Kenneth Covinsky, Medicine, University of California, San Francisco, San Francisco, CA; Joel Tsevat, Medicine, University of Cincinnati, Cincinnati, OH; Albert W. Wu, Health Policy and Management, Johns Hopkins University, Baltimore, MD

D. QOL Potpourri

Room N1-01

Chair: Carolyn Gotay

89/ ELECTRONIC VERSUS PAPER QUESTIONNAIRES: A FURTHER COMPARISON IN PEOPLE WITH ASTHMA

Donald M. Bushnell, Mona L. Martin, HRA, Inc, Seattle, WA; Bhash Parasuraman, Health Economics and Outcomes Research, AstraZeneca, Wayne, PA

90/ ADMINISTRATION OF SEIQOL-DW: THREATS TO RELIABILITY

Marjan J. Westerman, EMGO/Social Medicine, Vrije Universiteit, Amsterdam, The Netherlands; Tony Hak, Methodology, Faculteit Bedrijfskunde / Erasmus Universiteit, Rotterdam, The Netherlands

91/ TOWARDS BRIEFER QOL INSTRUMENTS: A POPULATION APPROACH

T. G. Ganiats, K. M. David, E. J. Groessl, W. J. Sieber, R. M. Kaplan, UCSD Health Outcomes Assessment Program, University of California San Diego, La Jolla, CA

92/ DIFFERENCES IN PERCEPTION OF QUALITY OF LIFE AND GOALS FOR IMPROVEMENT WITH TREATMENT AMONG PATIENTS, FAMILY MEMBERS AND PROVIDERS

Marion A. Becker, David Thornton, Department of Mental Health Law and Policy, Louis de la Parte Florida Mental Health Institute, Tampa, Florida; Ronald J. Diamond, Department of Psychiatry, University of Wisconsin-Madison, Madison, Wisconsin

93/ THE CHILD HEALTH QUESTIONNAIRE (CHQ): COMPARISON OF THE QUALITY OF LIFE (QOL) SCORES OBTAINED BY THE PARENT REPORT (PF50) AND THE SELF REPORT (CF87)

Chantal Rodary, Biostatistics, Bellon Nicolas, Institut Gustave Roussy, Villejuif, France; Jeanne Landgraf, Health Act, Boston, MA; Chantal Kalifa, Institut Gustave Roussy, Villejuif, France; André Baruchel, hôpital Saint Louis, Paris, France; Erica Quintana, Institut Curie, Paris, France

E. Psychometric Methods

Room N

Chair: Peter Fayers

94/ ITEM REDUCTION: DO DIFFERENT METHODS PRODUCE DIFFERENT SCALES?

Jeremy C. Hobart, Afsane Riaz, Neurological Outcome Measures Unit, Institute of Neurology, London, UK; Donna L. Lamping, Health Services Research Unit, London School of Hygiene & Tropical Medicine, London, UK; Ray Fitzpatrick, Health Services Research Unit, Oxford University, Oxford, UK; Alan J. Thompson, Neurological Outcome Measures Unit, Institute of Neurology, London, UK

95/ PSYCHOMETRIC PROPERTIES OF FACT-AN NORMATIVE DATA: RESULTS FROM A WEB-BASED SURVEY

D. Gagnon, RWJ Pharmaceutical Research Institute, Raritan, NJ; Christina Vandroos, Janssen-Cilag Pharmaceutical SACI, Pefki, Athens, Greece; M. Zagari, B. Shilling, RWJ Pharmaceutical Research Institute, Raritan, NJ; D. Cella, Northwestern University, Evanston, IL

96/ PRECISION AND BREVITY: VITALITY ASSESSMENTS USING COMPUTERIZED ADAPTIVE TESTING METHODS

Julie H. Zhao, Quality Metric, Inc., Lincoln, RI; Jakob B. Bjorner, The National Institute of Occupational Health, Copenhagen, Denmark; Mark Kosinski, Kimberly A. Laliberte, John E. Ware Jr., Quality Metric, Inc., Lincoln, RI

97/ PSYCHOMETRIC PROPERTIES OF THE GLOBAL INDEX OF SAFETY (GIS): A NEW INSTRUMENT TO ASSESS DRUG SAFETY

Luis Prieto, José A. Sacristán, Juan C. Gómez, Clinical Research Department, Lilly SA, Alcobendas, Spain

98/ A COMPARISON OF LIKERT SCALE AND VISUAL ANALOGUE SCALES IN CHILDREN: RESPONSE DIFFERENCES AND PREFERENCES

Henriette van Laerhoven, Bert H. Derkx, Hester J. Loonen, Paediatrics, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands

Oral V: Friday, November 9 (2:00 pm - 3:30 pm)**Location****A. Musculoskeletal Disease****Room O****Chair: Marianne Sullivan**

99/ FATIGUE AND QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS

Ines Rupp, Department of Social Medicine, Academic Medical Centre/University of Amsterdam, Amsterdam, The Netherlands; Hendriek C. Boshuizen, Division of Public Health Research, National Institute of Public Health and Environment, Bilthoven, The Netherlands; Catharina E. Jacobi, Department of Social Medicine, Academic Medical Centre/University of Amsterdam, Amsterdam, The Netherlands; Huibert J. Dinant, Jan van Breemen Institute, Amsterdam, The Netherlands; Geertruis A. van den Bos, Department for Health Services Research, National Institute of Public Health and Environment, Bilthoven, The Netherlands

100/ QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS

Ayhan A. Lash, School of Nursing, Northern Illinois University, DeKalb, IL

101/ THE OUTCOME OF HIP AND KNEE REPLACEMENT FOR OSTEOARTHRITIS: LONG-TERM FOLLOW-UP

Francois A. Bethoux, Deborah M. Miller, The Mellen Center / U10, Mary LoGrasso, George M. Muschler, Department of Orthopaedic Surgery / A41, The Cleveland Clinic Foundation, Cleveland, OH; JoAnna B. Younts, Younts Consulting, Raleigh, NC

102/ THE RELIABILITY AND VALIDITY OF THE QUALITY OF LIFE INSTRUMENT FOR THE JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS

Takako Morita, Department of Preventative Medicine, Kyushu University, Fukuoka, Japan; Jun Nagano, Institute of Health Science, Kyushu University, Kasuga, Japan; Suminori Kono, Department of Preventative Medicine, Kyushu University, Fukuoka, Japan; Yasuro Nishibayashi, Mikisanyo Hospital, Miki, Japan

103/ PERSPECTIVES ON PEDIATRIC OUTCOMES: A COMPARISON OF PARENTS' AND PATIENTS' RATING OF QUALITY OF LIFE FOLLOWING ORTHOPAEDIC INTERVENTION

Julie C. Choe, Soo J. Im, Pediatric Orthopaedics, InCHOIR, New York, NY; Michael G. Vitale, Pediatric Orthopaedics, Children's Hospital of New York, New York, NY; Mark E. Spellmann, School of Social Work, New York University, New York, NY; David P. Roye, Pediatric Orthopaedics, Children's Hospital of New York, New York, NY

B. Psychological Aspects**Room L****Chair: Carol Moinpour**

104/ SATISFACTION AND DISSATISFACTION: ARE THEY MERELY OPPOSITES?

Elizabeth A. Hahn, David Cella, Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Evanston, IL

105/ RELATIONSHIPS BETWEEN SATISFACTION WITH LIFE DOMAINS AND SATISFACTION WITH LIFE AS A WHOLE IN PEOPLE WITH PHYSICAL DISABILITIES

Marcel W. Post, Luc P. de Witte, Research, iRv, Institute for Rehabilitation Research, Hoensbroek, The Netherlands

106/ QUALITY OF LIFE OF CHINESE CANCER PATIENTS: OPTIMISM AS MEDIATOR

Clara L. Yu, R. Fielding, Com. Med., C. L. Chan, Social Work and Soc. Administration, J. S. Sham, Clinical Oncology, Hong Kong University, Hong Kong, China

107/ MAJOR DEPRESSIVE DISORDER (MDD) IN CHRONIC PAIN PATIENTS: CORRELATION OF THE SF-36 WITH PHYSICIAN DETERMINED DIAGNOSIS USING DSM-IV CRITERIA

Thomas E. Elliott, Division of Education and Research, Colleen M. Renier, Donna K. Anderson, Jeanette A. Palcher, St. Mary's/Duluth Clinic Health System, Duluth, MN

108/ PREDICTING PSYCHOSOCIAL OUTCOME OF PATIENTS UNDERGOING LUMBAR DISC SURGERY

Max Leibetseder, Social Medical Service, Government of Salzburg, Salzburg, Salzburg, Austria; Karoline V. Greimel, Institute of Clinical Psychology, General Hospital, Salzburg, Salzburg, Austria; Wolfgang P. Piotrowski, Gabriele Kohlboeck, Neurosurgery, Christian Doppler Medical Center, Salzburg, Salzburg, Austria; Regine Klinger, Institute of Psychology III, University of Hamburg, Hamburg, Germany

C. Predicting Outcomes**Room N1-O1****Chair: Geri Padilla**

109/ ASSOCIATION OF GENERIC AND SPECIFIC HEALTH RELATED QUALITY OF LIFE WITH MORTALITY IN COPD PATIENTS
 A. Domingo-Salvany, HSR Unit (HSRU), R. Lamarca, M. Ferrer, HSRU, J. Garcia-Aymerich, Respiratory and Environmental Research Unit (RERU), J. M. Antó, RERU, G. Vilagut, HSRU, IMIM, Barcelona, Spain, M. Félez, Hospital del Mar, Barcelona, Spain, A. Khalaf, Hospital de la Magdalena, Castelló, Spain, E. Monsó, Hospital Germans Trias i Pujol, Badalona, Spain; R. Marrades, Hospital Clínic, Barcelona, Spain, J. Serra-Battle, Hospital General, Vic, Spain, J. Alonso, HSRU, IMIM, Barcelona, Spain

110/ PREDICTORS OF MORTALITY IN PATIENTS WITH CHRONIC RESPIRATORY FAILURE
 Mauro Carone, Respiratory Disease, Fondazione Salvatore Maugeri, Veruno, (NO), Italy; Sabina A. Antoniu, Clinic of Pulmonary Disease, GR. T. PoPa University of Medicine and Pharmacy, Iasi, Iasi, Romania; Paul W. Jones, Division of Physiological Medicine, St. George's Hospital Medical School, London, UK; Claudio F. Donner, Division of Pulmonary Disease, Fondazione Salvatore Maugeri, Veruno, (NO), Italy

111/ IS IT POSSIBLE TO PREDICT PATIENT'S QOL AFTER OPEN HEART SURGERY?
 Zoran R. Potic, Djordje Jakovljevic, Marijela M. Potic, Miroslava Popov, Ninoslav D. Radovanovic, Cardiovascular Surgery, Institute of CVD, Sremska Kamenica, Vojvodina, Yugoslavia

112/ RELATIONSHIP BETWEEN COMORBIDITIES AND HEALTH-RELATED QUALITY OF LIFE IN CHRONIC RESPIRATORY FAILURE: A QUASS GROUP STUDY
 Sabina A. Antoniu, European Respiratory Fellow at Divisione di Pneumologia, Mauro Carone, Claudio F. Donner, Divisione di Pneumologia, Salvatore Maugeri Foundation, Veruno, NO, Italy; Paul W. Jones, Division of Physiological Medicine, St. George's Hospital Medical School, London, UK

113/ SURVIVAL, QUALITY OF LIFE AND THE SEVERITY OF SYMPTOMS OF CANCER PATIENTS
 Tito R. Mendoza, Shelley Wang, Cielito Reyes-Gibby, Charles S. Cleeland, Pain Research Group, The University of Texas M.D. Anderson Cancer Center, Houston, TX

D. Assessing Change**Room N****Chair: Tara Symonds**

114/ DEFINING RECOVERY: THE APPLICATION OF CLUSTER ANALYSIS TO LONGITUDINAL HEALTH STATUS DATA IN PHYSIOTHERAPY PATIENTS.
 Dorcas E. Beaton, Neuromusculoskeletal Program, St Michael's Hospital, Toronto, ON, Canada; Carol Kennedy, Michael Manno, Deirdre McKenzie, Sheilah Hogg-Johnson, Institute for Work & Health, Toronto, ON, Canada; Laurie Hurley, Marla Nayer, College of Physiotherapy of Ontario, Toronto, ON, Canada

115/ ROC ANALYSIS OF WEIGHT LOSS TO ACHIEVE CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE
 Ross D. Crosby, Biomedical Statistics, Neuropsychiatric Research Institute, Fargo, ND; Ronette L. Kolotkin, Psychiatry, Duke University Medical Center, Durham, NC; G. R. Williams, Knoll Pharmaceuticals, Abbott Laboratories, Mount Olive, NJ; Guilford G. Hartley, Department of Medicine, Hennepin County Medical Center, Minneapolis, MN

116/ RESPONSIVENESS OF THE QUALITY OF LIFE IN EPILEPSY INVENTORY (QOLIE-89) IN AN ANTIEPILEPTIC DRUG TRIAL
 Sehyun Kim, Preventive Medicine, College of Medicine, Pochon CHA University, Sungnam, Kyonggi-do, Korea; Ron D. Hays, General Internal Medicine, UCLA, Los Angeles, CA; Gretchen L. Birbeck, Neurology & Epidemiology, Michigan State University, East Lansing, MI; Barbara G. Vickrey, Neurology, UCLA, Los Angeles, CA

117/ WHAT IS A CLINICALLY MEANINGFUL CHANGE IN THE MEASUREMENT OF FATIGUE?
 David Cella, David T. Eton, Jin-Shei Lai, Amy H. Peterman, Evanston Northwestern Healthcare (ENH), Northwestern University (NU), Evanston, IL

118/ MULTISAMPLE MEAN AND COVARIANCE STRUCTURE MODELS FOR ASSESSING RESPONSIVENESS
 Thomas Kohlmann, Institute for Social Medicine, Medical University of Luebeck, Luebeck, Germany; Joachim Leonard, Boehringer Ingelheim Pharma KG, Ingelheim am Rhein, Germany; Heiner Raspe, Institute for Social Medicine, Medical University of Luebeck, Luebeck, Germany; Henning Zeidler, Hannover Medical School, Hannover, Germany

E. Mixed Methods
Chair: Madeleine King

Room M

119/ A COMPARISON OF THE DISCRIMINATIVE AND EVALUATIVE PROPERTIES OF SF-36 SCALES AND SUMMARY MEASURES AND THE SF-6D INDEX

John Brazier, Scharr, The University of Sheffield, Sheffield, UK; Samuel J. Sinclair, Barbara Gandek, John E. Ware, Jr., Health Assessment Laboratory, Boston, MA

120/ USING STRUCTURAL EQUATION MODELS (SEM) TO INTERPRET TREATMENT SATISFACTION AND QUALITY OF LIFE DATA: THE CASE FOR INHALED INSULIN

Ralph R. Turner, PHASE V Technologies, Inc., Wellesley Hills, MA, Marcia A. Testa, Biostatistics, Harvard School of Public Health, Boston, MA

121/ VALUE SHIFT AFTER DISABILITY ONSET: A MINOR ISSUE?

Marcel P. Dijkers, Rehabilitation Medicine, Mount Sinai School of Medicine, New York, NY

122/ COMPARISON OF UNWEIGHTED SATISFACTION SCORES AND SCORES WEIGHTED BY RELATIVE IMPORTANCE IN MEASURING QUALITY OF LIFE FOR ADULTS WITH CHRONIC HEALTH PROBLEMS

Janet E. Jeffrey, School of Nursing, York University, Toronto, ON, Canada

123/ ASSESSMENT OF QUALITY OF LIFE IN CHRONIC BRONCHITIS AND ITS ACUTE EXACERBATIONS: COMPARISON OF A GENERIC AND A CONDITION-SPECIFIC MEASURE

Helen A. Doll, Oxford Outcomes, Oxford, Oxon, UK; Isabelle Duprat-Lomon, Health Economics and Outcomes Research, Bayer Pharma, Paris, France; Erika D. Ammerman, Oxford Outcomes, Oxford, Oxon, UK; Pierre-Philippe Sagnier, Health Economics and Outcomes Research, Bayer plc, Slough, Berkshire, UK

Posters I: Wednesday, November 7 (12:00 pm - 4:00 pm) Lounge Forum

Meet the Authors: 2:45 - 3:15 pm

Oncology

124/ AN INDIVIDUALIZED APPROACH IN THE MEASUREMENT OF QUALITY OF LIFE IN LONG-TERM SURVIVORS OF HODGKIN'S DISEASE

Lena Wettergren, Department of Medicine and Division of Hematology, Karolinska Institutet and Hospital, Stockholm, Sweden; Magnus Björkholm, Department of Medicine and Division of Hematology, Karolinska Institutet and Hospital, Stockholm, Sweden; Ann Bowling, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK; Ulla Axdorff, Division of Hematology, Karolinska Hospital, Stockholm, Sweden; Ann Langius-Eklöf, Department of Nursing, Karolinska Institutet, Stockholm, Sweden

125/ QUALITY OF LIFE IN LONG-TERM PROSTATE CANCER SURVIVORS AND THEIR SPOUSES

Carolyn C. Gotay, Miles Y. Muraoka, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI

126/ QUALITY OF LIFE OF MALIGNANT BRAIN TUMOR PATIENTS UNDERGOING GAMMA KNIFE RADIOSURGERY

Peggy A. Ward-Smith, School of Nursing, The University of Missouri - Kansas City, Kansas City, MO

127/ EFFECTS OF PSYCHOSOCIAL INTERVENTION ON QUALITY OF LIFE IN PATIENTS WITH HEAD AND NECK CANCER

Karin M. Petruson, Ewa Silander, Eva Hammerlid, Department of Otolaryngology, Head and Neck Surgery, Sahlgrenska University Hospital, Göteborg, Sweden

128/ PSYCHOSOCIAL CONSEQUENCES OF PREVENTIVE HEALTH OPTIONS AMONG WOMEN AT INCREASED RISK OF DEVELOPING OVARIAN CANCER: A PILOT STUDY

Judith Hollenstein, Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Eveline M. Bleiker, Division of Psychosocial Research and Epidemiology, Marc van Beurden, Department of Gynecology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Heiddis Valdimarsdottir, Department of Cancer Prevention and Control, Mount Sinai Hospital, New York, NY; Neil A. Aaronson, Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands

129/ GENDER DIFFERENCES IN FACTORS PREDICTING QUALITY OF LIFE AFTER SURGERY FOR COLORECTAL CANCER PATIENTS

M. Berend, J. Siebmann, P. Boll, T. Küchler, D. Henne-Bruns, B. Kremer, Reference Centre Quality of Life, Christian-Albrechts-University, Kiel, Germany

130/ COLORECTAL CANCER SCREENING: COMPLIANCE OF FAMILIES AT HIGH RISK

Eveline M. Bleiker, Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Fred H. Menko, Department of Clinical Genetics, University Hospital Vrije Universiteit, Amsterdam, The Netherlands; Lidwina D. Wever, Miranda A. Gerritsma, Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Irma Kluijft, Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands; Babs G. Taal, Department of Gastroenterology, Neil K. Aaronson, Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands

131/ GENETIC COUNSELING FOR COLORECTAL CANCER: DISTRESS 1-11 YEARS LATER

Eveline M. Bleiker, Lidwina D. Wever, Miranda A. Gerritsma, Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Fred H. Menko, Department of Clinical Genetics, University Hospital Vrije Universiteit, Amsterdam, The Netherlands; Babs G. Taal, Department of Gastroenterology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Irma Kluijft, Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands; Neil K. Aaronson, Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands

132/ QUALITY OF LIFE ASSESSMENT IN RANDOMIZED PHASE III TRIAL IN STAGE IV NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH THE QOL-ANTICANCER DRUGS (QOL-ACD) QUESTIONNAIRE

Taketoshi Matsumoto, Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Yasuo Ohashi, Department of Biostatistics, University of Tokyo, Bunkyo-ku, Tokyo, Japan; Hideo Kunitoh, Department of Internal Medicine & Thoracic Oncology, National Cancer Center Hospital Central, Chuo-ku, Tokyo, Japan; Kazumasa Noda, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Koshiro Watanabe, Division of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan

133/ HOW POTENT IS POTENT? EVALUATION OF SEXUAL FUNCTION AND BOTHER IN MEN WHO REPORT POTENCY: DATA FROM CAPSURE

Deborah P. Lubeck, Gary Grossfeld, Peter Carroll, Urology, University of California San Francisco, San Francisco, CA; James M. Henning, Outcomes Research, TAP Pharmaceutical Products Inc., Lake Forest, IL

134/ EVALUATION OF QUALITY OF LIFE AFTER LIVER TRANSPLANTATION IN JAPAN

Hirohisa Imai, Public Health, Miyazaki Medical College, Miyazaki, Miyazaki, Japan; Katsuhiko Oga, Radiological Technology, College of Medical Technology Hokkaido, Sapporo, Hokkaido, Japan

135/ A PROSPECTIVE COMPARISON OF QUALITY OF LIFE INSTRUMENTS IN PATIENTS WITH OESOPHAGEAL CANCER

V. Kavadas, J. M. Blazeby, Division of Surgery, Bristol Royal Infirmary, Bristol, UK; C. W. Vickery, Department of Surgery, R. G. Berrisford, Department of Thoracic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon, UK; C. P. Barham, D. Alderson, Division of Surgery, Bristol Royal Infirmary, Bristol, UK

136/ A PROSPECTIVE RANDOMIZED STUDY ON THE IMPACT OF PSYCHOONCOLOGICAL INTERVENTION IN CANCER PATIENTS INCLUDING QUALITY OF LIFE AND PSYCHO-ENDOCRINO-IMMUNOLOGICAL PARAMETERS

Mechthild M. Determann, Holger Kalthoff, Department of General Surgery, Volker E. Kollenbaum, Cancer Centre, Nicholas Zavazava, Institute of Immunology, Bernd Kremer, Doris Henne-Bruns, Department of General Surgery, University Hospital, Kiel, Germany

Oncology (continued)**137/ QUALITY OF LIFE IMPACT ON SATISFACTION WITH CARE IN CANCER INPATIENTS**

Emmanuel Desandes, Thierry Conroy, Recherche Clinique, Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France; Serge Briancon, Francis Guillemin, Fabienne Empereur, Epidemiologie et Evaluation Cliniques, Chu de Nancy, Nancy, France; Francois Guillemin, Chirurgie, Isabelle Leonard, Recherche Clinique, Centre Alexis Vautrin, Vandoeuvre-les-Nancy, Nancy, France; Anne Bredart, Unite de Psycho-oncologie, Institut Curie, Paris, France; Pierre Bey, Radiotherapie, Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France

138/ IMPACT OF COPING, FUNCTIONALITY, AND SYMPTOMS ON THE QUALITY OF LIFE OF HAEMATOLOGICAL CANCER PATIENTS

Jose L. Pais-Ribeiro, Faculdade de Psicologia, Universidade do Porto, Porto, Portugal; Eunice Sa, ISPA, ISPA, Lisboa, Portugal

139/ AN EMPIRICAL META-ANALYSIS OF FIVE DIFFERENT STUDIES EXPLORING QUALITY OF LIFE AFTER PROSTATE CANCER

J. U. Siebmann, M. Berend, T. Kuchler, Reference Centre Quality of Life, Christian-Albrechts-University, Kiel, Germany

140/ THE NEED FOR PSYCHOSOCIAL SUPPORT IN PATIENTS WITH MALIGNANT CHOROIDAL MELANOMA

Jens Reimer, Department of Neurology, University of Bochum, Bochum, Germany; Anja Fleiss, Gabriele H. Franke, Institute of Medical Psychology, University of Essen, Essen, Germany

141/ DETERMINING CLINICALLY SIGNIFICANT CHANGES IN FATIGUE SUBSCALE HEALTH-RELATED QUALITY OF LIFE SCORES FOR CANCER PATIENTS

Heather-Jane Au, Melina Dharma-Wardene, Martin Palmer, Cross Cancer Institute, Edmonton, AB, Canada; David Dupere, Queen Elizabeth II HSC, Halifax, NS, Canada; John Hanson, Cross Cancer Institute, Edmonton, AB, Canada

142/ TESTING THE LUNG CANCER SYMPTOM SCALE (LCSS) MODEL IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM)

Patricia J. Hollen, School of Nursing, Northeastern University, Boston, MA; Richard J. Gralla, Division of Medical Oncology, Columbia University, New York, NY; Astra Liepa, Global Economic Affairs, Xiaochun Li, Department of Statistics, James Rusthoven, ALIMTA team, Eli Lilly and Co., Indianapolis, IN

143/ RELATIONSHIP BETWEEN CANCER LOCUS OF CONTROL AND QUALITY OF LIFE

Vitor L. Rodrigues, Pedro L. Ferreira, Helena F. Ribeiro, Centre for Health Studies and Research, University of Coimbra, Coimbra, Portugal

144/ THE RELATIONSHIP BETWEEN INFORMATION SATISFACTION AND QUALITY OF LIFE IN CANCER

Clara L. Yu, R. Fielding, Community Medicine, C. L. Chan, Social Work and Soc. Administration, J. S. Sham, Clinical Oncology, Hong Kong University, Hong Kong, China

145/ IMPROVEMENT IN HEMOGLOBIN LEVELS REDUCES FATIGUE AND IMPROVES HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF ANEMIC CANCER PATIENTS

J. D. Kallich, Health Economics and Epidemiology, H. Erder, G. Rossi, E. Poulsen, A. Colowick, J. Isitt, The NESP 980290/980297 Study Groups, Amgen Inc., Thousand Oaks, CA

146/ PSYCHOLOGICAL DISTRESS AND SEXUAL FUNCTIONING OF OVARIAN CANCER SURVIVORS

Karen Basen-Engquist, Behavioral Science, Diane Bodurka-Bevers, Gynecologic Oncology, Cindy L. Carmack Taylor, Behavioral Science, The University of Texas, M. D. Anderson Cancer Center, Houston, TX

147/ SYMPTOMS PREDICT REDUCED HRQOL DURING RADIOTHERAPY AMONG PATIENTS WITH LUNG, COLORECTAL AND PANCREAS CANCER

Xin Shelley Wang, Pain Research Group, Nora A. Janjan, Ritsuko Komaki, Radiation Oncology, Mary Easley, Tito Mendoza, Gary Mobley, Charles S. Cleeland, Pain Research Group, University of Texas, MD Anderson Cancer Center, Houston, TX

148/ EARLY QUALITY OF LIFE IN LOCALIZED PROSTATE CANCER: AN EXAMINATION OF TREATMENT-RELATED, DEMOGRAPHIC, AND PSYCHOSOCIAL FACTORS

David T. Eton, Center on Outcomes, Research, & Education, Evanston Northwestern Healthcare & Northwestern University, Evanston, IL; Stephen J. Lepore, Department of Psychology, Brooklyn College-CUNY, Brooklyn, NY; Vicki S. Helgeson, Department of Psychology, Carnegie Mellon University, Pittsburgh, PA

149/ MENTAL ADJUSTMENT TO CANCER AND SOCIAL SUPPORT: IMPORTANT FACTORS FOR THE QUALITY OF LIFE OF OVARIAN CANCER SURVIVORS

Georg Kemmler, B. Holzner, V. Meraner, T. Bodner, Department of Psychiatry, G. Zeimet, Department of Internal Medicine, B. Sperner-Unterweger, Department of Psychiatry, Innsbruck University Clinics, Innsbruck, Austria

150/ THE RELATIONSHIP BETWEEN PAIN SEVERITY, PAIN-RELATED INTERFERENCE AND HEALTH RELATED QUALITY OF LIFE IN SWEDISH CANCER PATIENTS

Tito R. Mendoza, Pain Research Group, University of Texas, M.D. Anderson Cancer Center, Houston, TX; Bengt Bergman, Department of Respiratory Medicine, Sahlgrenska University Hospital, Goteborg, Sweden; Colin Durnin, Knoll Pharmaceuticals, London, UK; Charles S. Cleeland, Pain Research Group, The University of Texas, M.D. Anderson Cancer Center, Houston, TX

151/EFFECT OF CAREGIVER PERCEPTION OF PREPAREDNESS ON BURDEN IN AN ONCOLOGY POPULATION

Mary J. Scherbring, Nursing, Mayo Medical Center, Rochester, MN

152/ THE PATIENT AND THEIR DOCTOR: A CONTEXT FOR UNDERSTANDING THE DESIRE TO HASTEN DEATH

Brian Kelly, Frank Varghese, Psychiatry, University of Queensland, Brisbane, Queensland, Australia; Marguerite Robertson, Palliative Care Hospice, Mount Olivet Hospital, Brisbane, Queensland, Australia; Paul Burnett, Research and Graduate Training, Charles Sturt University, Wagga Wagga, NSW, Australia; Dan Pelusi, Shirlene Badger, Psychiatry, University of Queensland, Brisbane, Queensland, Australia

Oncology (continued)**153/ QOLTI-F: A MEASURE OF THE QOL OF FAMILY CAREGIVERS OF PALLIATIVE CARE PATIENTS**

S. Robin Cohen, Department of Oncology, McGill University, Montreal, QC, Canada; Anne Leis, Community Health & Epidemiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; Patricia Porterfield, David Hsu, Palliative Care, Vancouver Hospital & Health Sciences Centre, Vancouver, BC, Canada; David Kuhl, Family & Community Medicine, Providence Health Centre, Vancouver, BC, Canada; Cecile Charbonneau, Palliative Care Research Team, Maison Michel Sarrazin, Quebec City, QC, Canada; Jane Poulson, Palliative Medicine & General Internal Medicine, The Toronto Hospital, Toronto, ON, Canada; Carmelita McNeil, Palliative Care Research, McGill University, Montreal, QC, Canada; Paul Ritvo, Preventive Oncology, Cancer Care Ontario, Toronto, ON, Canada

154/ DECISIVE FACTORS OF QUALITY OF LIFE OF BLADDER CANCER SURVIVORS FIVE YEARS AFTER THE TREATMENTS IN FRANCE

Tomohiro Matsuda, Inserm U558, Toulouse, France; Catherine Exbrayat, Registre des Cancers de l'Isere, Meylan, France; Isabelle Aptel, Pascale Grosclaude, Registre des Cancers du Tarn, Toulouse, France

155/ IMPACT OF A SECOND PRIMARY CANCER ON QUALITY OF LIFE IN BREAST CANCER SURVIVORS

Carolyn C. Gotay, Marya Levintova-Romero, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI

156/ SEXUAL FUNCTION IN WOMEN WITH A HISTORY OF CERVICAL CANCER TREATED BY RADIOTHERAPY

Pernille T. Jensen, Department of Gynecology, Copenhagen University Hospital, Copenhagen, Denmark; Mogens Groenvold, Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark; Marianne C. Klee, Department of Oncology, Herlev Hospital, Copenhagen, Denmark; David Machin, Institute of General Practice and Primary Care, Northern General Hospital, Sheffield, UK

157/ QUALITY OF LIFE OF BREAST CANCER SURVIVORS IN THE ACUTE, EXTENDED AND PERMANENT PHASES OF SURVIVORSHIP

Lori J. Andreas, Adult Oncology/ Bone Marrow Transplant, OHSU, Portland, Oregon

158/ HOW TO MEASURE THE ATTITUDE OF WOMEN WITH BREAST CANCER TOWARDS TRADEOFFS BETWEEN QUALITY AND QUANTITY OF LIFE

Wendy J. Post, Office for MTA, University Hospital Groningen, Groningen, The Netherlands; Anne M. Stiggelbout, Department of Medical Decision Making, Leiden University Medical Center, Leiden, The Netherlands

159/ THE CANCER OUTCOMES MEASUREMENT WORKING GROUP (COMWG): AN NCI INITIATIVE TO IMPROVE THE SCIENCE OF OUTCOMES MEASUREMENT IN CANCER

Joseph Lipscomb, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD; Carolyn C. Gotay, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI; Claire F. Snyder, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD

380/ ADVANTAGES OF JOINT USE OF EORTC QLQ-C30 AND FACT-G IN MALIGNANT LYMPHOMA PATIENTS

Andrei A. Novik, Tatyana I. Ionova, Anton S. Povzun, Anton V. Kishtovich, Multinational Center of Quality of Life Research, Military Medical Academy, St. Petersburg, Russia

Chronic Diseases**160/ HRQOL IN PEOPLE WITH APHASIA: PRELIMINARY FINDINGS FROM A PILOT STUDY**

Katerina Hilari, Department of Language and Communication Science, City University, London, UK; Sally Byng, Connect—the Communication Disability Network, London, UK

161/ CONSTIPATION AND QUALITY OF LIFE IN THE CANADIAN POPULATION COMPARED TO PRIMARY CARE PATIENTS

S. Ferrazzi, Janssen-Ortho Inc., Toronto, Canada; E. J. Irvine, McMaster University, Hamilton, ON, Canada; P. Pare, L'Hotel Dieu de Quebec, QC, Canada; W. G. Thompson, University of Ottawa, Ottawa, ON, Canada; L. Rance, Janssen-Ortho Inc., Toronto, ON, Canada; T. Faloon, University of Ottawa, Ottawa, ON, Canada

162/ QUALITY OF LIFE IN UNIVERSITY STUDENTS WITH CHRONIC HEALTH PROBLEMS: COPING AND CONTEXT

Fuschia M. Sirois, Michelle L. Melia-Gordon, Timothy A. Pychyl, Psychology, Carleton University, Ottawa, ON, Canada

163/ EVALUATING QUALITY OF LIFE IN PATIENTS AFTER TREATMENT OF AN OPEN TIBIAL FRACTURE BY USING THE NOTTINGHAM HEALTH PROFILE

Jörg Klewer, Public Health, Dresden Medical School, Dresden, Germany; Werner Knopp, Department of Orthopedic Surgery, Medical School of Göttingen, Göttingen, Germany; Joachim Kugler, Public Health, Dresden Medical School, Dresden, Germany

164/ DETERMINANTS OF QUALITY OF LIFE IN LUNG TRANSPLANT PATIENTS: IMPACT OF PERSONAL FACTORS, DISEASE STAGE AND COMPLEMENTARY THERAPY USE

Barbara J. Matthees, Nursing, Minnesota State University Moorhead, Moorhead, MN; Cynthia R. Gross, Academic Health Center, Mary Jo Kreitzer, Center for Spirituality and Healing, Kay Savik, School of Nursing, Marshall I. Hertz, Academic Health Center, University of Minnesota, Minneapolis, MN

165/ FACT-AN SHOWS SENSITIVITY TO CHRONIC ILLNESSES: RESULTS FROM A WEB-BASED SURVEY

Christina Vadoros, Janssen-Cilag Pharmaceutical SACI, Pefki, Athens, Greece; M. Zagari, D. Gagnon, B. Shilling, The R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ; D. Cella, Northwestern University, Evanston, IL

Rheumaty Arthritis/Osteoporosis

166/ QUALITY OF LIFE AND COPING STRATEGIES IN FEMALE ALOPECIA

Silke Schmidt, Department of Medical Psychology, University Hospital Eppendorf, Hamburg, Germany; Tobias Fischer, Peter Elsner, Department of Dermatology, Bernhard Strauss, Department of Medical Psychology, University Hospital Jena, Jena, Germany

167/ EFFECTS OF COPING ON MENTAL OUTCOME IN PERSONS WITH SPINAL CORD LESION

Magnus L. Elfström, Anna Rydén, Health Care Research Unit, Göteborg University, Göteborg, Sweden; Margareta Kreuter, Department of Physiotherapy, Sahlgrenska University Hospital, Göteborg, Sweden; Lars-Olof Persson, Marianne Sullivan, Health Care Research Unit, Göteborg University, Göteborg, Sweden

168/ ASSESSING QUALITY OF LIFE IN OSTEOPOROSIS CLINICAL TRIALS

Stephen P. McKenna, Lynda C. Doward, Abigail L. Dewar, Galen Research, Manchester Science Park, Manchester, UK

169/ EVIDENCE SUPPORTING THE VALIDITY OF THE NOTTINGHAM HEALTH PROFILE IN RHEUMATOID ARTHRITIS

J. Michael Woolley, Wing W. Chan, Amgen Inc., Thousand Oaks, CA

381/ QUALITY OF LIFE AND AGE RELATIONSHIP IN RHEUMATOID ARTHRITIS PATIENTS

A. Tsepkova, Multinational Center of Quality of Life Research, St. Petersburg, Russia; T. Shemerovskaya, Rheumatological Center, St. Petersburg, Russia; A. Kishtovich, T. Ionova, Multinational Center of Quality of Life Research, St. Petersburg, Russia

Diseases of the Skin

170/ THE PRACTICALITIES OF QUALITY OF LIFE MEASURES IN OSTEOPOROSIS CLINICAL TRIALS

Christel Naujoks, Global Health Economics, Novartis Pharma AG, Basel, Switzerland

171/ QUALITY OF LIFE IN PATIENTS WITH ATOPIC DERMATITIS: USING THE JAPANESE VERSION OF THE SF-36 HEALTH STATUS QUESTIONNAIRE

Keiko Fukuroku, Satoshi Ogino, School of Allied Health Science, Faculty of Medicine, Suita, Osaka, Japan; Takuzou Nagano, Nagano Dermatology and Allergy Clinic Osaka Toyonaka, Osaka, Japan; Takao Harada, Schering-Plough K.K. Osaka, Osaka, Japan

172/ HELIOTHERAPY AT THE DEAD SEA IMPROVES QUALITY OF LIFE IN PSORIATIC PATIENTS : A PROSPECTIVE STUDY

Marianne Amir, Behavioral Sciences and Social Work, Daniel Vardy, Department of Dermatology, Tal Narkiss, Gideon Becker, Department of Behavioral Sciences, Dan Buskila, Department of Internal Medicine, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Neurologic Diseases

173/ A METHOD FOR ESTIMATING THE CONTRIBUTION OF DISEASE TO HRQL SCORES: A STUDY OF PERSONS WITH PSORIASIS

Stephen Rapp, Psychiatry and Behavioral Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Catherine Cottrell, Psychology, Arizona State University, Tempe, AZ; Mark Leary, Psychology, Wake Forest University, Winston-Salem, NC

174/ AN ASSESSMENT OF HEALTH-RELATED QUALITY-OF-LIFE OF PATIENTS WITH MIGRAINE

Bala S. Nadesan, Pharmaceutical Sciences, Texas Tech University, HSC, School of Pharmacy, Amarillo, TX; Paul Cady, Vaughn Culbertson, Pharm. Pract. & Administration Sciences, Idaho State University, Pocatello, ID

175/ HOW CONSISTENT IS SELF-REPORTED HEALTH-RELATED QUALITY OF LIFE IN THE FACE OF COGNITIVE IMPAIRMENT IN MS PATIENTS?

Monika L. Baier, Center for Research Methodology and Biometrics, AMC Cancer Research Center, Lakewood, CO; Deborah M. Miller, Department of Neurology, Mellen Center for MS Treatm, Cleveland Clinic Foundation, Cleveland, OH

176/ THE NHP INDEX OF DISTRESS IN PARKINSON'S DISEASE

Peter Hagell, Section of Restorative Neurology, Birgitta Sandlund, Jan Reimer, Martin Grabowski, Division of Neurology, Olle Lindvall, Section of Restorative Neurology, Department of Clinical Neuroscience, Lund, Sweden

177/ TREATMENT AND HEALTHCARE SATISFACTION AMONG PEOPLE WITH MIGRAINE HEADACHES

Joan A. Mackell, Pfizer Inc., New York, NY; Diana D. McDonnell, Consumer Health Sciences, Princeton, NJ

178/ TREATMENT AND QUALITY OF LIFE AMONG PEOPLE WITH MIGRAINES

Joan A. Mackell, Pfizer, Inc., New York, NY; Diana D. McDonnell, Consumer Health Sciences, Princeton, NJ

179/ QUALITY OF LIFE IN GERMAN PATIENTS WITH MYASTHENIA GRAVIS

Jörg Klewer, Linda Wondzinski, Annette Friedrichs, Public Health, Dresden Medical School, Dresden, Germany; Dieter Pöhlau, Department of Neurology, Hachen Hospital, Sundern, Germany; Joachim Kugler, Public Health, Dresden Medical School, Dresden, Germany

180/ QUALITY OF LIFE IN PATIENTS WITH MULTIPLE SCLEROSIS LIVING AS SINGLE

Joachim Kugler, Public Health, Dresden Medical School, Dresden, Germany; Dieter Pöhlau, Department of Neurology, Hachen Hospital, Sundern, Germany; Jörg Klewer, Public Health, Dresden Medical School, Dresden, Germany

181/ ASSESSMENT OF HEALTH STATUS IN PATIENTS WITH CEREBRAL PALSY: WHAT IS THE ROLE OF QUALITY OF LIFE MEASURES?

Michael G. Vitale, Pediatric Orthopaedics, Children's Hospital of New York, New York, NY; Julie C. Choe, Pediatric Orthopaedics, Annetine C. Geljins, Alan J. Moskowitz, Surgery, InCHOIR, New York, NY; Joshua E. Hyman, Francis Y. Lee, David P. Roye, Pediatric Orthopaedics, Children's Hospital of New York, New York, NY

withdrawn

Neurologic Diseases (continued)**182/ A COMPREHENSIVE REVIEW OF CAREGIVER BURDEN MEASURES IN ALZHEIMER'S DISEASE**

Jeff Borenstein, Cedars-Sinai Health System, Zynx Health Inc., Beverly Hills, CA; Sobin Chang, Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Eileen Reyes, Simcha M. Russak, Research, Cedars-Sinai Health System, Zynx Health Inc., Beverly Hills, CA; Aaryn S. Cohen, Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Chiun-Fang Chiou, Research, Cedars-Sinai Health System, Zynx Health Inc., Beverly Hills, CA

378/ PSYCHOLOGICAL ADJUSTMENT THAN CLINICAL SEVERITY IS MORE STRONGLY ASSOCIATED WITH HQOL OF PATIENTS WITH PARKINSON'S DISEASE

Yoshimi Suzukamo, Epidemiology and Health Care Research, Kyoto University, Kyoto, Japan; Sadayoshi Ohbu, Neurology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan; Tomoyoshi Kondo, Junko Kohmoto, Neurology, Wakayama Medical University, Wakayama, Japan; Masanori Nagaoka, Neurology, National Rehabilitation Center for the Disabled, Tokorozawa, Saitama, Japan; Shunichi Fukuhara, Epidemiology and Health Care Research, Kyoto University, Kyoto, Japan

379/ QUALITY OF LIFE IMPAIRMENT IN MULTIPLE SCLEROSIS PATIENTS

Petr I. Denisov, Andrei A. Novik, Tatyana I. Ionova, Elena M. Vereschagina, Anton V. Kishtovich, Multinational Quality of Life Research Center, Military Medical Academy, St. Petersburg, Russia

Interpretation/Theory**183/ THE INFLUENCE OF GENDER ON HEALTH-RELATED QUALITY OF LIFE (HRQL) OF FAMILY CAREGIVERS OF STROKE SURVIVORS**

Carole L. White, Sharon Wood-Dauphinee, Nancy E. Mayo, James Hanley, Epidemiology & Biostatistics, McGill University, Montreal, QC, Canada

184/ QUALITY OF LIFE OF ENROLLEES AND NON-ENROLLEES IN FORMAL WEIGHT-LOSS PROGRAMS

Donald L. Patrick, Health Services, University of Washington, Seattle, WA; Donald M. Bushnell, Health Research Associates, Seattle, WA; Laura A. Glauda, Dennis D. Gagnon, Margaret Rothman, The R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ

185/ A PHILOSOPHICAL ANALYSIS OF THE MEANING OF SUFFERING

Laura M. DeHelian, Nursing, Cleveland State University, Cleveland, OH

186/ RELATING CONCEPTS OF DISEASE & ILLNESS IN HRQL RESEARCH

Michael A. Hagan, Researcher, Health Systems Strategies, Columbia University, Mailman School of Public Health, Denville, NJ; Steven M. Albert, Assistant Professor of Neuropsychology and Public Health, Gertrude H. Sergievsky Center, Columbia University, Denville, NJ

187/ ASSESSING THE SUBJECTIVE IMPACT ON INFORMAL CAREGIVERS OF CARING FOR CANCER PATIENTS: A REVIEW OF CONCEPTS AND MEASURES

Claire F. Snyder, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD

188/ FACTORS THAT PREDICT HRQL IN PATIENTS WITH RELAPSING REMITTING MS: RESULTS OF AN 8-YEAR STUDY

Deborah M. Miller, Richard Rudick, Mellen Center, Neurology, Cleveland Clinic Foundation, Cleveland, OH; Monika Baier, Garry Cutter, Center for Research Methodology and Biometrics, AMC Cancer Center, Lakewood, CO; David Daughtery, Neurology, Walter Reed Army Medical Center, Washington, DC; Bianca Weinstock-Guttman, Neurology, Buffalo General Hospital, Buffalo, NY; Michele Mass, Neurology, Oregon Health Sciences Center, Portland, OR; Elizabeth Fisher, Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH; Nancy Simonian, Medical Research, Biogen, Inc., Cambridge, MA

189/ WHAT DO WE MEASURE: HRQL OR HRQL DETERMINANTS?

Marie-Claude Simeoni, Christophe Sapin, Audrey Clement, Stéphanie Antonioti, Pascal Auquier, Public Health Department, Medical School, Marseille, France

Population Health**190/ A NEW CONCEPTUAL MODEL FOR TREATMENT SATISFACTION: WHAT IS IT? WHY MEASURE IT? AND, HOW BEST TO USE IT**

Meryl Brod, Vice President, Scientific and Research Affairs, Susan Mathias, Vice President, Health Outcomes Research, The Lewin Group, San Francisco, CA; Erin Sullivan, Research Scientist, The Lewin Group, Boston, MA; Shoshana Colman, Senior Research Manager, The Lewin Group, San Francisco, CA

191/ TIME PRESSURE AND EMOTIONAL WELL-BEING IN THE LIVES OF CANADIAN ADOLESCENTS AGED 12 TO 18 (1986 TO 1998)

Jiri Zuzanek, Roger Mannell, Recreation and Leisure Studies, University of Waterloo, Waterloo, ON, Canada

192/ DETERMINANTS FOR ADOLESCENT QUALITY OF LIFE: A LONGITUDINAL STUDY

Lynn H. Meuleners, Andy H. Chan, W. Binns, School of Public Health, Curtin University of Technology, Perth, Western Australia, Australia; Anthony G. Lowe, General Practice, Combined Universities Centre for Rural Health, Geraldton, Western Australia, Australia

193/ OVERALL QUALITY OF LIFE IN THE GENERAL NORWEGIAN POPULATION MEASURED BY THE QOLS-N

Astrid K. Wahl, Faculty of Health, Buskerud College, Drammen, Norway; Berit R. Hanestad, Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway; Tone Rustoen, Faculty of Nursing, Oslo University College, Oslo, Norway; Anners Lerdal, Øistein Knudsen Jr., Faculty of Health, Buskerud College, Drammen, Norway

194/ QUALITY OF LIFE AND SELF-RATED HEALTH

Dagmar Dzuřova, Charles University, Prague, Czech Republic; Eva Dragomirecka, Prague Psychiatric Center, Prague, Czech Republic

Population Health (continued)

195/ HEALTH RELATED TRADITIONAL BEHAVIORS CAN ALSO BE DISCRIMINATED BY HRQOL INSTRUMENTS: WHOQOL-BREF IN A POPULATION AND HEALTH SURVEY

Erhan Eser, Public Health (Halk S.), Gonul Dinc, Cemil Ozcan, Ümit C. Atman, Ahmet M. Oral, Public Health, Celal Bayar University Medical Faculty, Department of Public Health, Manisa, Turkey

196/ EFFECTS OF ALTERNATIVE MEDICINE ON THE QUALITY OF LIFE OF RESIDENTS IN A JAPANESE LARGE POPULATION SURVEY

Kauzo Uebaba, International Research Center for Traditional Medicine, Toyama City, Toyama Prefecture, Japan; Feng-Hao Xu, Akira Nagata, International Research Center for Traditional Medicine, Toyama City, Toyama Prefecture, Japan; Hideki Origasa, Toshihisa Morioka, Biostatistics, Toyama Medical & Pharmaceutical University, Toyama City, Toyama Prefecture, Japan

197/ MEASURING FATIGUE IN THE GENERAL POPULATION

Anners Lerdal, Faculty of Health, Buskerud College, Drammen, Norway; Torbjørn Moum, Faculty of Medicine, University of Oslo, Oslo, Norway; Astrid K. Wahl, Faculty of Health, Buskerud College, Drammen, Norway; Tone Rustøen, Faculty of Nursing, Oslo University College, Oslo, Norway; Øistein Knudsen Jr., Faculty of Health, Buskerud College, Drammen, Norway; Berit R. Hanestad, Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway

198/ THE HEALTH STATUS OF MIGRANT FARM WORKERS IN GEORGIA - AN INVISIBLE BUT INTEGRAL SEGMENT OF OUR POPULATION

Tom Himelick, Emory Physician Assistant Program, Alison Lauber, Department of Family and Preventive Medicine, Emory University, Atlanta, GA; Teresa Zyczynski, Health Economics and Outcomes Research, AstraZeneca LP, Wayne, PA; Cheryl Silberman, Elizabeth Adams, Health Economics and Outcomes Research, AstraZeneca LP, Wilmington, DE

199/ WELLNESS BEHAVIORS AS AN INDICATOR OF HEALTH-RELATED QUALITY OF LIFE

Michelle L. Melia-Gordon, Fuschia M. Sirois, Timothy A. Pychyl, Psychology, Carleton University, Ottawa, ON, Canada

200/ WORKERS' QUALITY OF LIFE: TOWARDS A NEW APPROACH OF INDUSTRIAL MEDICINE?

Jean-Louis San Marco, Public Health Department, Medical School, Marseille, France; Véronique Pellissier, Christian Mechetti, Jacques Viala-Artigues, Christophe Sapin, Pascal Auquier, Public Health Department, Marseille, France

201/ HEALTH-RELATED QUALITY OF LIFE AND OCCUPATION

Trond Riise, Bente E. Moen, Monica W. Nortvedt, Department of Public Health, University of Bergen, Bergen, Norway

202/ THE INFLUENCE OF LIFE-STYLE FACTORS ON HEALTH-RELATED QUALITY OF LIFE

Monica W. Nortvedt, Trond Riise, Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway

203/ HOW MIGRATION AFFECTS THE HEALTH RELATED QUALITY OF LIFE?: THE COMPARISON OF THE HRQOL OF THE NATIVE AND IMMIGRANT REPRODUCTIVE AGED WOMEN

Erhan Eser, Gonul Dinc, Cemil Ozcan, Public Health (Halk S.), CBU Medical Faculty, Manisa, Turkey

204/ IMPACT OF COMMUNITY MENTAL HEALTH SERVICES ON USERS' QUALITY OF LIFE: A COMPARISON OF THREE SYSTEMS

Leo R. Poirier, Malijai Caulet, Louise Fournier, Public Health, Montreal Health and Social Services Board, Montreal, QC, Canada; Celine Mercier, Div. de Recherche Psychosociale, Centre de Recherche de l'hôpital Douglas, Verdun, QC, Canada; Alain D. Lesage, Centre de Recherche Fernand-Seguin, Hôpital L. H. Lafontaine, Montreal, QC, Canada; Deena White, GRASP, Université de Montreal, Montreal, QC, Canada

Late-Breaker Abstracts A-F:

A/ BULIMIA NERVOSA - SUICIDAL IDEATION AND SYMPTOMS OF OBSESSIONALITY

A. Martischng, B. Steinbrenner, M. Schonauer-Cejpek, M. Steinbauer, University Hospital of Psychiatry, Graz, Austria

B/ MEASURING EMOTIONAL WELL-BEING OF CHINESE CANCER PATIENTS: RELIABILITY AND VALIDITY OF THE DEPRESSION SUBSCALE OF THE CHINESE VERSION OF THE HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS)

CM Wong¹, C Yu¹, D Kwong², D Chan², C Lee²; ¹Dept. Com Med, HKU, China; ²Dept. Clin Oncol, Queen Mary Hospital, HK, China

C/ THE EFFECTS OF EX ANTE RISKS ON VALUATIONS OF HEALTH SCENARIOS – IMPLICATIONS FOR THE QALY

Isabel M F Taylor, University of Sheffield, Sheffield, South Yorkshire, UK

D/ ADJUSTING DISTRIBUTIONS OF THE HEALTH UTILITIES INDEX MARK 3 UTILITY SCORES OF HEALTH-RELATED QUALITY OF LIFE

Jian Sun, Institute of Health Economics, Edmonton, Alberta, CA

E/ WHAT IMPACTS A WOMAN'S QUALITY OF LIFE AT SIX WEEKS POSTPARTUM?

Lisa K. Sharp and Susan E. Gerber, Northwestern University Medical School, Chicago, IL, USA

F/ SPIRITUALITY, RELIGIOSITY AND SUBJECTIVE QUALITY OF LIFE IN ISRAEL: PRELIMINARY RESULTS

Carmit Gaber and Marianne Amir, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Posters II: Thursday, November 8 (10:30 am - 5:00 pm) Lounge Forum

Meet the Authors: 3:30 - 4:00 pm

Clinical Practice

205/ USING A HEALTH STATUS INDICATOR TO INFORM PROGRAM DECISION-MAKING IN TWO OUTPATIENT MENTAL HEALTH SERVICES

David L. Lewis, Father Sean O'Sullivan Research Centre, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada; Gail C. Coulas, Sociology, McMaster University, Hamilton, ON, Canada

206/ QUALITY OF LIFE AND PRECARIOUSNESS: COMPARISON OF OBJECTIVE AND SUBJECTIVE HEALTH ASSESSMENT

Stéphanie Antoniotti, Public Health Department, Medical School, Marseille, France; Rémi Didelot, Doria Health Centre, Marseille, France; Christophe Sapin, Marie-Claude Simeoni, Public Health Department, Medical School, Marseille, France; Pascal Auquier, Public Health Department, Medical School, Marseille, France

207/ DOES HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN ROUTINE PRACTICE IMPROVE PATIENT OUTCOMES?

P. L. Lua, M. S. Salek, Centre for Socioeconomic Research, Cardiff University, Cardiff, UK.; N. Pratheepawanit, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand; I. G. Finlay, Velindre NHS Trust & University of Wales, College of Medicine, Cardiff, UK

208/ USING HEALTH STATUS QUESTIONNAIRES IN CLINICAL PRACTICE: A SURVEY OF HEALTHCARE PROFESSIONALS' VIEWS

Marissa Vicari, Dorothy L. Keininger, Mapi Research Institute, Lyon, France

209/ FUNCTION AND QUALITY OF LIFE MORBIDITY IN THE TREATMENT OF EXTREMITY SOFT TISSUE SARCOMA: THE NEED FOR SHARED DECISION-MAKING

Aileen M. Davis, Research, Toronto Rehabilitation Institute, Toronto, ON, Canada; Brian O'Sullivan, Charles N. Catton, Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada; Robert Turcotte, Orthopaedics, L'Hopital Maisonneuve-Rosemont, Montreal, QC, Canada; Robert S. Bell, Jay S. Wunder, Surgery, Mount Sinai Hospital, Toronto, ON, Canada; Anna Sadura, Andrew Day, Joe Pater, Benny Zee, Clinical Trials Group, National Cancer Institute, Queen's University, Kingston, ON, Canada

210/ ANGIOPLASTY PATIENT 36 MONTH SURVIVAL: THE ROLE OF QUALITY OF LIFE IN CLINICAL PRACTICE DECISIONS

Colleen M. Renier, Division of Education and Research, Carl E. Heltné, Regional Heart Center, Jeanette A. Palcher, Division of Education and Research, St. Mary's/Duluth Clinic Health System, Duluth, MN

211/ INTRODUCING HRQL INTO DAILY ROUTINE PRACTICE: HOW DO THE PHYSICIANS RESPOND?

Preben Bendtsen, Socialmedicine, Matti Leijon, Margareta Kristenson, Public Health Science, Health and Environment, Linköping, Sweden

212/ MEASUREMENT OF CONTINUITY AND CO-ORDINATION OF PATIENT CARE IN A CANCER CENTRE

Laura Booth, Peter Selby, Pamela Lynch, Cancer Medicine Research Unit, Imperial Cancer Research Fund, Leeds, UK; Julia Brown, Northern and Yorkshire Clinical Trials and Research, University of Leeds, Leeds, UK; Galina Velikova, Cancer Medicine Research Unit, Imperial Cancer Research Fund, Leeds, UK

382/ ARE QUALITY OF LIFE PARAMETERS OF PROGNOSTIC VALUE FOR THE PRESENCE OF DUODENAL ULCER RELAPSE?

Vassily Shuvaev, Multinational Center of Quality of Life Research, St. Petersburg, Russia

Aging

213/ QUALITY OF LIFE IN ELDERLY PERSONS SUPPORTED BY MANDATORY HEALTH CARE SYSTEM

Michiko Kobayashi, Ken Matsuoka, Tomoko Namba, Sachiyo Okabayashi, Shizuko Sugimoto, Michiko Ogushi, Akikazu Fukuoka, Sumie Masuyama, Kouji Miura, Tsukasa Kawanishi, Naoko Yui, Atsuko Suzuki, Haruyasu Fujita, Soichiro Maruyama, Kozaburo Adachi, Kanehisa Morimoto, Takashi Mandai, Japanese Society of Quality of Life Research, Kobe, Hyogo, Japan

214/ HOW DO WE AGE? AN ANALYSIS OF SYMPTOMS AND FUNCTION IN A COMMUNITY COHORT

T. G. Ganiats, Family and Preventive Medicine, K. M. David, R. M. Kaplan, E. Barrett-Connor, UC San Diego, La Jolla, CA

Respiratory Diseases

215/ CAN PHARMACEUTICAL CARE IMPROVE THE HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS WITH REACTIVE AIRWAYS DISEASE? A RANDOMIZED TRIAL

Morris Weinberger, Michael D. Murray, William M. Tierney, Medicine, Regenstrief Institute, Indianapolis, IN; David G. Marrero, Michael G. Lykens, Lisa E. Harris, Roopa Seshadri, Helena Caffrey, Medicine, Indiana University, Indianapolis, IN; Nancy Brewer, Medicine, Regenstrief Institute, Indianapolis, IN; Jeffrey A. Newell, Community Care, CVS/pharmacy, Woonsocket, RI; Joyce Collins, CVS/pharmacy, Indianapolis, IN

216/ LONG-TERM QUALITY OF LIFE IMPROVEMENTS IN ASTHMATIC ADULTS UNDERGOING EVIDENCE-BASED ASTHMA DISEASE MANAGEMENT PROGRAM

Ágota Szende, Health Economics, Astra Zsele, Debrecen, Hungary; Gabriella Jona, Zsolt Mogyorosy, Melinda Szaraz, Gizella Berki, Agnes Kuntar, Medical, Misszio Egészségügyi Központ, Veresegyház, Hungary, Eva Farkas, Respiratory Outpatient Clinic, Godollo, Hungary, Gyula Berta, Pulmonology, Hospital for Chest Diseases, Mosdos, Hungary

Diseases of the Eye

217/ QUALITY OF LIFE IN MYOPIC PATIENTS TREATED WITH DAY SURGERY

Takashi Mandai, Kozaburo Adachi, Kanehisa Morimoto, Shunji Tsuboi, Haruyasu Fujita, Soichiro Maruyama, Fumio Nomura, Atsuko Suzuki, Michiko Kobayashi, Yoshiko Naka, Rika Hayashida, Sachiyo Okabayashi, Tomoko Namba, Ken Matsuoka, Japanese Society of Quality of Life Research, Kobe, Hyogo, Japan

218/ CONTRIBUTION OF DIFFERENT CLINICAL VISUAL OUTCOMES TO THE IMPROVEMENT IN PERCEIVED VISUAL FUNCTION AFTER CATARACT SURGERY

Xavier Castells, Department of Studies, Hospital del Mar, Health Services Research Unit, IMIM-IMAS, Barcelona, Spain; Mercè Comas, Department of Studies, Hospital del Mar, Health Services Research Unit, IMIM, Barcelona, Spain; Ana Martínez-Palmer, Miguel Castilla, Department of Ophthalmology, Hospital del Mar, Barcelona, Spain; Josep Garcia-Arumí, Vicente Martínez, Department of Ophthalmology, Hospital de la Vall d'Hebron, Barcelona, Spain; Jordi Alonso, Health Services Research Unit, Institut Municipal d'Investigació Mèdica, IMIM-IMAS, Barcelona, Spain

219/ EVALUATION OF A GENERAL AND DISEASE-SPECIFIC QUALITY OF LIFE INSTRUMENT FOR CYTOMEGALOVIRUS RETINITIS

Barbara K. Martin, Adele M. Kaplan Gilpin, Epidemiology, Douglas A. Jabs, Ophthalmology, Albert W. Wu, Health Policy and Management, Johns Hopkins University School of Public Health, Baltimore, MD

Pain

220/ PAIN SCALE RATINGS AND SATISFACTION WITH PAIN CONTROL IN THE HOSPICE SETTING: RESPONSES TO CHANGES IN THE PATIENT'S LEVEL OF PAIN

Stephan F. Gohmann, Economics, University of Louisville, Louisville, KY

221/ DISCRIMINATIVE ASPECTS OF QUALITY OF LIFE IN PATIENTS WITH VULVAL DISEASES

Silke Schmidt, Department of Medical Psychology, University Hospital of Hamburg, Hamburg, Germany; Claudia Hartmann, University Hospital of Jena, Jena, Germany; Bernhard Strauss, Department of Medical Psychology, University Hospital of Jena, Jena, Germany

222/ EXPLORATIVE STUDY ON COMPLIANCE AND ACCEPTANCE OF CHRONIC PAIN PATIENTS TREATED WITH BUPRENORPHIN TRANSDERMAL SYSTEM (BTDS)

Astrid Anderson-Hillemecher, Medical Affairs + Health Economy, Grünenthal GmbH, Aachen, Germany; Alarcos Cieza, Heribert Limm, Institute for Medical Psychology, University, Munich, Germany

223/ EVALUATION OF A NOVEL PAIN MANAGEMENT PROGRAMME AND ITS IMPACT ON QUALITY OF LIFE

N. Pratheepawanit, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand; M. S. Salek, Centre for Socioeconomic Research, Cardiff University, Cardiff, UK; I. G. Finlay, Velindre NHS Trust, University of Wales College of Medicine, Cardiff, UK

Renal Diseases

224/ MEASUREMENT OF CHANGES IN DISEASE-SPECIFIC AND GENERIC QUALITY OF LIFE (QOL) OF END-STAGE RENAL DISEASE PATIENTS AFTER KIDNEY TRANSPLANTATION

Gabriele H. Franke, Psychology of Rehabilitation, University of Applied Sciences, Stendal, Germany; Saxonia-Anhaltina, Jens Reimer, Thomas Philipp, Uwe Heemann, University of Essen, Department of Nephrology and Hypertension, Essen, Germany, Northrhine-Westfalia

225/ LONG-TERM QUALITY OF LIFE AND COMORBID CONDITIONS IN THE DUTCH LUNG TRANSPLANT PROGRAM: A LONGITUDINAL STUDY

Karin M. Vermeulen, Jan-Paul Ouwens, Office for MTA, Wim van der Bij, Department of Pulmonary Diseases, Wim J. de Boer, Department of Thoracic Surgery, Gerard H. Koëter, Department of Pulmonary Diseases, Elisabeth M. TenVergert, Office for MTA, University Hospital Groningen, Groningen, The Netherlands

226/ EVALUATION OF THE SF-36 AND EQ-5D FOR USE IN RENAL TRANSPLANTATION CLINICAL TRIALS

Diane Whalley, Stephen McKenna, Galen Research, Manchester, UK; Zoltan Kalo, Novartis Pharma AG, Basel, Switzerland

227/ PREVALENCE OF ERECTILE DYSFUNCTION OF MALE RENAL TRANSPLANT PATIENTS AND ITS RELATION WITH HEALTH RELATED QUALITY OF LIFE

Pablo Rebollo, Nefrología-I, H. Central Asturias. Institute Reina Sofia of Nephro, Oviedo, Asturias, Spain; Francisco Fernandez-Vega, Nefrología-I, H. Central Asturias, Oviedo, Asturias, Spain; Francisco Ortega, Jose M. Baltar, Servicio de Nefrología-I, H. Central Asturias, Institute Reina Sofia, Oviedo, Asturias, Spain; Jaime Alvarez-Grande, Servicio de Nefrología-I, H. Central Asturias, Oviedo, Asturias, Spain

228/ QUALITY ASSURANCE IN KIDNEY TRANSPLANTATION – THE APPROACH IN ESSEN, GERMANY

Jens Reimer, Department of Neurology, Ruhr University Bochum, Bochum, Germany; Gabriele H. Franke, Institute of Medical Psychology, Thomas Philipp, Uwe Heemann, Department of Nephrology, University of Essen, Essen, Germany

229/ A PROSPECTIVE, CONTROLLED STUDY ON THE EFFECT OF DIALYSIS TO THE QUALITY OF LIFE OF RENAL FAILURE PATIENTS IN CHINA

Li Lingjiang, Mental Health Institute, Hunan Medical University, Changsha, Hunan, P.R.China

230/ USE OF KARNOFSKY PERFORMANCE SCALE FOR EVALUATION QUALITY OF LIFE IN CLINICAL GRADING CAPD PATIENTS IN NORTH-EAST OF THAILAND

Supaphan Sunpithayakul, Srinagarind Hospital, Faculty of Medicine, Chonlatip Pongsakol, Jirayut Junma, Medicine Department, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

231/ QUALITY OF LIFE DETERMINANTS IN A DIALYSIS POPULATION

Laura Schwartzmann, Department of Medical Psychology, School of Medicine, University of Uruguay, Montevideo, Uruguay; Sonia Dergazarian, Inés Olaizola, Aida Guerra, Servicio de Asistencia Renal Integral, Montevideo, Uruguay; Teresa Ceretti, Graciela Porley, Department of Medical Psychology, School of Medicine, University of Uruguay, Montevideo, Uruguay

Cardiovascular Diseases**232/ QUALITY OF LIFE AND THE DURATION OF TREATMENT WITH ORAL ANTICOAGULANTS IN PATIENTS WITH VENOUS THROMBOSIS**

Mirjam Locadia, Mirjam Sprangers, Department of Medical Psychology, Martin Prins, Department of Clinical Epidemiology and Biostatistics, Academic Medical Centre, Amsterdam, The Netherlands

233/ ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN HYPERTENSION: DO WE NEED MORE QUESTIONNAIRES?

Kasem S. Akhras, Global Outcomes Research, Pharmacia Corporation, Skokie, IL; Kunle Adesina, Linda N. Abetz, Mapi Values, Bollington, Macclesfield, UK

234/ DEVELOPING AN INTERVENTION TO ENHANCE QUALITY OF LIFE AFTER MYOCARDIAL INFARCTION: WHAT ARE THE PATIENTS' NEEDS?

Tove A. Hanssen, Jan E. Nordrehaug, Kjellaug N. Shandiz, Department of Heart Disease, Haukeland University Hospital, Bergen, Norway; Berit R. Hanestad, Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway

235/ ASSESSING QUALITY OF LIFE IN HYPERTENSION PATIENTS WITH THE WHOQOL-100 QUESTIONNAIRE

Popi Kounti, Maria Coccossis, Gina Triantafyllou, Department of Psychiatry, Ioannis Tountas, Department of Hygiene and Epidemiology, Pavlos Sakkas, George N. Christodoulou, Department of Psychiatry, Medical School, University of Athens, Athens, Greece

236/ IS SELF PERCEPTION OF HEALTH THE MOST IMPORTANT FACTOR CONTRIBUTING TO IMPROVEMENT OF QUALITY OF LIFE IN HIGH RISK CORONARY PATIENTS AFTER THE OPERATION ?

Bogoljub B. Mihajlovic, Djordje Jakovljevic, Zoran R. Potic, Marijela M. Potic, Ninoslav Radovanovic, Cardiovascular surgery, Institute of CVD, Sremska Kamenica, Vojvodina, Yugoslavia

237/ RESPONSIVE HEALTH-RELATED QUALITY OF LIFE DOMAINS IN THE TREATMENT OF HYPERTENSION: A SYSTEMATIC REVIEW OF PUBLISHED STUDIES AND MEASURES

Kunle B. Adesina, Linda N. Abetz, Health Outcomes, Mapi Values, Macclesfield, Cheshire, UK; Kasem S. Akhras, Global Outcomes Research, Pharmacia, Skokie, IL; Marie-Pierre Emery, Health Outcomes, Mapi Research Institute, Lyon, France

238/ RELATIONSHIP BETWEEN SYMPTOMS AND SF-36 PCS AND MCS SCORES IN TREATED HYPERTENSIVE PATIENTS

Steven R. Erickson, College of Pharmacy, Brent C. Williams, Larry D. Gruppen, School of Medicine, University of Michigan, Ann Arbor, MI

Methods**239/ DIFFERENTIAL WEIGHTINGS OF THE CLINICAL IMPORTANCE OF QUALITY OF LIFE STATEMENTS BY PROFESSIONALS IN TWO COUNTRIES: EXPERIENCE WITH THE EPILEPSY PSYCHO-SOCIAL EFFECTS SCALE**

John E. Chaplin, Department of Paediatrics, Lund University, LUND, Sweden; Kristina Malmgren, Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Gothenburg, Sweden; Pamela Thompson, Institute of Neurology, Sahlgrenska University Hospital, London, UK

240/ IS THE EFFECT REAL OR AN ARTIFACT?

Michael A. Hagan, Health Systems Strategies, Columbia University, Mailman School of Public Health, New York, NY; Zhiliang Ying, Department of Statistics, Columbia University, New York, NY

241/ PHYSICAL PERFORMANCE, TOXICITY, AND QUALITY OF LIFE AS ASSESSED BY THE PHYSICIAN AND THE PATIENT

Minna-Liisa Luoma, Department of Psychology, Liisa Hakamies-Blomqvist, Swedish School of Social Science, University of Helsinki, Helsinki, Finland; Johanna Sjöström, Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Carl Blomqvist, Department of Oncology, Uppsala University Hospital, Uppsala, Sweden

242/ RESULTS FROM THREE PHYSICIAN CONSENSUS PANELS DETERMINING CLINICALLY SIGNIFICANT CHANGES IN HEALTH-RELATED QUALITY OF LIFE AMONG CHRONIC DISEASE OUTPATIENTS

K. W. Wyrwich, Division of Health Services Research, F. D. Wolinsky, School of Public Health, Saint Louis University, St. Louis, MO; W. M. Tierney, Division of General Internal Medicine and Geriatrics, K. Kroenke, Regenstrief Institute for Healthcare, Indiana University, Indianapolis, IN, A. N. Babu, Department of Medicine, Saint Louis University, St. Louis, MO

243/ AGREEMENT BETWEEN SELF AND PROXY ASSESSMENT IN ELDERLY PATIENTS WITH HIP FRACTURES

C. Allyson Jones, Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada; David H. Feeny, Institute of Health Economics, Edmonton, AB, Canada

244/ RESPONSE SHIFT OF A HEALTH-RELATED QUALITY OF LIFE ASSESSMENT AS A PREDICTOR OF SUSTAINED WEIGHT LOSS IN OBESE PATIENTS

Ivan Barofsky, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD; Kevin R. Fontaine, Department of Medicine, University of Maryland, Baltimore, MD; Susan J. Bartlett, Shawn C. Franckowiak, Ross E. Andersen, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

245/ EFFECT OF MODE OF ADMINISTRATION ON THE WALKING IMPAIRMENT QUESTIONNAIRE IN PERIPHERAL ARTERIAL DISEASE PATIENTS

Karin S. Coyne, Mary Kay Margolis, MEDTAP International, Bethesda, MD; Judy Regensteiner, University of Colorado Health Sciences Center, Denver, CO; Susan Grandy, Kim A. Gilchrist, DuPont Pharmaceuticals Company, Wilmington, DE; Dennis A. Revicki, MEDTAP International, Inc., Bethesda, MD

246/ OBTAINING SELF-REPORTS ABOUT HRQL FROM COGNITIVELY IMPAIRED RESPONDENTS

Sarah C. Smith, Donna L. Lamping, Health Services Research Unit, London School of Hygiene & Tropical Medicine, London, UK; Beth Foley, Joanna Murray, Sube S. Banerjee, Institute of Psychiatry, King's College, London, UK

247/ IMPACT OF A CHANGE IN MODE OF ADMINISTRATION ON QUESTIONNAIRE RETURN DURING A STUDY OF THE OUTCOME OF HIP AND KNEE REPLACEMENT

Francois A. Bethoux, Deborah M. Miller, The Mellen Center / U10, George M. Muschler, Department of Orthopaedic Surgery / A41, The Cleveland Clinic Foundation, Cleveland, OH

Validation

- 248/ COMPARISON OF PHYSICIAN AND PATIENT RATINGS OF QUALITY OF LIFE IN URUGUAYAN CANCER PATIENTS
Juan J. Dupueto, Departamento de Psicología Médica, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay; Carla Francolino, Departamento de Psicología Médica, Liliana Servente, Irene Gotta, Departamento de Biofísica, Facultad de Medicina, Montevideo, Uruguay
- 249/ RESPONSIVENESS OF THE ACNE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE (ACNE-QOL)
Sheri Fehnel, RTI Health Solutions, Lori McLeod, Statistics Research Division, Research Triangle Institute, RTP, NC; Jane Brandman, Outcomes Research, Pfizer Pharmaceutical Group, New York, NY; Connie McLaughlin-Miley, Outcomes Research, Pfizer Pharmaceutical Group, Ann Arbor, MI
- 250/ PSYCHOMETRIC PROPERTIES OF THE NEI-VFQ - A PSYCHODIAGNOSTIC INVENTORY MEASURING DISEASE-SPECIFIC QUALITY OF LIFE OF VISUALLY IMPAIRED PEOPLE
Gabriele H. Franke, Psychology of Rehabilitation, University of Applied Sciences, Stendal, Germany; Saxonía-Anhaltina, Jens Reimer, Ruhr University Bochum, Department of Neurology, St. Josef Hospital, Bochum, Germany; Northrhine-Westfalia, Joachim Esser, University of Essen, Center for Ophthalmology, Essen, Germany, Northrhine-Westfalia
- 251/ THE STROKE SURVIVOR FUNCTIONING AND WELL-BEING SCALE
Patrick J. Doyle, Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA; Malcolm R. McNeil, Department of Communication Science and Disorders, University of Pittsburgh, Pittsburgh, PA; Joseph M. Mikolic, Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA; Luis Prieto, FPCE Blanquerna, Universitat Ramon Llull, Barcelona, Spain
- 252/ PSYCHOMETRIC VALIDATION OF THE ITALIAN PAVK-86 QUESTIONNAIRE
Inge Kirchberger, QUALI-team, Research & Consulting in Health and Soci., Augsburg, Germany; Edmundo E. Dagrosa, Jürgen Müller, Medical Department/Clinical Development, Aventis Pharma Germany, Bad Soden, Germany
- 253/ CONCEPTUALIZATION AND DESIGN OF AN INDIVIDUALIZED MEASURE OF BPH IMPACT
Asha V. Hareendran, Outcomes Research, Pfizer Ltd., Sandwich, UK; Mona L. Martin, Donald M. Bushnell, Jane E. Goodman, Health Research Associates, Inc., Seattle, WA
- 254/ INITIAL PSYCHOMETRIC PERFORMANCE OF AN INDIVIDUALIZED MEASURE OF BPH PATIENT IMPACT (BPH-PIM)
Mona L. Martin, Health Research Associates, Inc, Seattle, WA; Asha V. Hareendran, Outcomes Research, Pfizer Ltd., Sandwich, UK; Donald M. Bushnell, Jane E. Goodman, Health Research Associates, Inc., Seattle, WA
- 255/ QUALITY OF LIFE AND DEMOGRAPHICS IN PRIMARY CARE AND RHEUMATOLOGY SAMPLES
Erik J. Groessl, R. M. Kaplan, T. G. Ganiats, K. M. David, W. J. Sieber, University of California San Diego, La Jolla, CA
- 256/ THE VALIDITY AND RELIABILITY OF THE TAAQOL: A HEALTH-RELATED QUALITY OF LIFE INSTRUMENT COMPRISING HEALTH STATUS WEIGHTED BY THE IMPACT OF PROBLEMS ON WELL BEING
Jeanet Bruil, Minne Fekkes, Ton Vogels, Erik Verrips, Child Health, Quality of life, TNO Prevention and Health, Leiden, The Netherlands
- 257/ THE SCOPA-PS: A PSYCHOSOCIAL QUESTIONNAIRE FOR PATIENTS WITH PARKINSON'S DISEASE
Johan Marinus, Martine Visser, Bob van Hilten, Neurology, Anne M. Stiggelbout, Medical Decision Making, Leiden University Medical Center, Leiden, The Netherlands
- 258/ QOL-OLD INSTRUMENT TO ASSESS QUALITY OF LIFE IN THE ELDERLY
Erzebet AC-Nikolic, Olja Niciforovic Surkovic, Svetlana Kvrjic, Institute for Public Health, Novi Sad, Vojvodina, Yugoslavia; Zoran Potic, Institute for Cardiovascular Diseases, Novi Sad, Vojvodina, Yugoslavia
- 259/ THE PSYCHOMETRICS OF THE HOSPITAL ANXIETY & DEPRESSION SCALE: FACTOR AND ITEM-RESPONSE BASED ANALYSES
Adam B. Smith, Galina Velikova, Peter J. Selby, ICRF Cancer Medicine Research Unit, St. James's University Hospital, Leeds, West Yorkshire, UK
- 260/ RELIABILITY AND VALIDITY OF 'NEWSQOL': THE NEWCASTLE STROKE-SPECIFIC QUALITY OF LIFE MEASURE
Deborah Buck, Ann Jacoby, Primary Care, University of Liverpool, Liverpool, UK; Gary A. Ford, Wolfson Unit of Clinical Pharmacology, University of Newcastle, Newcastle upon Tyne, UK
- 261/ FEASIBILITY OF THE SF-12 HEALTH SURVEY IN A REGIONAL POPULATION SURVEY IN AUSTRIA
Inge Kirchberger, QUALI-team, Research & Consulting in Health and Soci., Augsburg, Germany; Franz Piribauer, Public Health Directorate, State Government, Graz, Styria, Austria; Elisabeth Santigli, University Clinic for Dental Medicine, University of Graz, Graz, Styria, Austria
- 262/ ATTITUDES TOWARDS QUALITY OF LIFE AND SURVIVAL IN METASTATIC BREAST CANCER: A COMPARISON OF INSTRUMENTS
Anne M. Stiggelbout, Sylvia J. Jansen, Department of Medical Decision Making, Marianne A. Nooy, Department of Clinical Oncology, Job Kievit, Department of Medical Decision Making, Leiden University Medical Center, Leiden, The Netherlands
- 263/ A HEALTH RELATED QUALITY OF LIFE MEASURE FOR USE IN PATIENTS WITH ERECTILE DYSFUNCTION: A VALIDATION STUDY
Deborah P. Lubeck, David Latinin, ~~withdrawn~~ Urology, University of California, San Francisco, San Francisco, CA; David Penson, Urology, University of Washington, Seattle, WA; Shilpa Mehta, Outcomes Research, TAP Pharmaceutical Products Inc., Lake Forest, IL
- 264/ PSYCHOMETRIC VALIDATION OF CONTRACEPTIVE RING ACCEPTABILITY QUESTIONNAIRE
Annoesjka Novak, Health Economics Department, NV Organon, Oss, The Netherlands; Linda Abetz, MAPI Values Ltd., Cheshire, UK; Christine de la Loge, MAPI Values, Lyon, France

Validation (continued)**265/ QUALITY OF LIFE IN DERMATOLOGY: DEVELOPMENT OF VQ-DERMATO'S SINGLE INDEX**

Christophe Sapin, Public Health Department, Medical School, Marseille, France; Jean-Jacques Grob, Dermatology Department, St. Marguerite Hospital, Marseille, France; Stéphane Robitail, Marie-Claude Simeoni, Pascal Auquier, Public Health Department, Medical School, Marseille, France

266/ VALIDATION OF A FRENCH INSTRUMENT MEASURING HOSPITALISED PATIENT SATISFACTION: QSH

Stéphanie Antoniotti, Public Health Department, Medical School, Marseille, France; José Labarere, Public Health Department, Grenoble, France; Laurent Gerbaud, Public Health Department, Clermont-Ferrand, France; Dominique Bertrand, Public Health Department, Annecy, France; Christophe Sapin, Audrey Clement, Public Health Department, Marseille, France; Patrice Francois, Public Health Department, Grenoble, France; Pascal Auquier, Public Health Department, Marseille, France

267/ PSYCHOMETRIC PROPERTIES OF IBS-QOL QUESTIONNAIRE AND ITS RELATIONSHIP WITH SF-36

Fabio Arpinelli, Giovanni Visona, Luca Cavazzuti, Medical Department, GlaxoWellcome S.p.A., Verona, Italy; Mauro Niero, Nadia C. Oprandi, University of Verona, Verona, Italy

268/ VALIDATION OF THE COMMUNITY DEMENTIA QUALITY OF LIFE PROFILE (CDQLP): COMPARISON WITH THE EUROQOL-5D (EQ-5D)

M. D. Walker, M. S. Salek, Centre for Socioeconomic Research, Cardiff University, Cardiff, UK; A. J. Bayer, Department of Geriatric Medicine, University of Wales College of Medicine, Cardiff, UK

269/ COMPARISON OF TWO DISEASE-SPECIFIC QUALITY OF LIFE (QOL) MEASURES: VALIDATION OF THE COMMUNITY DEMENTIA QUALITY OF LIFE PROFILE (CDQLP)

M. D. Walker, M. S. Salek, Centre for Socioeconomic Research, Cardiff University, Cardiff, UK; A. J. Bayer, Department of Geriatric Medicine, University of Wales College of Medicine, Cardiff, UK

270/ THE QUALITY OF LIFE INSTRUMENTS DATABASE (QOLID)

Marie-Pierre Emery, Mapi Research Institute, Lyon, France; Marcello Tamburini, Istituto Nazionale Tumori, Milano, Italy; Elodie Pasquier, Mapi Research Institute, Lyon, France

271/ RELIABILITY AND VALIDITY OF A NEWLY DEVELOPED QUALITY-OF-LIFE QUESTIONNAIRE SPECIFIC TO MENOPAUSE

York F. Zoellner, Social Pharmacy, Humboldt University, Berlin, Germany; Phillip Oliver, General Practice & Primary Care, John E. Brazier, Scharr, University of Sheffield, Sheffield, UK; Jeannette Alt, Women's Health, Solvay Pharmaceuticals, Hannover, Germany; Marion Schaefer, Social Pharmacy, Humboldt University, Berlin, Germany

272/ A SPECIFIC QUALITY OF LIFE SCALE IN UPPER LIMB LYMPHOEDEMA: THE ULL-27 QUESTIONNAIRE

Robert Launois, Alexandre Coffi Megnigbeto, Sante Publique, Universite Paris XIII, Bobigny Cedex, France

273/ PRELIMINARY FINDINGS IN THE DEVELOPMENT OF THE SPIRITUALITY MODULE FOR THE WHOQOL IN URUGUAY

Betina Caporale, Adriana Bagnulo, Medical Psychology, Medical College, State University, Montevideo, Montevideo, Uruguay

274/ VALIDATION AND RESCORING OF THE MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE

Stacie A. Hudgens, Elizabeth A. Hahn, Center on Outcomes, Research and Education (CORE), Randall E. Williams, Karen Spronk, Michael Memmini, Cardiology, Evanston Northwestern Healthcare (ENH), Evanston, IL; Thomas S. Rector, Medicine/Cardiovascular Division, University of Minnesota, Minneapolis, MN

275/ THE RELIABILITY AND VALIDITY OF A NEW GENERIC MEASURE OF HEALTH-RELATED QUALITY OF LIFE FOR USE AMONGST THE KAMBA OF KENYA

Annabel Bowden, Julia A. Fox-Rushby, Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK; Lilian Nyandieka, John W. Kangeri, Centre for Public Health Research, Kenya Medical Research Institute, Nairobi, Kenya

276/ TESTING THE PSYCHOMETRIC PROPERTIES OF THE PSORIQL: A PSORIASIS-SPECIFIC QUALITY OF LIFE INSTRUMENT

Stephen P. McKenna, Sharon A. Cook, Diane Whalley, Lynda C. Doward, Galen Research, Manchester, UK; Daniel van Assche, Novartis Pharma AG, Basel, Switzerland

277/ DEVELOPMENT AND VALIDATION OF DEEP VEIN THROMBOSIS QOL SCALE

Stacie A. Hudgens, Center on Outcomes, Research and Education (CORE), Joseph A. Caprini, Surgery, Carol A. Caprini, David Cella, CORE, Lakshman R. Sehgal, Surgery, Evanston Northwestern Healthcare, Evanston, IL

278/ MEASURING SOCIAL PARTICIPATION: DEVELOPING A SHORT FORM OF THE GLASGOW HEALTH STATUS INVENTORY: THE PARTICIPATION SCALE

Graeme Hawthorne, Centre for Health Program Evaluation, The University of Melbourne, West Heidelberg, Victoria, Australia; Anthony Hogan, Simpson Centre for Health Innovation, University of New South Wales Clinical School, Liverpool Health Service, Sydney, NSW, Australia

279/ THE RELATIVE RESPONSIVENESS OF GENERIC AND DISEASE-SPECIFIC MEASURES OF HRQOL IN PATIENTS UNDERGOING CORONARY REVASCULARISATION

Sara Schroter, Donna L. Lamping, Health Services Research Unit, London School of Hygiene & Tropical Medicine, London, UK

280/ FINAL PSYCHOMETRIC EVALUATION OF THE CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE (CROQ-CABG/PTCA)

Sara Schroter, Donna L. Lamping, Health Services Research Unit, London School of Hygiene & Tropical Medicine, London, UK

281/ DEVELOPMENT AND VALIDATION OF DISEASE-SPECIFIC MEASURES FOR CHOROIDAL MELANOMA - A CANCER OF THE EYE

Michele Melia, Department of Ophthalmology, Johns Hopkins University, Baltimore, MD; Claudia S. Moy, Neuroscience, NINDS, Bethesda, MD; Sandra M. Reynolds, Department of Ophthalmology, Johns Hopkins University, Baltimore, MD; Carol M. Mangione, Division of General Internal Medicine, UCLA School of Medicine, Los Angeles, CA; David Cella, Center on Outcomes Research and Education, Evanston Northwestern Healthcare, Evanston, IL

Validation (continued)

282/ EXPLORATORY FACTOR ANALYSIS (EFA) OF THE QUALITY OF LIFE RADIATION THERAPY INSTRUMENT & HEAD AND NECK MODULE (QOL-RTI/HN) USING MULTI-NATIONAL SAMPLES

Clement K. Gwede, Darlene Johnson, Bonnie Sauder, Andy Trotti, Radiation Oncology, Moffitt Cancer Center, Tampa, FL

283/ INTERPRETING THE MOS SF_36: HOW MANY SUM SCORES ARE APPROPRIATE?

Corina Guethlin, Harald Walach, Institute of Environmental Medicine & Hospital Epidemiology, University Hospital, Freiburg, Germany

284/ METHODOLOGY FOR CHOICE OF ITEMS : DESIGNING A QUALITY OF LIFE INSTRUMENTS FOR HIP AND KNEE OSTEOARTHRITIS

Francis Guillemin, Epidemiologie et Evaluation Cliniques, Hopital Marin, Nancy, France; Joel Coste, Departement Biostatistique et Informatique Medicale, Hopital Cochin, Paris, France; Jacques Pouchot, Service de Médecine Interne, Hopital Louis Mourier, Paris, France; Nathalie Retel-Rude, Laboratoire de Biostatistique, Faculté de Médecine, Besançon, France; Elisabeth Spitz, Departement de Psychologie, Université de Metz, Metz, France; Michèle Baumann, Ecole de Sante Publique Upres, Faculte de Medecine, Vandoeuvre les Nancy, France; Cyrille Tarquinio, Departement de Psychologie, Université de Metz, Metz, France

285/ HOW MUCH IS "VERY MUCH"? DEVELOPING A RATING SCALE FOR PORTUGUESE SPEAKING COUNTRIES

Benjamin J. Arnold, S. Eremenco, C. H. Chang, D. Cella, CORE, ENH, Evanston, IL; J. L. P. Ribeiro, Faculdade de Psicologia, Universidade do Porto, Porto, Portugal; M. P. Doro, Bone Marrow Transplant Unit, University Hospital, Curitiba, Parana, Brazil; R. Harris, CORE, ENH, Evanston, IL

286/ SHOULD SYMPTOMS BE SCALED FOR INTENSITY, FREQUENCY, OR BOTH?

Chih-Hung Chang, Center on Outcomes, Research and Education, David Cella, Susan Clarke, Evanston Northwestern Healthcare, Evanston, IL; Jamie H. von Roenn, Northwestern University Medical School, Chicago, IL; Allen W. Heinemann, Rehabilitation Institute of Chicago, Chicago, IL

Utility

287/ TEST-RETEST RELIABILITY AND INTERPRETATION OF UTILITY SCORES: EVIDENCE FROM ELECTIVE TOTAL HIP ARTHROPLASTY

David H. Feeny, Chris Blanchard, Institute of Health Economics, Edmonton, AB, Canada; Jeffrey Mahon, Department of Epidemiology and Biostatistics, Robert Bourne, Cecil Rorabeck, Department of Surgery, Larry Stitt, Susan Webster-Bogaert, Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada

288/ UTILITY ASSESSMENT AMONG PATIENTS WITH DRY EYE DISEASE

John G. Walt, Global Pharmaco-economic Strategy & Research; Rhett Schiffman, Ophthalmology Clinical Research, Allergan, Irvine, CA; Stacy Evans, Gary Lebovics, Research, Analytica, New York, NY

289/ HOW TO COMBINE PREFERENCE-BASED QOL SCORES OF PATIENTS COLLECTED IN LONGITUDINAL CLINICAL TRIALS WITH CLINICAL DATA TO ARRIVE AT ONE OVERALL OUTCOME MEASURE?

Paul Krabbe, Margriet Hartman, Medical Technology Assessment, Roland Laan, Rheumatology, University Medical Centre Nijmegen, Nijmegen, The Netherlands

290/ MODELING PREFERENCES FOR COMPLEX HEALTH STATES

Jacek A. Kopec, Health Care and Epidemiology, University of British Columbia, Vancouver, BC, Canada; Rollin Brant, Community Health Sciences, University of Calgary, Calgary, AB, Canada

291/ COST-UTILITY ANALYSIS OF UNIVERSAL AND INDICATED PREVENTION PROGRAMS

E. Michael Foster Ph.D., Eunjeong Kang MPH, Health Policy and Administration, The Pennsylvania State University, State College, PA

292/ CAN WE AND HOW TO WEIGHT THE DIMENSIONS OF QUALITY OF LIFE MEASURES

Kaiping G. Yao, Chui De Chiu, Psychology, National Taiwan University, Taipei, Taiwan, R.O.C.

293/ A FRAMEWORK FOR CALCULATING CANADIAN DISABILITY WEIGHTS

Karla M. Nobrega, Julie Bernier, Jean-Marie Berthelot, Health Analysis and Modeling Group, Statistics Canada, Ottawa, ON, Canada; Robert A. Spasoff, Epidemiology, University of Ottawa, Ottawa, ON, Canada

294/ USING THE WHOQOL-BREF INSTRUMENT AND TIME-TRADE-OFF UTILITY FOR INSTITUTIONALIZED ELDERLY PEOPLE IN TAIWAN

Kuan-Lang Lai, Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan; Rong-Jye Tzeng, Department of Education and Training, Tri-Service General Hospital, Taipei, Taiwan; Bing-Long Wang, Department of Research, Senyeong Kao, School of Public Health, National Defense Medical Center, Taipei, Taiwan

Posters III: Friday, November 9 (10:30 pm - 5:00 pm)

Lounge Forum

Meet the Authors: 3:30 - 4:00 pm

Pediatrics

295/ SOCIAL COMPETENCE, EMOTIONAL/BEHAVIORAL PROBLEMS AND GLOBAL SELF WORTH IN A SWEDISH SAMPLE OF 7-9-YEAR-OLD CHILDREN WITH ASTHMA

Kjell L. Reichenberg, Nordic School of Public Health, Göteborg, Sweden; Anders G. Broberg, Department of Psychology, Göteborg University, Göteborg, Sweden

296/ FAMILY CLOSENESS, PARENTAL LOCUS OF CONTROL AND PARENTING EFFICACY IN CHILDHOOD ASTHMA

Kjell Reichenberg, Nordic School of Public Health, Göteborg, Sweden; Anders G. Broberg, Department of Psychology, Göteborg University, Sweden

297/ QUALITY OF LIFE IN CHILDREN AND ADOLESCENTS WITH DISABILITIES AND THEIR FAMILIES INTRODUCING THE EUROPEAN DISABKIDS PROJECT

Monika Bullinger, Department of Medical Psychology, Universitätskrankenhaus Eppendorf, Hamburg, Germany; Ute Thyen, Department of Paediatrics Medical University Luebeck, Lübeck, Germany; Henrik Koopman, Department of Paediatrics Leiden University Medical, Leiden, The Netherlands; Peter Hoare, Department of Psychiatry, University of Edinburgh, Edinburgh, Scotland; Marie Claude Simeoni, Department of Public Health, University of Marseille, Marseille, France; Anathanasios Vidalis, Department of Paediatric Respiratory Unit, Hippocratio Hospital, Thessaloniki, Greece; John Eric Chaplin, University of Lund, Lund, Sweden; Michael Quittan, Department of Physical Medicine and Rehabilitation, University of Vienna, Vienna, Austria; DISABKIDS Group, Department of Medical Psychology, Universitätskrankenhaus Eppendorf, Hamburg, Germany

298/ THE HEALTH OF CHILDREN IN EUROPE-A QUALITY OF LIFE PERSPECTIVE

Monika Bullinger, Department of Medical Psychology, Universitätskrankenhaus Eppendorf, Hamburg, Germany; Ulrike Ravens-Sieberer, KIDSCREEN group, Department of Epidemiology and Health Reporting, Robert Koch Institute, Berlin, Germany, DISABKIDS Group, Department of Medical Psychology, Universitätskrankenhaus Eppendorf, Hamburg, Germany

299/ THE CORE VSP-A AND ITS SPECIFIC MODULE: A GENERIC HRQL INSTRUMENT FOR ILL AND HEALTHY ADOLESCENTS

Marie-Claude Simeoni, Christophe Sapin, Audrey Clement, Mohammed El Khammar, Pascal Auquier, Public Health Department, Medical School, Marseille, France

300/ VALIDATION IN FRENCH OF THE CHILD HEALTH QUESTIONNAIRE PARENT FORM (CHQ-PF50) IN CHILDREN AGED 9-19 YEARS SUFFERING FROM CANCER

Chantal Rodary, Biostatistics, Nicolas Bellon, Institut Gustave Roussy, Villejuif, France; Jeanne Landgraf, Health Act, Boston, MA; Chantal Kalifa, Institut Gustave Roussy, Villejuif, France; Pascal Chastagner, CHRU Hopital d'enfants, Vandoeuvre les Nancy, France; Jean-Pierre Vannier, Hôpital Charles Nicolle, Rouen, France

301/ DEVELOPMENT, VALIDATION OF HRQL MEASUREMENT IN CHILDREN: VSP-AE

Pascal Auquier, Public Health Department, Medical School, Marseille, France; Audrey Clement, Christophe Sapin, Mohammed El Khammar, Jean-Louis San Marco, Public Health Department, Medical School, Marseille, France; Marie-Claude Simeoni, Public Health Department, Medical School, Marseille, France

302/ QUALITY OF LIFE IN CARERS OF SEVERELY DISABLED CHILDREN WITH SEVERE FEEDING PROBLEMS

Santanu Maity, Adrian G. Thomas, Department Of Paediatric Gastroenterology, Booth Hall Childrens Hospital, Manchester, UK; Alison Bachlet, P. B. Sullivan, John Radcliffe Infirmary, Oxford, UK; M. Eltumi, Watford General Infirmary, Watford, UK; Bridget Lambert, John Radcliffe Infirmary, Oxford, UK

303/ RELIABILITY AND DISCRIMINANT VALIDITY OF THE CHILD HEALTH QUESTIONNAIRE 28-ITEM PARENT FORM (CHQ-PF28) AS PEDIATRIC GENERIC HEALTH STATUS MEASURE

Hein Raat, Marie-Louise Essink-Bot, Department of Public Health, Erasmus University, Rotterdam, ZH, The Netherlands; Jeanne M. Landgraf, Health Act, Boston, MA

304/ SCREENING FOR AND PROMOTION OF HEALTH RELATED QUALITY OF LIFE IN CHILDREN AND ADOLESCENTS - A EUROPEAN PUBLIC HEALTH PERSPECTIVE

Ulrike Ravens-Sieberer, Child and Adolescent Health, Robert Koch Institute, Berlin, Germany; Thomas Abel, Social and Preventive Medicine, University of Bern, Bern, Switzerland; Pascal Auquier, Department of Public Health, University of Marseille, Marseille, France; Bärbel-Maria Bellach, Epidemiology and Health Reporting, Robert Koch Institute, Berlin, Germany; Jeanet Bruil, Prevention and Health, TNO, Leiden, The Netherlands; Wolfgang Duer, Ludwig Boltzmann Institute for Sociology of Health an, Vienna, Austria; Mick Power, Department of Psychiatry, University of Edinburgh, Edinburgh, Great Scotland, Luis Rajimil, Catalan Agency for Health Technology, Assessment, Barcelona, Spain; the European KIDSCREEN Group

384/ DEVELOPMENT OF RUSSIAN VERSION OF THE PEDSQL GENERIC CORE SCALES

Andrei Novik, Tatyana Ionova, Tatyana Nikitina, Anton Kishtovich, Multinational Center of Quality of Life Research, Military Medical Academy, St. Petersburg, Russia

HIV/AIDS

305/ A LONGITUDINAL STUDY ON HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH HIV-INFECTION

Claes G. Cederfjäll, Department of Nursing, Karolinska Institutet, Stockholm, Sweden; Ann Langius-Eklöf, Department of Nursing, Knut Lidman, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; Regina Wredling, Department of Nursing, Karolinska Institutet, Stockholm, Sweden

306/ HEALTH-RELATED QUALITY OF LIFE IN HIV+ PATIENTS TAKING HAART

Rita Murri, Cosmo Del Borgo, Prospero Limongelli, Infectious Diseases, Catholic University of Rome, Rome, Italy

307/ SATISFACTION WITH SEXUAL LIFE IN HIV+ PATIENTS

Rita Murri, Massimo Fantoni, Cosmo Del Borgo, Prospero Limongelli, Infectious Diseases, Catholic University of Rome, Rome, Italy

Clinical Trials

308/ IMPLEMENTING QUALITY OF LIFE IN EORTC CLINICAL TRIALS

Andrew Bottomley Ph.D., Quality of Life Unit, EORTC Data Center, Brussels, Belgium; Dr. Henning Flechtner, Klinik fuer Psychiatrie und Psychotherapie des Kinde, Universitaet zu Koeln, Koeln, Germany, on behalf of EORTC Quality of Life Group

309/ A DECISIVE STEP TOWARDS THE RECOGNITION OF PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS: REPORT OF A MEETING AT THE FDA ON FEBRUARY 16, 2001

Catherine Acquadro, ERIQA Group, Mapi Research Institute, Lyon, France

310/ USEFULNESS OF QUALITY OF LIFE (QOL) INFORMATION IN A TRIAL OF A MATRIX METALLOPROTEINASE INHIBITOR (MMPi) MARIMASTAT.

Andrea Bezjak, DRO, Frances A. Shepherd, Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada; Lesley Seymour, A. Sadura, Dongsheng Tu, Joseph Pater, Central Office, NCIC Clinical Trials Group, Kingston, ON, Canada; G. Giaccone, C. Debruyne, S. Ahmedzai, EORTC, EORTC Central Office, Brussels, Belgium

311/ PSYCHOMETRIC PROPERTIES OF CYCLOSPORINE CAPSULE SATISFACTION SURVEY (CCSS)

Amitabh Singh, Talat Ashraf, Azmi Nabulsi, Rebecca Hoffman, Global Epidemiology and Outcomes Research, Abbott Laboratories, Abbott Park, IL

Gastrointestinal Diseases

312/ QUALITY OF LIFE OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS WHO HAVE EXPERIENCED FAECAL INCONTINENCE (FI): A PATIENT CENTRED APPROACH

C. Speed, On behalf of the QoLiFI Research Team, University of Newcastle upon Tyne, Newcastle, UK

313/ SYMPTOMS OF GASTRO-OESOPHAGEAL REFLUX DISEASE HAVE A NEGATIVE IMPACT ON HEALTH-RELATED QUALITY OF LIFE

Nicholas J. Talley, Professor of Medicine, Division of Medicine, University of Sydney, Penrith, Australia; Ola Junghard, Biostatistics Clinical Science; Ingela K. Wiklund, Outcomes Research, AstraZeneca R&D Mölndal, Mölndal, Sweden

314/ IMPACT OF GASTROINTESTINAL SYMPTOMS AND AFFECTIVE DISORDERS ON HEALTH-RELATED QUALITY OF LIFE (HRQL) IN US PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS)

Ingela Wiklund, Outcomes Research, AstraZeneca, Molndal, Sweden; George Longstreth, Kaiser Permanente, San Diego, CA; Emeran Mayer, UCLA, Los Angeles, CA; Jorgen Naesdal, Ingalill Wilson, AstraZeneca, Molndal, Sweden

315/ EVALUATION OF A COMPUTERISED TOUCH-SCREEN QUESTIONNAIRE TO MEASURE QUALITY OF LIFE IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE

Santanu Maity, Adrian G. Thomas, Department Of Paediatric Gastroenterology, Booth Hall Childrens Hospital, Blackley, Manchester, UK

Endocrine Diseases

316/ DETERMINANTS OF QUALITY OF LIFE IN PEOPLE WITH DIABETES MELLITUS

Pedro L. Ferreira, Conceicao Neves, Centre for Health Studies and Research, Manuela Carnevalheiro, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

317/ SYMPTOMS OF DIABETIC RETINOPATHY AND THEIR IMPACT ON HEALTH-RELATED QUALITY OF LIFE

Mary Kay Margolis, Karin Coyne, MEDTAP International, Inc., Bethesda, MD; Gwendolyn Kiebert, MEDTAP International, Inc., London, UK; Tessa Kennedy-Martin, Lilly Research Centre, Windlesham, Surrey, UK; Timothy Baker, MEDTAP International, Inc., Bethesda, MD; Ronald Klein, Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI; Helen Simpson, Guys, Kings, and St. Thomas' School of Medicine, London, UK; Dennis Revicki, MEDTAP International, Inc., Bethesda, MD

318/ GENDER DIFFERENCES IN QUALITY OF LIFE OF PATIENTS WITH DIABETES MELLITUS

Corinna Petersen, Matthias Morfeld, Monika Bullinger, Department of Medical Psychology, University Hospital Hamburg- Eppendorf, Hamburg, Hamburg, Germany

319/ COPING AND DISTRESS BEFORE AND AFTER OBESITY TREATMENT

Anna Ryden, Jan Karlsson, Lars-Olof Persson, Charles Taft, Health Care Research Unit, Jarl S. Torgerson, SOS Secretariat, Internal Medicine, Marianne Sullivan, Health Care Research Unit, Göteborg University, Göteborg, Sweden

320/ HEALTH-RELATED QUALITY OF LIFE IN OBESE SEEKING TREATMENT COMPARED TO NON-OBESE REFERENCE SUBJECTS

Jan Karlsson, Health Care Research Unit, Lars Sjöström, Marianne Sullivan, Health Care Research Unit, Institute of Internal Medicine, Göteborg, Sweden

321/ DO MEN AND WOMEN RESPOND DIFFERENTLY TO WEIGHT CHANGE?

J. Michael Woolley, Jinhai Shi, M. Haim Erder, Amgen Inc., Thousand Oaks, CA

Mental Health

322/ QUALITY OF LIFE & PSYCHOLOGICAL DISTRESS AMONG CAREGIVERS OF DEMENTIA PATIENTS IN INDIA

Santosh K. Chaturvedi, Psychiatry, National Institute of Mental Health & Neurosciences, Bangalore, India

323/ ASSOCIATIONS BETWEEN FIVE-FACTOR MODEL OF PERSONALITY AND QUALITY OF LIFE IN INDONESIAN WOMEN WITH BREAST CANCER

Magdalena S. Halim, Psychology, AtmaJaya Indonesia Catholic University, Jakarta Selatan, Indonesia; Jan J. L. Derksen, Cees P. F. van der Staak, Clinical Psychology and Personality, University of Nijmegen, Nijmegen, The Netherlands

Mental Health (continued)

324/ QUALITY OF LIFE AND MENTAL HEALTH IN YOUNG IRANIAN POPULATION

Ali Montazeri, Kazem Hosseini, Jila Sadighi, Mohammad Shariati, Farzaneh Maftoon, Mohammad Heydari, Iranian Institute of Health Sciences Research, Tehran, Iran

325/ ISSUES INVOLVED IN ASSESSING QUALITY OF LIFE IN BIPOLAR DISORDER

Stephen P. McKenna, PhD., David M. Meads, BS.c., Sharon A. Cook, BS.c., Galen Research, Manchester Science Park, Manchester, UK; Mairead M. Kearney, MD, Global Health Economics and Disease Management, Novartis Pharma AG, Basel, Switzerland

326/ COGNITIVE FACTORS IN SYMPTOM ASSESSMENT: ARE WE ASKING TOO MUCH?

Deborah L. Jonas, Nancy Kline Leidy, MEDTAP International, Inc., Bethesda, MD; Cheryl C. Silberman, AstraZeneca, Wilmington, DE; Mary Kay Margolis, MEDTAP International, Inc., Bethesda, MD; Anne Heyes, AstraZeneca, Cheshire, UK

327/ WAS IT A GOOD MOVE? IMPROVEMENT IN QUALITY OF LIFE AMONG CHRONIC MENTAL PATIENTS MOVING FROM A HOSPITAL TO A HOSTEL

Roberto Umansky, Division of Psychiatry, Marianne Amir, Dafna Chen, Department of Behavioral Sciences, Boris Nemetz, Monika Friedman, Ety Zidon, Division of Psychiatry, Ben-Gurion University of the Negev, Beer-Sheva, Israel

328/ IMPACT OF DEPRESSIVE SYMPTOMS IN SOCIAL FUNCTIONING AND QUALITY OF LIFE IN A BRAZILIAN PRIMARY CARE SERVICE USERS

Marcelo P. Fleck, Ana Flávia B. Lima, Sérgio N. Louzada, Gustavo Schestatsky, Alexandre Henriques, Vivian R. Borges, Suzi Camey, LIDO Group, Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

329/ QUALITY OF LIFE FOR POOR AFRICAN-AMERICAN WOMEN WITH DEPRESSION

Lori Frank, Dennis Revicki, MEDTAP International, Inc., Bethesda, MD; Kelly Grotzinger, Global Health Outcomes, GlaxoSmithKline, Collegeville, PA

330/ SOCIAL SUPPORT AND QUALITY OF LIFE IN CHRONIC MENTAL DISEASE PATIENTS SUBMITTED TO DIFFERENT HOUSING TREATMENT PROGRAMS

Jose L. Pais-Ribeiro, Faculdade de Psicologia, Universidade do Porto, Porto, Portugal; Clara Guterres, ISPA, ISPA, Lisboa, Portugal

331/ DOES CHANGE IN DEPRESSION STATUS PREDICT CHANGE IN HRQOL?

Marianne Amir, Behavioral Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Stephen McKenna, Galen Research, Manchester, UK; Mona L. Martin, Donald M. Bushnell, Health Research Associates, Inc., Seattle, WA; Diane Whalley, Galen Research, Manchester, UK; Donald L. Patrick, Department of Health Services, University of Washington, Seattle, WA

332/ HEALTHCARE RESOURCE USE AMONG CAREGIVERS OF PEOPLE WITH SCHIZOPHRENIA

Richard E. White, Audra N. Boscoe, Health Economics and Outcomes Research, John Travers, Senior Medical Director, AstraZeneca, Wilmington, DE; Diana D. McDonnell, Consumer Health Sciences, Princeton, NJ

333/ MENTAL WELL BEING AMONG CAREGIVERS OF PEOPLE WITH SCHIZOPHRENIA

John Travers, Senior Medical Director, Richard E. White, Audra N. Boscoe, Health Economics and Outcomes Research, AstraZeneca, Wilmington, DE; Diana D. McDonnell, Consumer Health Sciences, Princeton, NJ

383/ PERSONALITY AND QUALITY OF LIFE

Guus Van Heck, Jolanda De Vries, Clinical Health Psychology, Tilburg University, Tilburg, The Netherlands

Analytic

334/ FACTOR STRUCTURE OF THE QUALITY OF LIFE IN REFLUX AND DYSPEPSIA (QOLRAD) QUESTIONNAIRE EVALUATED IN PATIENTS WITH HEARTBURN PREDOMINANT REFLUX DISEASE

Károly R. Kulich, Ingela Wiklund, Outcomes Research, Ola Junghard, Statistician, AstraZeneca R&D Mölndal, Mölndal, Sweden

335/ USING THE MANN-WHITNEY STATISTIC TO IMPROVE THE INTERPRETATION OF ORDINAL SCALES: AN APPLICATION TO THE PATIENT SATISFACTION WITH INSULIN THERAPY QUESTIONNAIRE

Joseph C. Cappelleri, Robert A. Gerber, Global Research & Development, Pfizer Inc., Groton, CT; Avansh K. Mishra, Pfizer Pharmaceuticals Group, Pfizer Inc., New York, NY

336/ VALID RESULTS DESPITE MISSING DATA?

Corina Guethlin, Harald Walach, Institute of Environmental Medicine & Hospital Epidemiology, University Hospital, Freiburg, Germany

337/ THE DEVELOPMENT AND UTILISATION OF THE EORTC QUALITY OF LIFE ITEM BANK

Stephanie Vachalec, Andrew Bottomley, Quality of Life Unit, EORTC Data Center, Brussels, Belgium; Jane Blazeby, Department of Surgery, Bristol Royal Infirmary, Bristol, UK; Pascal Ruyskart, IT Unit, EORTC Data Center, Brussels, Belgium; Henning Flechtner, Klinik fuer Psychiatrie und Psychotherapie des Kinde, EORTC Data Center, Koeln, Germany; Kristin Bjordal, Radiotherapy & Oncology, Norwegian Radium Hospital, Montebello, Norway

338/ CLINICAL POTENTIAL OF LONGITUDINAL QOL PROFILES

Barbara A. Elliott, Department of Family Medicine, UMD-School of Medicine, Duluth, MN; Ronald R. Regal, Department of Mathematics and Statistics, UMD, Duluth, MN; Colleen M. Renier, Thomas E. Elliott, Division of Education and Research, SMDC, Duluth, MN

339/ METHODS FOR INTEGRATING THE SF-12 INTO A ROUTINE CENSUS BASED HOUSEHOLD SURVEY

Franz Piribauer, Public Health Directorate, State-Government, Graz, Styria, Austria; Inge Kirchberger, Quali-Team Augsburg, Quality of Life Consulting Company, Augsburg, Bavaria, Germany; Elisabeth Santigli, University Clinic for Dental Medicine, University of Graz, Graz, Styria, Austria; Jeannette Klimont, Health and Population Statistics, Statistics Austria Vienna, Vienna, Austria

Analytic (continued)**340/ CHANGE IN QUALITY OF LIFE IN RELATION TO HEALTH-RELATED BEHAVIOUR**

Wolfgang Weidenhammer, Centre for Complementary Medicine Research, Department of Internal Medicine II, Technical University Munich, München, Germany; Stefanie Wunderlich, Sanitas Dr.Köhler-Parkkliniken, Hospital for Complementary Medicine, Bad Elster, Germany; Dieter Melchart, Centre for Complementary Medicine Research, Department of Internal Medicine II, Technical University Munich, München, Germany

341/ MULTIPLE FACTOR ANALYSIS: APPLICATION IN THE VALIDATION OF MULTI-ITEM SCALES

Benoit Arnould, Patrick Marquis, Mapi Values, Lyon, France; Jérôme Pagès, ENSAR-INSFA, Rennes, France

342/ COHEN CONFIRMED? EMPIRICAL EFFECT SIZES FOR THE QLQ-C30

Madeleine T. King, Centre for Health Economics Research & Evaluation, University of Sydney, Sydney, NSW, Australia

343/ TESTING RASCH ITEM ANALYSIS

Jeremy C. Hobart, Neurological Outcome Measures Unit, Institute of Neurology, London, UK; Benjamin D. Wright, MESA Psychometric Laboratory, University of Chicago, Chicago, IL; Afsane Riazzi, Alan J. Thompson, Neurological Outcome Measures Unit, Institute of Neurology, London, UK

344/ UNDERSTANDING CHANGE OVER TIME IN THE SELF-RATED HEALTH OF SURVIVING OLDER ADULTS

Kathleen W. Wyrwich, Division of Health Services Research, Saint Louis University, St. Louis, MO; Robert B. Wallace, College of Public Health, University of Iowa, Iowa City, IA; Fredric D. Wolinsky, School of Public Health, Saint Louis University, St. Louis, MO

345/ COULD LINEAR REGRESSION BE REPLACED BY ITEM RESPONSE THEORY ANALYSIS WHEN ADDRESSING CRITERION-REFERENCE INTERPRETATION OF TEST SCORES? A DISCUSSION EXAMPLE

Luis Prieto, FPCE Blanquerna, Universitat Ramon Llull, Barcelona, Spain; Jordi Alonso, Jose M. Valderas, Health Services Research Unit, Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain

346/ APPLYING ITEM RESPONSE THEORY (IRT) ON ITEMS DEVELOPED WITHIN THE FRAMEWORK OF CLASSICAL TEST THEORY (CTT)

Elof Dimenas, Ingela Wiklund, Outcomes Research, Jonas Carlsson, Biostatistics, AstraZeneca R&D, Molndal, Sweden

347/ MODELING LONGITUDINAL QOL DATA USING REGRESSION SPLINES

Carl A. de Moor, Departments of Behavioral Science and Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX

348/ SOME LOGICAL PROBLEMS WITH TESTS FOR CLINICALLY IMPORTANT CHANGES IN HRQOL

Dennis D. Gagnon, RWJ Pharmaceutical Research Institute, Raritan, NJ

Cross-Cultural**349/ RELIABILITY AND VALIDITY OF MODIFIED LUNG CANCER SYMPTOM SCALE (LCSS) IN MULTINATIONAL SAMPLE OF PATIENTS WITH PLEURAL MESOTHELIOMA**

Astra M. Liepa, Global Economic Affairs, Eli Lilly and Co., Indianapolis, IN; Patricia J. Hollen, School of Nursing, Northeastern University, Boston, MA; Richard J. Gralla, Division of Medical Oncology, Columbia University, New York, NY; James J. Rusthoven, Medical Group, Alimta Team, Eli Lilly and Co., Indianapolis, IN

350/ AN INDONESIAN VERSION OF THE ROTTERDAM SYMPTOM CHECKLIST: A PSYCHOMETRIC EVALUATION

Magdalena S. Halim, Psychology, Atmajaya Indonesia Catholic University, Jakarta Selatan, Indonesia; Jan J. L. Derksen, Cees P. F. van der Staak, Clinical Psychology & Personality, University of Nijmegen, Nijmegen, The Netherlands

351/ RELIABILITY AND VALIDITY OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-BREAST (FACT-B): WOMEN'S HEALTH OUTCOME STUDY-01 (WHOS-01)

Kojiro Shimozuma, Japan Medical Association Research Institute (JMARI), Tokyo, Japan; Yasuo Ohashi, School of Health Science and Nursing, University of Tokyo, Tokyo, Japan; Kimio Yoshimura, National Cancer Center Research Institute, Tokyo, Japan; Shigemichi Iha, Kurashiki Medical Center, Kurashiki, Okayama, Japan; Hideyuki Saeki, Shozo Ohsumi, National Shikoku Cancer Center, Matsuyama, Ehime, Japan; Katsumasa Kuroi, Toyosu Hospital, Showa University School of Medicine, Tokyo, Japan; Noriyuki Katsumata, National Cancer Center Hospital, Tokyo, Japan; Takahiro Okamoto, Tokyo Women's Medical University, Tokyo, Japan; Katsuhiro Tanaka, Kawasaki Medical School, Kurashiki, Okayama, Japan

352/ VALIDITY OF THE SPANISH CHILD HEALTH AND ILLNESS PROFILE, ADOLESCENT EDITION (CHIP-AE)

V. Serra, Agència d'Avaluació Tecnologia i Recerca Mèdiques, Barcelona, Spain; L. Rajmil, AATM, Barcelona, Spain; J. Alonso, Institut Municipal d'Investigació Mèdica, Barcelona, Spain; B. Starfield, A. Riley, Johns Hopkins University, Baltimore, MD

353/ QUALITY OF LIFE IN THE AUSTRIAN GENERAL POPULATION: "NORMATIVE DATA" FOR THE FACT-G

Bernhard Holzner, Department of Biological Psychiatry, Georg Kemmler, Department of General Psychiatry, Christina de Paoli, Department of Biological Psychiatry, Martin Kopp, Department of General Psychiatry, Richard Greil, Department of Internal Medicine, Wolfgang Fleischhacker, Barbara Sperner-Unterweger, Department of Biological Psychiatry, University Hospital Innsbruck, Innsbruck, Austria

354/ PRELIMINARY ANALYSIS OF THE CULTURAL VALIDATION OF THE WHOQOL-100 IN URUGUAY

Adriana Bagnulo, Laura Schwartzmann, Medical Psychology, Medical College, State University Montevideo, Montevideo, Uruguay

355/ SEQUENTIAL VS. PARALLEL APPROACH TO MULTICULTURAL SCALE DEVELOPMENT: CASES FROM THE FACIT MEASUREMENT SYSTEM

Sonya L. Eremenco, Chih-Hung Chang, David Cella, CORE, ENH, Evanston, IL

356/ THE LOGISTICS OF HEALTH-RELATED QUALITY OF LIFE (HRQL) RESEARCH AMONG ETHNIC MINORITY CANCER POPULATIONS

Rianne Hoopman, Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Sahsenem Celik, Fadoua El Haddouchi, Neil K. Aaronson, Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, NL

Cross-Cultural (continued)**357/ DYSPEPSIA-RELATED QUALITY OF LIFE: TRANSCULTURAL ADAPTATION AND PSYCHOMETRIC VALIDATION INTO SPANISH OF THE DISPEPSIA-RELATED HEALTH SCALES**

Miguel Ruiz, Faculty of Psychology, Autonoma University Madrid, Madrid, Spain; Rejas Javier, Health Outcomes Research, Medical Division, Pfizer Spain, Alcobendas, Madrid, Spain; Soto Javier, Health Outcomes Research, Medical Division, Pharmacia Spain Madrid, Madrid, Spain

358/ PROSPECTIVE VALIDATION STUDY OF SPANISH VERSION OF THE KIDNEY TRANSPLANT QUESTIONNAIRE (KTQ)

Pablo Rebollo, Servicio de Nefrología-I, H.Central de Asturias, Institute Reina Sofia of Neph, Oviedo, Asturias, Spain; Francisco Ortega, Servicio de Nefrología-I, H.Central de Asturias, Institute Reina Sofia, Oviedo, Asturias, Spain; Monica Garcia-Mendoza, Jose M. Baltar, Jaime Alvarez-Grande, Servicio de Nefrología-I, H.Central de Asturias, Oviedo, Asturias, Spain

359/ LINGUISTIC VALIDATION OF THE KING'S HEALTH QUESTIONNAIRE (KHQ) IN 34 LANGUAGES

Katrin Conway, Laurence Chevallet, Mapi Research Institute, Lyon, France; Tara Symonds, Pfizer Ltd, Sandwich, UK

360/ VALIDITY AND RELIABILITY OF EQ-5D DOMAINS IN ASIANS IN SINGAPORE WITH RHEUMATIC DISEASES

Nan Luo, Department of Pharmacy, National University of Singapore, Singapore; Ling-Huo Chew, School of Health Sciences, Nanyang Polytechnic Singapore, Singapore; Kok-Yong Fong, Dow-Rhoo Koh, Swee-Cheng Ng, Kam-Hon Yoon, Sheila Vasoo, Department of Medicine, Shu-Chuen Li, Department of Pharmacy, Julian Thumboo, Department of Medicine, National University of Singapore, Singapore

361/ CROSS-CULTURAL ADAPTATION OF THE SF-36 AND SF-12 PHYSICAL AND MENTAL SUMMARY SCALES ON A THE CHINESE POPULATION

Cindy L. Lam, Family Medicine Unit, Department of Medicine, The University of Hong Kong, Hong Kong SAR, China; Barbara Gandek, Health Assessment Lab, Boston, MA

362/ SWEDISH SF-36 VERSION 2.0 - CONSTRUCT AND CRITERION-RELATED VALIDITY

Charles Taft, Jan Karlsson, Marianne Sullivan, Health Care Research Unit, Sahlgrenska University Hospital, Göteborg, Sweden

363/ EVALUATING THE PERFORMANCE OF A NEW SLOVAK VERSION OF THE INCONTINENCE-RELATED QUALITY OF LIFE MEASURE (I-QOL)

Donald M. Bushnell, Mona L. Martin, HRA, Inc, Seattle, WA; Jan Svihra, Department of Urology, Jessenius School of Medicine, Comenius University, Martin, Slovak Republic

364/ KOREAN VALIDATION OF THE KIDNEY DISEASE QUALITY OF LIFE (KDQOL) INSTRUMENT: A PILOT STUDY

Sehyun Kim, Preventive Medicine, Hye J. Park, Nursing, College of Medicine, Pochon CHA University, Sungnam, Kyonggi-do, Korea; Jin S. Yong, Sung S. Han, Nursing, Catholic University, Seoul, Korea; Kyeong S. Kim, Dong H. Yang, Nephrology, College of Medicine, Pochon CHA University, Sungnam, Kyonggi-do, Korea

365/ USING THE DELPHI METHOD TO DETERMINE EXPERT CONSENSUS IN THE CONSTRUCTION OF A NEW EUROPEAN HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE (HRQL) FOR CHILDREN AND ADOLESCENTS

Michael Herdman, Luis Rajmil, and the KIDSCREEN and DISABKIDS groups, Catalan Agency for Health Technology Assessment, Barcelona, Spain

366/ COMPARATIVE PERFORMANCE OF THE SF-36 BY ETHNICITY

Denise R. Globe, Joanne Wu, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA

367/ TESTING FOR VALIDITY OF A NEWLY DEVELOPED JAPANESE VERSION OF THE MOS SOCIAL SUPPORT SURVEY

Hideki Origasa, Biostatistics, Toyama Medical and Pharmaceutical University Toyama, Toyama, Japan; Hideki Nomura, General Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan; Masami Matsumura, Nephrology, Ishikawa Prefectural Hospital, Kanazawa, Ishikawa, Japan; Toshihisa Morioka, Tomoharu Matsukura, Biostatistics, Toyama Medical and Pharmaceutical University Toyama, Toyama, Japan

368/ VALIDITY OF A NEWLY DEVELOPED JAPANESE SS-QOL (STROKE-SPECIFIC QUALITY OF LIFE) MEASURE

Hideki Origasa, Biostatistics, Toyama Medical and Pharmaceutical University Toyama, Toyama, Japan; Takeshi Nakano, Neurology, Toyoshina Red-Cross Hospital, Matsumoto, Nagano, Japan; Toshihisa Morioka, Biostatistics, Toyama Medical and Pharmaceutical University Toyama, Toyama, Japan; Mufumi Ohwa, Cardiology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan

369/ AN INNOVATIVE APPROACH TO THE DEVELOPMENT OF A SINGLE SPANISH TRANSLATION FOR USE IN MORE THAN ONE COUNTRY

Alyson M. Grove, Erika D. Ammerman, Oxford Outcomes, Oxford, UK; Silvia C. Bonicatto, QoL and Pharmacoeconomics, Fundonar Foundation, La Plata, Argentina; Eduardo Medina Cárdenas, University of Chile, Santiago, Chile; Carlos Kiyan, University of Peru, Lima, Peru; George R. Parkerson, Department of Community and Family Medicine, Duke University Medical Center, Durham, NC; Sandra L. Ford, Global Outcomes Research, Pharmacia Corporation, Kalamazoo, MI

370/ CULTURAL ADAPTATION OF QUALITY OF LIFE INSTRUMENTS FROM THE WEST TO THE EAST: WHAT IS DIFFERENT?

Eva Dragomirecka, Psychiatric Demography Unit, Pavla Selepova, Prague Psychiatric Center, Prague, Czech Republic

371/ THE SPANISH NIH-CHRONIC PROSTATITIS SYMPTOM INDEX: TRANSLATION AND LINGUISTIC VALIDATION

Mark S. Litwin, Departments of Urology and Health Services, UCLA, Los Angeles, CA; Michael P. O'Leary, Alex Adler, Department of Surgery, Harvard Medical School, Division of Urologic Surgery, Boston, MA; Elizabeth A. Calhoun, Institute for Health Services and Health Policy Studies, Northwestern University, Chicago, IL; Michel A. Pontari, Department of Urology, School of Medicine, Philadelphia, PA; Sonya L. Eremenco, Chih-Hung Chang, Linda Odom, CORE, ENH, Evanston, IL; Mary McNaughton Collins, General Medicine Division, Massachusetts General Hospital, Boston, MA

372/ TRANSLATION, RELIABILITY, AND VALIDITY OF THE 12-ITEM GENERAL HEALTH QUESTIONNAIRE AMONG YOUNG PEOPLE IN IRAN

Ali Montazeri, Faranak Farzadi, Azita Goshtasebi, Mariam Vahdani, Gholamreza Garmaroudi, Abolfazl Fateh, Iranian Institute of Health Sciences Research, Tehran, Iran

373/ CHALLENGES AND SOLUTIONS TO DESIGNING AND CONDUCTING GLOBAL RESEARCH

Catherine Marle, The Lewin Group, Levallois-Perret, France; Meryl Brod, The Lewin Group, San Francisco, CA; Pascale Peeters, The Lewin Group, Levallois-Perret, France; Erin Sullivan, The Lewin Group, Boston, MA

374/ THE VALIDATION STUDY OF RUSSIAN VERSION GASTROINTESTINAL SYMPTOM RATING SCALE (GSRS) IN PEPTIC ULCER PATIENTS

I. Wiklund, AstraZeneca R&D Molndal, Molndal, Sweden, A. A. Novik, Department of Hematology, Military Medical Academy, St. Petersburg, Russia; T. Ionova, QOL Group, N. L. Denisov, A. V. Kishtovich, V. A. Shuvaev, Multinational Center of Quality of Life Research, St. Petersburg, Russia

375/ A COMPARATIVE STUDY OF PHYSICAL AND MENTAL HEALTH IN RUSSIA AND THE UNITED STATES

Tatyana I. Ionova, Multinational Center of Quality of Life Research, Military Medical Academy, St. Petersburg, Russia; Barbara Gandek, Health Assessment Lab, Boston, MA; Andrei A. Novik, Anna A. Tsepkova, Anton V. Kishtovich, Yuriy A. Sukhonos, Multinational Center of Quality of Life Research, Military Medical Academy, St. Petersburg, Russia

376/ PROPOSED GUIDELINES FOR THE 1ST STEP OF CROSS-CULTURAL ADAPTATION OF PATIENT REPORTED OUTCOMES (PROS) MEASURES

Katrin Conway, Isabelle Mear, Catherine Acquadro, ERIQA Group, Mapi Research Institute, Lyon, France

377/ Abstract 1501

RELIABILITY AND VALIDITY OF A SWEDISH VERSION OF CHILD HEALTH QUESTIONNAIRE (CHQ)

Ulla Norrby, Department of Pediatrics, Sahlgrenska University Hospital/Ostra, Goteborg, Sweden; Lena A. Nordholm, Department of Occupational Therapy and Physiotherapy, Goteborg University, Goteborg, Sweden

Late-Breaker Abstracts G-L:

G/ GOAL ATTAINMENT SCALING (GAS): A METHOD FOR INTERPRETATION OF QOL-CHANGES IN ONCOLOGICAL INPATIENT REHABILITATION?

Michael T. Moser, Joachim Weis, Hans Helge Bartsch, Tumor Biology Center, Freiburg, Germany

H/ SAMPLE SIZES FOR THE SF-6D PREFERENCE BASED MEASURE OF HEALTH FROM THE SF-36: A COMPARISON OF TWO METHODS

Stephen J. Walters, John E. Brazier, University of Sheffield, Sheffield UK

I/ PHONE IT IN OR FILL IT IN? COMPARING SYMPTOM ASSESSMENT USING THE INTERACTIVE VOICE RESPONSE SYSTEM WITH THE TRADITIONAL PAPER AND PENCIL METHOD

Tito R. Mendoza, Karen O. Anderson, Xin Shelley Wang, Mary Easley, Gary Mobley, Charles S. Cleeland, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

J/ THE RELATION OF DISTRIBUTION- AND ANCHOR-BASED APPROACHES TO INTERPRETATION OF CHANGES IN HEALTH-RELATED QUALITY OF LIFE

Geoffrey R. Norman, PhD, Femida Gwadry Sridhar, MSc., Gordon H. Guyatt, MD, Stephen D. Walter, PhD, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, CA

K/ THE IMPACT OF STABILITY OF ORAL ANTICOAGULANT THERAPY UPON PATIENT PERCEIVED HEALTH STATUS AND QUALITY OF LIFE

F. Jaffary, T. Khan, HA Wynne, PJ Kesteven, F. Kamali, University of Newcastle Upon Tyne, Newcastle Upon Tyne, UK

L/ COMPARING HEALTH STATUS, FATIGUE AND SYMPTOMS BETWEEN NON-CIRRHOTIC AND CIRRHOTIC LIVER PATIENTS; A SURVEY

Simone M. van der Plas, Bettina E. Hansen, Solko W. Schalm, Department of Hepatology, Department of Epidemiology and Biostatistics, Erasmus Medical Center Rotterdam, NL

Poster Discussion Session I: Wednesday, November 7 (3:15 - 3:45 pm)

Location

A/ Contribution of Psychosocial Factors to HRQL Chair: **Hanna McGee**

Room P

166/ EFFECTS OF COPING ON MENTAL OUTCOME IN PERSONS WITH SPINAL CORD LESION, Magnus Elfström, MSc, Göteborg University, Göteborg, Sweden

148/ EARLY QUALITY OF LIFE IN LOCALIZED PROSTATE CANCER: AN EXAMINATION OF TREATMENT-RELATED, DEMOGRAPHIC, AND PSYCHOSOCIAL FACTORS, David Eton, PhD, Evanston Northwestern Healthcare & Northwestern University, Evanston, Illinois, USA

149/ MENTAL ADJUSTMENT TO CANCER AND SOCIAL SUPPORT: IMPORTANT FACTORS FOR THE QUALITY OF LIFE OF OVARIAN CANCER SURVIVORS, George Kemmler, PhD, Innsbruck University Clinics, Innsbruck, Austria

150/ THE RELATIONSHIP BETWEEN PAIN SEVERITY, PAIN-RELATED INTERFERENCE AND HEALTH RELATED QUALITY OF LIFE IN SWEDISH CANCER PATIENTS, Tito Mendoza, PhD, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

B/ HRQL in Patients Caregivers Chair: **Sharon Wood-Dauphinee**

Room M

153/ QOLTI-F: A MEASURE OF THE QOL OF FAMILY CAREGIVERS OF PALLIATIVE CARE PATIENTS, S. Robin Cohen, PhD, McGill University, Montreal, Quebec, Canada

151/ EFFECT OF CAREGIVER PERCEPTION OF PREPAREDNESS ON BURDEN IN AN ONCOLOGY POPULATION, Mary Scherbring, MS, Mayo Medical Center, Rochester, MN, USA

182/ THE INFLUENCE OF GENDER ON HEALTH-RELATED QUALITY OF LIFE (HRQL) OF FAMILY CAREGIVERS OF STROKE SURVIVORS, Carole White, MSc, McGill University, Montreal, PQ, Canada

186/ ASSESSING THE SUBJECTIVE IMPACT ON INFORMAL CAREGIVERS OF CARING FOR CANCER PATIENTS: A REVIEW OF CONCEPTS AND MEASURES, Claire Snyder, MHS, National Cancer Institute, Bethesda, MD, USA

C/ Longer Term Outcomes in Cancer Patients Chair: **Andrew Bottomley**

Room O

155/ IMPACT OF A SECOND PRIMARY CANCER ON QUALITY OF LIFE IN BREAST CANCER SURVIVORS, Carolyn Gotay, PhD, University of Hawaii, Honolulu, HI, USA

156/ SEXUAL FUNCTION IN WOMEN WITH A HISTORY OF CERVICAL CANCER TREATED BY RADIOTHERAPY, Pernille Jensen, MD, Copenhagen University Hospital, Copenhagen, Denmark

154/ DECISIVE FACTORS OF QUALITY OF LIFE OF BLADDER CANCER SURVIVORS FIVE YEARS AFTER THE TREATMENTS IN FRANCE, Tomohiro Matsuda, INSERM U558, Toulouse, France

187/ FACTORS THAT PREDICT HRQoL IN PATIENTS WITH RELAPSING REMITTING MS: RESULTS OF AN 8-YEAR STUDY, Deborah Miller, PhD, Cleveland Clinic Foundation, Cleveland, OH, USA

157/ QUALITY OF LIFE OF BREAST CANCER SURVIVORS IN THE ACUTE, EXTENDED AND PERMANENT PHASES OF SURVIVORSHIP, Lori Andreas, MSN, OHSU, Portland, Oregon, USA

D/ Socio-Economic, Lifestyle Factors and HRQL Chair: **Astrid Wahl**

Room N

201/ THE INFLUENCE OF LIFE-STYLE FACTORS ON HEALTH-RELATED QUALITY OF LIFE, Monica Nortvedt, PhD, University of Bergen, Bergen, Norway

188/ WHAT DO WE MEASURE: HRQL OR HRQL DETERMINANTS? Marie-Claude Simeoni, MD, Medical School, Marseille, France

199/ WORKERS' QUALITY OF LIFE: TOWARDS A NEW APPROACH OF INDUSTRIAL MEDICINE? Jean-Louis San Marco, MD, PhD, Medical School, Marseille, France

202/ HOW MIGRATION AFFECTS THE HEALTH RELATED QUALITY OF LIFE? THE COMPARISON OF THE HRQoL OF THE NATIVE AND IMMIGRANT REPRODUCTIVE AGED WOMEN, Erhan Eser, CBU Med Fac, Manisa, Turkey

200/ HEALTH-RELATED QUALITY OF LIFE AND OCCUPATION, Trond Riise, University of Bergen, Bergen, Norway

E/ What Should We Be Measuring to Inform Decision Making/Policy
Chair: Donald Patrick

Room N1-01

158/ HOW TO MEASURE THE ATTITUDE OF WOMEN WITH BREAST CANCER TOWARDS TRADEOFFS BETWEEN QUALITY AND QUANTITY OF LIFE, Wendy Post, Dr, University Hospital Groningen, Groningen, NL

159/ THE CANCER OUTCOMES MEASUREMENT WORKING GROUP (COMWG): AN NCI INITIATIVE TO IMPROVE THE SCIENCE OF OUTCOMES MEASUREMENT IN CANCER, Joseph Lipscomb, PhD, National Cancer Institute, Bethesda, MD, USA

204/ USING A HEALTH STATUS INDICATOR TO INFORM PROGRAM DECISION-MAKING IN TWO OUTPATIENT MENTAL HEALTH SERVICES, David Lewis, PhD, St Joseph's Healthcare Hamilton, Hamilton, ON, CA

189/ A NEW CONCEPTUAL MODEL FOR TREATMENT SATISFACTION: WHAT IS IT? WHY MEASURE IT? AND, HOW BEST TO USE IT, Meryl Brod, PhD, The Lewin Group, San Francisco, California, USA

Poster Discussion Session II: Thursday, November 8 (4:00 - 4:30 pm)

Location

A/ Aging, Social Participation and HRQL Chair: Mogens Groenvold

Room N1-O1

278/ MEASURING SOCIAL PARTICIPATION: DEVELOPING A SHORT FORM OF THE GLASGOW HEALTH STATUS INVENTORY: THE PARTICIPATION SCALE, Graeme Hawthorne, PhD, The University of Melbourne, West Heidelberg, Victoria, Australia

213/ QUALITY OF LIFE IN ELDERLY PERSONS SUPPORTED BY MANDATORY HEALTH CARE SYSTEM, Michiko Kobayashi, Japanese Society of Quality of Life Research, Kobe, Hyogo, Japan

294/ USING THE WHOQOL-BREF INSTRUMENT AND TIME-TRADE-OFF UTILITY FOR INSTITUTIONALIZED ELDERLY PEOPLE IN TAIWAN, Kuan-Lang Lai, MSc, National Defense Medical Center, Taipei, Taiwan

214/ HOW DO WE AGE? AN ANALYSIS OF SYMPTOMS AND FUNCTION IN A COMMUNITY COHORT, Ted Ganiats, MD, UC San Diego, La Jolla, CA, USA

B/ Cardiovascular Diseases and HRQL Chair: Gaietà Permanyer-Miralda

Room M

236/ IS SELF PERCEPTION OF HEALTH THE MOST IMPORTANT FACTOR CONTRIBUTING TO IMPROVEMENT OF QUALITY OF LIFE IN HIGH RISK CORONARY PATIENTS AFTER THE OPERATION? Bogoljub Mihajlovic, PhD, Institute of CVD, Sremska Kamenica, Vojvodina, Yugoslavia

237/ RESPONSIVE HEALTH-RELATED QUALITY OF LIFE DOMAINS IN THE TREATMENT OF HYPERTENSION: A SYSTEMATIC REVIEW OF PUBLISHED STUDIES AND MEASURES, Kunle Adesina, MD, Mapi Values, Macclesfield, Cheshire, UK

238/ RELATIONSHIP BETWEEN SYMPTOMS AND SF-36 PCS AND MCS SCORES IN TREATED HYPERTENSIVE PATIENTS, Steven Erickson, PharmD, University of Michigan, Ann Arbor, Michigan, USA

279/ THE RELATIVE RESPONSIVENESS OF GENERIC AND DISEASE-SPECIFIC MEASURES OF HRQoL IN PATIENTS UNDERGOING CORONARY REVASCULARISATION, Sara Schroter, MSc, London School of Hygiene & Tropical Medicine, London, UK

280/ FINAL PSYCHOMETRIC EVALUATION OF THE CORONARY REVASCULARISATION OUTCOME QUESTIONNAIRE (CROQ-CABG/PTCA), Sara Schroter, MSc, London School of Hygiene & Tropical Medicine, London, UK

C/ HRQL in Cancer and HIV Patients Chair: David Cella

Room N

281/ DEVELOPMENT AND VALIDATION OF DISEASE-SPECIFIC MEASURES FOR CHOROIDAL MELANOMA—A CANCER OF THE EYE, Michele Melia, MS, Johns Hopkins University, Baltimore, MD, USA

241/ PHYSICAL PERFORMANCE, TOXICITY, AND QUALITY OF LIFE AS ASSESSED BY THE PHYSICIAN AND THE PATIENT, Minna-Liisa Luoma, MA, University of Helsinki, University of Helsinki, Finland

212/ MEASUREMENT OF CONTINUITY AND CO-ORDINATION OF PATIENT CARE IN A CANCER CENTRE, Laura Booth, Imperial Cancer Research Fund, Leeds, UK

282/ EXPLORATORY FACTOR ANALYSIS (EFA) OF THE QUALITY OF LIFE RADIATION THERAPY INSTRUMENT & HEAD AND NECK MODULE (QOL-RTI/HN) USING MULTI-NATIONAL SAMPLES, Clement Gwede, PhD, RN, Moffitt Cancer Center, Tampa, FL, USA

59/ QUALITY OF LIFE ASSESSMENT IN HIV: MODIFYING INSTRUMENTS FOR A CHANGING DISEASE? Waldo Belloso, MD, Argentina

D/ Interpretation HRQL Scores Chair: Jeff Sloan

Room O

242/ RESULTS FROM THREE PHYSICIAN CONSENSUS PANELS DETERMINING CLINICALLY SIGNIFICANT CHANGES IN HEALTH-RELATED QUALITY OF LIFE, Kathleen Wyrwich, PhD, Saint Louis University, St. Louis, MO, USA

283/ INTERPRETING THE MOS SF_36: HOW MANY SUM SCORES ARE APPROPRIATE? Corina Guethlin, University Hospital, Freiburg, Germany

286/ SHOULD SYMPTOMS BE SCALED FOR INTENSITY, FREQUENCY, OR BOTH? Chi-Hung Chang, PhD, Evanston Northwestern Healthcare, Evanston, IL, USA

285/ HOW MUCH IS "VERY MUCH"? DEVELOPING A RATING SCALE FOR PORTUGUESE SPEAKING COUNTRIES, Benjamin Arnold, BA, ENH, Evanston, IL, USA

284/ METHODOLOGY FOR CHOICE OF ITEMS: DESIGNING A QUALITY OF LIFE INSTRUMENTS FOR HIP AND KNEE OSTEOARTHRITIS, Francis Guillemin, MD, PhD, Hopital Marin, Nancy, France

E/ Methodological Issues in HRQL Measures

Room P

Chair: Ron Hays

247/ IMPACT OF A CHANGE IN MODE OF ADMINISTRATION ON QUESTIONNAIRE RETURN DURING A STUDY OF THE OUTCOME OF HIP AND KNEE REPLACEMENT, Francois Bethoux, MD, The Cleveland Clinic Foundation, Cleveland, OH, USA

244/ RESPONSE SHIFT OF A HEALTH-RELATED QUALITY OF LIFE ASSESSMENT AS A PREDICTOR OF SUSTAINED WEIGHT LOSS IN OBESE PATIENTS, Ivan Barofsky, PhD, Johns Hopkins University School of Medicine, Baltimore, MD, USA

243/ AGREEMENT BETWEEN SELF AND PROXY ASSESSMENT IN ELDERLY PATIENTS WITH HIP FRACTURES, C. Allyson Jones, PhD, University of Alberta, Edmonton, AB, CA

246/ OBTAINING SELF-REPORTS ABOUT HRQL FROM COGNITIVELY IMPAIRED RESPONDENTS, Sarah Smith PhD, London School of Hygiene & Tropical Medicine, London, UK

245/ EFFECT OF MODE OF ADMINISTRATION ON THE WALKING IMPAIRMENT QUESTIONNAIRE IN PERIPHERAL ARTERIAL DISEASE PATIENTS, Karin Coyne, PhD, MEDTAP International, Bethesda, MD, USA

Poster Discussion Session III: Friday, November 9 (4:00 - 4:30 pm)

Location

A/ Analytical Methods for HRQL Measurement Chair: Thomas Kohlmann

Room L

344/ UNDERSTANDING CHANGE OVER TIME IN THE SELF-RATED HEALTH OF SURVIVING OLDER ADULTS, Kathleen Wyrwich, PhD, Saint Louis University, St. Louis, MO, USA

345/ COULD LINEAR REGRESSION BE REPLACED BY ITEM RESPONSE THEORY ANALYSIS WHEN ADDRESSING CRITERION-REFERENCE INTERPRETATION OF TEST SCORES? A DISCUSSION EXAMPLE, Luis Prieto, PhD, FPCE Blanquerna, Universitat Ramon Llull, Barcelona, Spain

348/ SOME LOGICAL PROBLEMS WITH TESTS FOR CLINICALLY IMPORTANT CHANGES IN HRQOL, Dennis Gagnon, MA, MABE, RWJ Pharmaceutical Research Institute, Raritan, NJ, USA

347/ MODELING LONGITUDINAL QOL DATA USING REGRESSION SPLINES, Carl de Moor, PhD, UT MD Anderson Cancer Center, Houston, TX, USA

346/ APPLYING ITEM RESPONSE THEORY (IRT) ON ITEMS DEVELOPED WITHIN THE FRAMEWORK OF CLASSICAL TEST THEORY (CTT), Elof Dimenas, PhD, AstraZeneca R&D, Molndal, Sweden

B/ Cross Cultural Research Chair: Michael Herdman

Room M

349/ RELIABILITY AND VALIDITY OF MODIFIED LUNG CANCER SYMPTOM SCALE (LCSS) IN MULTINATIONAL SAMPLE OF PATIENTS WITH PLEURAL MESOTHELIOMA, Astra Liepa PharmD, Eli Lilly and Co., Indianapolis, IN, USA

351/ RELIABILITY AND VALIDITY OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-BREAST (FACT-B): WOMEN'S HEALTH OUTCOME STUDY-01 (WHOS-01), Kojiro Shimozuma MD, PhD, Apan Medical Association Research Institute, Tokyo, Japan

375/ A COMPARATIVE STUDY OF PHYSICAL AND MENTAL HEALTH IN RUSSIA AND THE UNITED STATES, Tatyana Ionova, PhD, Military Medical Academy, Saint-Petersburg, Russia

C/ Endocrine Diseases and HRQL Chair: Susan D. Mathias

Room N

317/ SYMPTOMS OF DIABETIC RETINOPATHY AND THEIR IMPACT ON HEALTH-RELATED QUALITY OF LIFE, Mary Kay Margolis, MPH, MHA, MEDTAP International, Inc., Bethesda, MD, USA

320/ HEALTH-RELATED QUALITY OF LIFE IN OBESE SEEKING TREATMENT COMPARED TO NON-OBESE REFERENCE SUBJECTS, Karlsson, Institute of Internal Medicine, Göteborg, Sweden

318/ GENDER DIFFERENCES IN QUALITY OF LIFE OF PATIENTS WITH DIABETES MELLITUS, Petersen, Dipl.-Psych, University Hospital Hamburg—Eppendorf-Hamburg, Hamburg, Germany

319/ COPING AND DISTRESS BEFORE AND AFTER OBESITY TREATMENT, Ryden, BSci, Göteborg University, Göteborg, Sweden

321/ DO MEN AND WOMEN RESPOND DIFFERENTLY TO WEIGHT CHANGE? Woolley, Ph.D., Amgen Inc., Thousand Oaks, CA, USA

D/ HIV/AIDS and HRQL Chair: Albert Wu

Room N1-O1

305/ A LONGITUDINAL STUDY ON HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH HIV-INFECTION, Claes Cederfjäll, RN, PhD-student, Karolinska Institutet, Stockholm, Sweden

306/ HEALTH-RELATED QUALITY OF LIFE IN HIV+ PATIENTS TAKING HAART, Murri, MD, Catholic University of Rome, Rome, Italy

307/ SATISFACTION WITH SEXUAL LIFE IN HIV+ PATIENTS, Murri, MD, Catholic University of Rome, Rome, Italy

E/ Mental Health and HRQL
Chair: Hans Ormel

Room O

331/ DOES CHANGE IN DEPRESSION STATUS PREDICT CHANGE IN HRQOL? Marianne Amir, PhD, Ben-Gurion University of the Negev, Beer-Sheva, Israel

330/ SOCIAL SUPPORT AND QUALITY OF LIFE IN CHRONIC MENTAL DISEASE PATIENTS SUBMITTED TO DIFFERENT HOUSING TREATMENT PROGRAMS, Jose Pais-Ribeiro, PhD, Universidade do Porto, Porto, Portugal

329/ QUALITY OF LIFE FOR POOR AFRICAN-AMERICAN WOMEN WITH DEPRESSION, Lori Frank, PhD, MEDTAP International, Inc., Bethesda, MD, USA

Poster Discussion Session III

Acknowledgements

ISOQOL 2001 Annual Meeting – Amsterdam

ISOQOL would like to thank the following organizations
who in various ways contributed to this meeting:

American Home Products

Boehringer-Ingelheim

Health Research Associates

Health Utilities, Inc.

Johnson & Johnson

MAPI

MEDTAP

Novartis

Pan Pacific Conference of ISOQOL

Pfizer

Pharmacia Upjohn

Quality Metric

Sanofli-Synthelabo

Exhibitors

ISOQOL 2001 Annual Meeting – Amsterdam

ISOQOL would like to thank the following companies for their participation as exhibitors at this year's meeting.

Be sure to visit them in the **Lounge Forum** during the meeting:

Assist Technologies

Assist Technologies, Inc. (AT) is a complete outsourcing service to collect/manage patient survey data as part of clinical trial or outcomes studies, replacing traditional paper surveys with easy to use touch-screens.

Assist Technologies, Inc. (AT), 3295 N. Drinkwater Boulevard, Scottsdale, Arizona 85251 USA
Tel.: 480/874-9400; FAX: 480/874-9414; e-mail: janet@assistentouch.com

Galen Research

Galen Research specializes in disease-specific QoL and utility assessment, including instrument development and adaptation. Collaborations with research organizations in Europe and Research Triangle Institute in the USA facilitate international capability.

Galen Research, Enterprise House, Manchester Science Park, Lloyd Street North, Manchester, M15 6SE, UK
Tel.: +44 (0) 161 226 4446; FAX: +44 (0) 161 226 4478; e-mail: spm@galen.eng.net

MAPI

MAPI is a non-profit international health outcomes organisation established to support and promote collaborative research in the field of patient reported outcomes (PROs).

MAPI Research Institute, 27, rue de la Villette, 69003 Lyon, FRANCE
Tel.: +33 (0) 4 72 13 66 67; FAX: +33 (0) 4 72 13 69 50; e-mail: kconway@mapi.fr

MEDTAP International, Inc.

MEDTAP International performs state-of-the-art health services research, specializing in studies of health outcomes, economic evaluation and modeling, policy research and analysis, and training in outcomes research methods. MEDTAP documents the impact of medical interventions as well as the use of medical resources and cost of care from the perspective of patients and their caregivers, health care providers, and society as a whole. Health care decision makers use this research to make better-informed judgments about the allocation of health resources.

MEDTAP International, Inc., 7101 Wisconsin Ave., Suite 600, Bethesda, MD 20814 USA
Tel.: 301/654-9729; FAX: 301/654-9864; e-mail: waller@MEDTAP.com

Institutional Membership

International Society for Quality of Life Research

ISOQOL has recently developed categories for institutional memberships for universities, institutions, and private companies. Institutional membership will benefit ISOQOL activities and programs while at the same time benefit your organization!

Listed below are membership categories which describe the different levels of institutional membership and the benefits of belonging to ISOQOL. Find one that best suits your needs and join today!!

Non-Profit Institutional Membership – Annual Contribution of \$1,000

Eligible Members: Universities and Non-profit organizations
 Benefits include: Five (5) individual memberships;
 Visibility among QOL/health outcomes researchers and the field;
 Ability to post job advertisements in newsletter and on website for free;
 Listing on website as a non-profit institutional member;
 Special rates for booths at annual meeting.

Institutional Membership – Annual Contribution of \$2,500

Eligible Members: Universities, contract research organizations and other companies
 Benefits include: Five (5) individual memberships;
 Visibility among QOL/health outcomes researchers and the field;
 Ability to post job advertisements in newsletter and on website for free;
 Listing on website as an institutional member;
 Special rates for booths at annual meeting.

Corporate Membership – Annual Contribution of \$5,000

Eligible Members: Pharmaceutical and medical device companies, health insurers and other companies
 Benefits include: Five (5) individual memberships;
 Visibility among QOL/health outcomes researchers and the field;
 Ability to post job advertisements in newsletter and on website for free;
 Listing on website as a corporate member;
 Special rates for booths at annual meeting.

Corporate Sponsor Membership – Annual Contribution of \$10,000 or more

Eligible Members: Pharmaceutical and medical device companies, health insurers and other companies
 Benefits include: Ten (10) individual memberships;
 Visibility among QOL/health outcomes researchers and the field;
 Ability to post job advertisements in newsletter and on website for free;
 Listing on website as a corporate sponsor;
 Special rates for booths at annual meeting;
 Ability to set up symposiums before or after annual meeting

We encourage you and your organization to become an institutional member of ISOQOL. Visit our website at www.isoqol.org to download an application form, or email us at info@isoqol.org.

*Thanks for
joining us
in 2001...*





See you in 2002...

Mark your calendars...

...for the ISOQOL 2002 meeting!

The Caribe Royale Resort Suites & Villas

The Caribe Royale is located in the Lake Buena Vista part of Orlando and offers complimentary transportation to Walt Disney World.

All rooms are suites - a beautiful property.

ISOQOL 2002
October 30 - November 2
Orlando, Florida USA



*Watch the ISOQOL website, www.isoqol.org,
for the Call for Abstracts in January!*